View Filing Data

Print Document View Excel Document

Document And Entity Information	6 Months Ended
Document And Entity Information	Jun. 30, 2019
Document And Entity Information [Abstract]
Entity Registrant Name	OPGEN INC
Document Type	S-4
Document Period End Date	Jun. 30, 2019
Amendment Flag	false
Entity Central Index Key	0001293818
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Current assets
Cash and cash equivalents	$ 3,055,894	$ 4,572,487	$ 1,847,171
Accounts receivable, net	772,914	373,858	809,540
Inventory, net	567,422	543,747	533,425
Prepaid expenses and other current assets	178,356	292,918	311,644
Total current assets	4,574,586	5,783,010	3,501,780
Property and equipment, net	197,502	1,221,827	835,537
Finance lease right-of-use assets, net	984,742	0
Operating lease right-of-use assets	1,381,830	0
Goodwill	600,814	600,814	600,814
Intangible assets, net	951,458	1,085,366	1,353,182
Other noncurrent assets	241,182	259,346	328,601
Total assets	8,932,114	8,950,363	6,619,914
Current liabilities
Accounts payable	1,258,908	1,623,751	1,691,712
Accrued compensation and benefits	1,190,500	1,041,573	746,924
Accrued liabilities	820,667	902,019	1,160,714
Deferred revenue	9,993	15,824	24,442
Short-term notes payable	343,330	398,595	1,010,961
Short-term finance lease liabilities	576,322	399,345	154,839
Short-term operating lease liabilities	958,992	0
Total current liabilities	5,158,712	4,381,107	4,789,592
Deferred rent	0	162,919	290,719
Note payable	494,897	660,340	0
Warrant liability	0	67	8,453
Long-term finance lease liabilities	379,825	437,189	130,153
Long-term operating lease liabilities	1,071,677	0
Total liabilities	7,105,111	5,641,622	5,218,917
Commitments (Note 9)
Stockholders' equity
Preferred stock	0	0	0
Common stock	176,457	86,457	22,653
Additional paid-in capital	170,190,415	165,313,902	150,114,671
Accumulated deficit	(168,524,652)	(162,078,525)	(148,710,427)
Accumulated other comprehensive loss	(15,217)	(13,093)	(25,900)
Total stockholders' equity	1,827,003	3,308,741	1,400,997
Total liabilities and stockholders' equity	$ 8,932,114	$ 8,950,363	$ 6,619,914

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01	$ 0.01
Common stock, shares authorized	50,000,000	50,000,000	50,000,000
Common stock, shares issued	17,645,720	8,645,720	2,265,320
Common stock, shares outstanding	17,645,720	8,645,720	2,265,320
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01	$ 0.01
Preferred stock, shares authorized	10,000,000	10,000,000	10,000,000
Preferred stock, shares issued	0	0	0
Preferred stock, shares outstanding	0	0	0

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Revenue
Total revenue	$ 1,009,543	$ 788,901	$ 2,029,720	$ 1,635,127	$ 2,946,307	$ 3,211,007
Operating expenses
Research and development	1,153,584	1,304,388	2,929,966	2,534,817	5,677,243	6,883,293
General and administrative	1,592,845	1,831,063	3,340,430	3,621,585	7,069,315	6,692,659
Sales and marketing	393,567	426,297	765,800	756,070	1,531,556	2,767,670
Impairment of right-of-use asset	0	0	520,759	0
Total operating expenses	3,590,470	4,044,813	8,372,613	7,906,922	16,126,549	18,476,798
Operating loss	(2,580,927)	(3,255,912)	(6,342,893)	(6,271,795)	(13,180,242)	(15,265,791)
Other (expense) income
Interest and other income (expense)	15,166	5	(9,256)	5,303	5,384	(87,255)
Interest expense	(37,129)	(54,533)	(93,573)	(112,379)	(191,195)	(233,505)
Foreign currency transaction gains (losses)	9,879	(21,762)	(472)	(9,581)	(10,431)	23,179
Change in fair value of derivative financial instruments	0	(11)	67	8,155	8,386	144,064
Total other expense	(12,084)	(76,301)	(103,234)	(108,502)	(187,856)	(153,517)
Loss before income taxes	(2,593,011)	(3,332,213)	(6,446,127)	(6,380,297)	(13,368,098)	(15,419,308)
Provision for income taxes	0	0	0	0	0	0
Net loss	(2,593,011)	(3,332,213)	(6,446,127)	(6,380,297)	$ (13,368,098)	$ (15,419,308)
Net loss available to common stockholders	$ (2,593,011)	$ (3,332,213)	$ (6,446,127)	$ (6,380,297)
Net loss per common share - basic and diluted	$ (0.15)	$ (0.57)	$ (0.48)	$ (1.29)	$ (2.22)	$ (9.80)
Weighted average shares outstanding - basic and diluted	17,645,720	5,826,947	13,518,648	4,950,517	6,009,065	1,573,769
Net loss	$ (2,593,011)	$ (3,332,213)	$ (6,446,127)	$ (6,380,297)	$ (13,368,098)	$ (15,419,308)
Other comprehensive (loss) gain - foreign currency translations	(4,950)	18,113	(2,124)	5,534	12,807	(32,076)
Comprehensive loss	(2,597,961)	(3,314,100)	(6,448,251)	(6,374,763)	(13,355,291)	(15,451,384)
Service [Member]
Operating expenses
Cost of products and services	251,981	179,402	396,463	347,955	625,516	520,338
Collaborations Revenue [Member]
Revenue
Total revenue	500,000	155,276	1,000,000	359,316	516,016	397,178
Product [Member]
Revenue
Total revenue	504,293	632,525	1,024,470	1,266,021	2,395,626	2,771,869
Operating expenses
Cost of products and services	198,493	303,663	419,195	646,495	1,222,919	1,612,838
Laboratory Service Revenue [Member]
Revenue
Total revenue	$ 5,250	$ 1,100	$ 5,250	$ 9,790	$ 34,665	$ 41,960

Condensed Consolidated Statements of Stockholders' Equity - USD ($)	Common Stock [Member] Public Placement [Member]	Common Stock [Member] At The Market Offering [Member] Sales Agreement [Member] Cowen And Company Limited Liability Company [Member]	Common Stock [Member] At The Market Offering [Member]	Common Stock [Member] October Two Thousand Eighteen Public Offering [Member]	Common Stock [Member]	Additional Paid In Capital [Member] Public Placement [Member]	Additional Paid In Capital [Member] At The Market Offering [Member]	Additional Paid In Capital [Member]	Accumulated Other Comprehensive Income [Member]	Retained Earnings [Member]	Public Placement [Member]	At The Market Offering [Member]	Total
Balance at Dec. 31, 2016	$ 10,122		$ 10,122	$ 10,122	$ 10,122	$ 136,442,302	$ 136,442,302	$ 136,442,302	$ 6,176	$ (133,291,119)			$ 3,167,481
Balance (in shares) at Dec. 31, 2016	1,012,171		1,012,171	1,012,171	1,012,171
Issuance of units, net of offering costs	$ 2,272		$ 3,808,836	$ 2,272	$ 2,272	$ 3,806,564	$ 3,808,836	3,806,564			$ 8,823,242	$ 3,808,836
Issuance of units, net of offering costs (in shares)	227,216		227,216	227,216	227,216	1,000,000	227,216				1,000,000	227,216
Issuance of RSUs	$ 60		$ 60	$ 60	$ 60	$ (60)	$ (60)	(60)
Issuance of RSUs (in shares)	6,025		6,025	6,025	6,025
Stock compensation expense						911,398	911,398	911,398					911,398
Foreign currency translation									(32,076)				(32,076)
Net loss										(15,419,308)			(15,419,308)
Balance at Dec. 31, 2017	$ 22,653		$ 22,653	$ 22,653	$ 22,653	150,114,671	150,114,671	150,114,671	(25,900)	(148,710,427)			1,400,997
Balance (in shares) at Dec. 31, 2017	2,265,320		2,265,320	2,265,320	2,265,320
Issuance of units, net of offering costs	$ 30,192					10,691,208					$ 10,721,400
Issuance of units, net of offering costs (in shares)	3,019,230
Issuance of RSUs					$ 54			(54)
Issuance of RSUs (in shares)					5,400
Stock compensation expense								238,190					238,190
Stock cancellation (in shares)					(31)
Foreign currency translation									(12,579)				(12,579)
Net loss										(3,048,084)			(3,048,084)
Balance at Mar. 31, 2018					$ 52,899			161,044,015	(38,479)	(151,758,511)			9,299,924
Balance (in shares) at Mar. 31, 2018					5,289,919
Balance at Dec. 31, 2017	$ 22,653		$ 22,653	$ 22,653	$ 22,653	150,114,671	150,114,671	150,114,671	(25,900)	(148,710,427)			1,400,997
Balance (in shares) at Dec. 31, 2017	2,265,320		2,265,320	2,265,320	2,265,320
Net loss													(6,380,297)
Balance at Jun. 30, 2018					$ 60,670			161,449,185	(20,366)	(155,090,724)			6,398,765
Balance (in shares) at Jun. 30, 2018					6,067,039
Balance at Dec. 31, 2017	$ 22,653		$ 22,653	$ 22,653	$ 22,653	150,114,671	150,114,671	150,114,671	(25,900)	(148,710,427)			1,400,997
Balance (in shares) at Dec. 31, 2017	2,265,320		2,265,320	2,265,320	2,265,320
Issuance of units, net of offering costs	$ 3,182		$ 597,743	$ 3,182	$ 3,182	$ 594,561	$ 597,743	594,561			$ 13,530,401	$ 597,743
Issuance of units, net of offering costs (in shares)	318,236	318,236	318,236	318,236	318,236	5,912,307	318,236				5,912,307	318,236
Issuance of RSUs	$ 57		$ 57	$ 57	$ 57	$ (57)	$ (57)	(57)
Issuance of RSUs (in shares)	5,650		5,650	5,650	5,650
Stock compensation expense						862,281	862,281	862,281					862,281
Stock cancellation (in shares)	(31)		(31)	(31)	(31)
Foreign currency translation									12,807				12,807
Net loss										(13,368,098)			(13,368,098)
Balance at Dec. 31, 2018	$ 86,457		$ 86,457	$ 86,457	$ 86,457	165,313,902	165,313,902	165,313,902	(13,093)	(162,078,525)			3,308,741
Balance (in shares) at Dec. 31, 2018	8,645,720		8,645,720	8,645,720	8,645,720
Balance at Mar. 31, 2018					$ 52,899			161,044,015	(38,479)	(151,758,511)			9,299,924
Balance (in shares) at Mar. 31, 2018					5,289,919
Issuance of units, net of offering costs	$ 6,731		$ 1,040				191,280				$ 6,731	$ 192,320
Issuance of units, net of offering costs (in shares)	673,077		104,043
Stock compensation expense								213,890					213,890
Foreign currency translation									18,113				18,113
Net loss										(3,332,213)			(3,332,213)
Balance at Jun. 30, 2018					$ 60,670			161,449,185	(20,366)	(155,090,724)			6,398,765
Balance (in shares) at Jun. 30, 2018					6,067,039
Balance at Dec. 31, 2018	$ 86,457		$ 86,457	$ 86,457	$ 86,457	165,313,902	165,313,902	165,313,902	(13,093)	(162,078,525)			3,308,741
Balance (in shares) at Dec. 31, 2018	8,645,720		8,645,720	8,645,720	8,645,720
Issuance of units, net of offering costs	$ 90,000					4,692,509					$ 4,782,509
Issuance of units, net of offering costs (in shares)	9,000,000
Stock compensation expense								98,033					98,033
Foreign currency translation									2,826				2,826
Net loss										(3,853,116)			(3,853,116)
Balance at Mar. 31, 2019					$ 176,457			170,104,444	(10,267)	(165,931,641)			4,338,993
Balance (in shares) at Mar. 31, 2019					17,645,720
Balance at Dec. 31, 2018	$ 86,457		$ 86,457	$ 86,457	$ 86,457	$ 165,313,902	$ 165,313,902	165,313,902	(13,093)	(162,078,525)			3,308,741
Balance (in shares) at Dec. 31, 2018	8,645,720		8,645,720	8,645,720	8,645,720
Net loss													(6,446,127)
Balance at Jun. 30, 2019													1,827,003
Balance at Mar. 31, 2019					$ 176,457			$ 170,104,444	$ (10,267)	$ (165,931,641)			4,338,993
Balance (in shares) at Mar. 31, 2019					17,645,720
Net loss													(2,593,011)
Balance at Jun. 30, 2019													$ 1,827,003

Condensed Consolidated Statements of Stockholders' Equity (10-K) - USD ($)	Common Stock [Member] Public Placement [Member]	Common Stock [Member] At The Market Offering [Member] Cowen And Company Limited Liability Company [Member] Sales Agreement [Member]	Common Stock [Member] At The Market Offering [Member]	Common Stock [Member] October Two Thousand Eighteen Public Offering [Member]	Common Stock [Member]	Additional Paid In Capital [Member] Public Placement [Member]	Additional Paid In Capital [Member] At The Market Offering [Member]	Additional Paid In Capital [Member]	Accumulated Other Comprehensive Income [Member]	Retained Earnings [Member]	Public Placement [Member]	At The Market Offering [Member]	Total
Balance at Dec. 31, 2016	$ 10,122		$ 10,122	$ 10,122	$ 10,122	$ 136,442,302	$ 136,442,302	$ 136,442,302	$ 6,176	$ (133,291,119)			$ 3,167,481
Balance (in shares) at Dec. 31, 2016	1,012,171		1,012,171	1,012,171	1,012,171
Stock option exercises	$ 12		$ 12	$ 12	$ 12	8,168	8,168	8,168					$ 8,180
Stock option exercises (in shares)	1,167		1,167	1,167	1,167								1,167
Issuance of units, net of offering costs	$ 2,272		$ 3,808,836	$ 2,272	$ 2,272	$ 3,806,564	$ 3,808,836	3,806,564			$ 8,823,242	$ 3,808,836
Issuance of units, net of offering costs (in shares)	227,216		227,216	227,216	227,216	1,000,000	227,216				1,000,000	227,216
Issuance of RSUs	$ 60		$ 60	$ 60	$ 60	$ (60)	$ (60)	(60)
Issuance of RSUs (in shares)	6,025		6,025	6,025	6,025
Stock compensation expense						911,398	911,398	911,398					$ 911,398
Legal settlement in common stock	$ 158		$ 158	$ 158	$ 158	109,841	109,841	109,841					109,999
Legal settlement in common stock (in shares)	15,843		15,843	15,843	15,843
Vendor payment in common stock	$ 29		$ 29	$ 29	$ 29	23,216	23,216	23,216					23,245
Vendor payment in common stock (in shares)	2,898		2,898	2,898	2,898
Foreign currency translation									(32,076)				(32,076)
Net loss										(15,419,308)			(15,419,308)
Balance at Dec. 31, 2017	$ 22,653		$ 22,653	$ 22,653	$ 22,653	150,114,671	150,114,671	150,114,671	(25,900)	(148,710,427)			1,400,997
Balance (in shares) at Dec. 31, 2017	2,265,320		2,265,320	2,265,320	2,265,320
Issuance of units, net of offering costs	$ 30,192					10,691,208					$ 10,721,400
Issuance of units, net of offering costs (in shares)	3,019,230
Issuance of RSUs					$ 54			(54)
Issuance of RSUs (in shares)					5,400
Stock compensation expense								238,190					238,190
Share cancellation (in shares)					(31)
Foreign currency translation									(12,579)				(12,579)
Net loss										(3,048,084)			(3,048,084)
Balance at Mar. 31, 2018					$ 52,899			161,044,015	(38,479)	(151,758,511)			9,299,924
Balance (in shares) at Mar. 31, 2018					5,289,919
Balance at Dec. 31, 2017	$ 22,653		$ 22,653	$ 22,653	$ 22,653	150,114,671	150,114,671	150,114,671	(25,900)	(148,710,427)			1,400,997
Balance (in shares) at Dec. 31, 2017	2,265,320		2,265,320	2,265,320	2,265,320
Net loss													(6,380,297)
Balance at Jun. 30, 2018					$ 60,670			161,449,185	(20,366)	(155,090,724)			6,398,765
Balance (in shares) at Jun. 30, 2018					6,067,039
Balance at Dec. 31, 2017	$ 22,653		$ 22,653	$ 22,653	$ 22,653	150,114,671	150,114,671	150,114,671	(25,900)	(148,710,427)			$ 1,400,997
Balance (in shares) at Dec. 31, 2017	2,265,320		2,265,320	2,265,320	2,265,320
Stock option exercises (in shares)													0
Issuance of units, net of offering costs	$ 3,182		$ 597,743	$ 3,182	$ 3,182	$ 594,561	$ 597,743	594,561			$ 13,530,401	$ 597,743
Issuance of units, net of offering costs (in shares)	318,236	318,236	318,236	318,236	318,236	5,912,307	318,236				5,912,307	318,236
Issuance of RSUs	$ 57		$ 57	$ 57	$ 57	$ (57)	$ (57)	(57)
Issuance of RSUs (in shares)	5,650		5,650	5,650	5,650
Stock compensation expense						862,281	862,281	862,281					$ 862,281
Share cancellation (in shares)	(31)		(31)	(31)	(31)
Interest settlement in common stock	$ 1,442		$ 1,442	$ 1,442	$ 1,442	271,168	271,168	271,168					272,610
Interest settlement in common stock, (in shares)	144,238		144,238	144,238	144,238
Foreign currency translation									12,807				12,807
Net loss										(13,368,098)			(13,368,098)
Balance at Dec. 31, 2018	$ 86,457		$ 86,457	$ 86,457	$ 86,457	165,313,902	165,313,902	165,313,902	(13,093)	(162,078,525)			3,308,741
Balance (in shares) at Dec. 31, 2018	8,645,720		8,645,720	8,645,720	8,645,720
Balance at Mar. 31, 2018					$ 52,899			161,044,015	(38,479)	(151,758,511)			9,299,924
Balance (in shares) at Mar. 31, 2018					5,289,919
Issuance of units, net of offering costs	$ 6,731		$ 1,040				191,280				$ 6,731	$ 192,320
Issuance of units, net of offering costs (in shares)	673,077		104,043
Stock compensation expense								213,890					213,890
Foreign currency translation									18,113				18,113
Net loss										(3,332,213)			(3,332,213)
Balance at Jun. 30, 2018					$ 60,670			161,449,185	(20,366)	(155,090,724)			6,398,765
Balance (in shares) at Jun. 30, 2018					6,067,039
Balance at Dec. 31, 2018	$ 86,457		$ 86,457	$ 86,457	$ 86,457	165,313,902	165,313,902	165,313,902	(13,093)	(162,078,525)			3,308,741
Balance (in shares) at Dec. 31, 2018	8,645,720		8,645,720	8,645,720	8,645,720
Issuance of units, net of offering costs	$ 90,000					4,692,509					$ 4,782,509
Issuance of units, net of offering costs (in shares)	9,000,000
Stock compensation expense								98,033					98,033
Foreign currency translation									2,826				2,826
Net loss										(3,853,116)			(3,853,116)
Balance at Mar. 31, 2019					$ 176,457			170,104,444	(10,267)	(165,931,641)			4,338,993
Balance (in shares) at Mar. 31, 2019					17,645,720
Balance at Dec. 31, 2018	$ 86,457		$ 86,457	$ 86,457	$ 86,457	$ 165,313,902	$ 165,313,902	165,313,902	(13,093)	(162,078,525)			3,308,741
Balance (in shares) at Dec. 31, 2018	8,645,720		8,645,720	8,645,720	8,645,720
Net loss													(6,446,127)
Balance at Jun. 30, 2019													1,827,003
Balance at Mar. 31, 2019					$ 176,457			$ 170,104,444	$ (10,267)	$ (165,931,641)			4,338,993
Balance (in shares) at Mar. 31, 2019					17,645,720
Net loss													(2,593,011)
Balance at Jun. 30, 2019													$ 1,827,003

Condensed Consolidated Statements of Cash Flows - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Cash flows from operating activities
Net loss	$ (6,446,127)	$ (6,380,297)	$ (13,368,098)	$ (15,419,308)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	450,952	317,652	730,884	669,088
Noncash interest expense	43,371	94,594	133,802	185,294
Stock compensation expense	184,004	452,080	862,281	911,398
Loss (gain) on sale of equipment	9,904	(5,253)	(5,253)	0
Change in fair value of warrant liability	(67)	(8,155)	(8,386)	(144,064)
Impairment of right-of-use asset	520,759	0
Unamortized discount on bridge loan at repayment			0	85,932
Changes in operating assets and liabilities:
Accounts receivable	(399,528)	291,273	432,814	(260,471)
Inventory	(23,824)	(81,321)	(11,273)	161,027
Other assets	429,558	(235,835)	486	(315,688)
Accounts payable	(301,376)	(219,565)	89,493	(563,357)
Accrued compensation and other liabilities	(285,953)	226,611	77,871	399,224
Deferred revenue	(5,831)	(10,320)	(8,618)	(12,955)
Net cash used in operating activities	(5,824,158)	(5,558,536)	(11,073,997)	(14,303,880)
Cash flows from investing activities
Purchases of property and equipment	(24,680)	(4,457)	(147,767)	(276,950)
Proceeds from sale of equipment	29,250	10,440	10,440	0
Net cash provided by investing activities	4,570	5,983	(137,327)	(276,950)
Cash flows from financing activities
Proceeds from issuance of common stock, net of issuance costs	4,782,509	192,320	597,743	3,808,836
Proceeds from issuance of units, net of selling costs	0	10,728,131	13,530,401	8,754,882
Proceeds from debt, net of issuance costs	15,481	309,900	381,253	1,168,222
Proceeds from exercise of stock options			0	76,537
Payments on debt	(237,414)	(55,582)	(371,573)	(1,255,198)
Payments on finance leases	(235,600)	(107,871)	(292,722)	(205,085)
Net cash provided by financing activities	4,324,976	11,066,898	13,845,102	12,348,194
Effects of exchange rates on cash	(1,321)	5,587	12,878	(37,517)
Net (decrease) increase in cash, cash equivalents and restricted cash	(1,495,933)	5,519,932	2,646,656	(2,270,153)
Cash, cash equivalents and restricted cash at beginning of period	4,737,207	2,090,551	2,090,551	4,360,704
Cash, cash equivalents and restricted cash at end of period	3,241,274	7,610,483	4,737,207	2,090,551
Supplemental disclosure of cash flow information
Cash paid for interest	97,599	17,785	57,393	48,211
Supplemental disclosures of noncash investing and financing activities:
Right-of-use assets acquired through finance leases	291,936	281,153
Shares issued to settle obligations			272,610	133,245
Property and equipment acquired through capital lease			706,778	0
Conversion of accounts payable to finance lease	$ 63,600	$ 174,968	156,775	0
Unpaid deferred offering costs			$ 0	$ 48,398

Organization

6 Months Ended

12 Months Ended

Jun. 30, 2019

Dec. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization

Note 1 – Organization

OpGen, Inc. (“OpGen” or the “Company”) was incorporated in Delaware in 2001. References in this report to the “Company” include OpGen and its wholly-owned subsidiaries. The Company’s headquarters and its principal operations are in Gaithersburg, Maryland. The Company also has operations in Copenhagen, Denmark, and Bogota, Colombia. The Company operates in one business segment.

OpGen is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. The Company is developing molecular information products and services for global healthcare settings, helping to guide clinicians with more rapid and actionable information about life threatening infections, improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. Its proprietary DNA tests and informatics address the rising threat of antibiotic resistance by helping physicians and other healthcare providers optimize care decisions for patients with acute infections.

The Company’s molecular diagnostics and informatics products, product candidates and services combine its Acuitas molecular diagnostics and Acuitas Lighthouse informatics platform for use with its proprietary, curated MDRO knowledgebase. The Company is working to deliver products and services, some in development, to a global network of customers and partners.

•

The Company’s Acuitas molecular diagnostic tests provide rapid microbial identification and antibiotic resistance gene information. These products include its Acuitas antimicrobial resistance, or AMR, Gene Panel (Urine) test in development for patients at risk for complicated urinary tract infection, or cUTI, and its Acuitas AMR Gene Panel (Isolates) test in development for testing bacterial isolates, and its QuickFISH and PNA FISH FDA-cleared and CE-marked diagnostics used to rapidly detect pathogens in positive blood cultures. Each of the Acuitas AMR Gene Panel tests is available for sale for research use only, or RUO.

•

The Company’s Acuitas Lighthouse informatics systems are cloud-based HIPAA compliant informatics offerings that combine clinical lab test results with patient and hospital information to provide analytics and actionable insights to help manage MDROs in the hospital and patient care environment. Components of the informatics systems include the Acuitas Lighthouse Knowledgebase and the Acuitas Lighthouse Software. The Acuitas Lighthouse Knowledgebase is a relational database management system and a proprietary data warehouse of genomic data matched with antibiotic susceptibility information for bacterial pathogens. The Acuitas Lighthouse Software system includes the Acuitas Lighthouse Portal, a suite of web applications and dashboards, the Acuitas Lighthouse Prediction Engine, which is a data analysis software, and other supporting software components. The Acuitas Lighthouse Software can be customized and made specific to a healthcare facility or collaborator, such as a pharmaceutical company. The Acuitas Lighthouse Software is not distributed commercially for antibiotic resistance prediction and is not for use in diagnostic procedures.

The Company’s operations are subject to certain risks and uncertainties. The risks include the risk that the Company will not receive 510(k) clearance for its Acuitas AMR Gene Panel tests and Acuitas Lighthouse Software on a timely basis, or at all, rapid technology changes, the need to retain key personnel, the need to protect intellectual property and the need to raise additional capital financing on terms acceptable to the Company. The Company’s success depends, in part, on its ability to develop, obtain regulatory approval for and commercialize its proprietary technology as well as raise additional capital.

Note 1 - Organization

OpGen, Inc. (“OpGen” or the “Company”) was incorporated in Delaware in 2001. References in this report to the “Company” include OpGen and its wholly-owned subsidiaries. The Company’s headquarters are in Gaithersburg, Maryland, and its principal operations are in Gaithersburg, Maryland. The Company also has operations in Woburn, Massachusetts, Copenhagen, Denmark, and Bogota, Colombia. The Company operates in one business segment.

OpGen, Inc. is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. The Company is developing molecular information products and services for global healthcare settings, helping to guide clinicians with more rapid and actionable information about life threatening infections, improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. Its proprietary DNA tests and informatics address the rising threat of antibiotic resistance by helping physicians and other healthcare providers optimize care decisions for patients with acute infections.

•

Liquidity and management's plans

6 Months Ended

12 Months Ended

Jun. 30, 2019

Dec. 31, 2018

Liquidation Basis Of Accounting Abstract [Abstract]

Liquidity and management's plans

Note 2 – Liquidity and management’s plans

The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Since inception, the Company has incurred, and continues to incur, significant losses from operations. The Company has funded its operations primarily through external investor financing transactions, including the following in 2018 and 2019 to date:

•

On March 29, 2019, the Company closed a public offering (the “March 2019 Public Offering”) of 9,000,000 shares of its common stock at a public offering price of $0.60 per share. The offering raised gross proceeds of $5.4 million and net proceeds of approximately $4.8 million.

•

On October 22, 2018, the Company closed a public offering (the “October 2018 Public Offering”) of 2,220,000 shares of its common stock at a public offering price of $1.45 per share. The offering raised gross proceeds of approximately $3.2 million and net proceeds of approximately $2.8 million.

•

On June 11, 2018, the Company executed an Allonge (the “Allonge”) to its Second Amended and Restated Senior Secured Promissory Note, dated June 28, 2017, with a principal amount of $1,000,000 issued to Merck Global Health Innovation Fund, LLC (“MGHIF”). The Allonge provided that accrued and unpaid interest of $285,512 due as of July 14, 2018, the original maturity date, be paid through the issuance of shares of OpGen’s common stock in a private placement transaction. In addition, the Allonge revised and extended the maturity date for payment of the Promissory Note to six semi-annual payments of $166,667 plus accrued and unpaid interest beginning on January 2, 2019 and ending on July 1, 2021. On July 30, 2018, the Company issued 144,238 shares of common stock to MGHIF in a private placement transaction for $285,512 of accrued and unpaid interest due as of July 14, 2018 under the MGHIF Note.

•

On February 6, 2018, the Company closed a public offering (the “February 2018 Public Offering”) of 2,841,152 units at $3.25 per unit, and 851,155 pre-funded units at $3.24 per pre-funded unit, raising gross proceeds of approximately $12 million and net proceeds of approximately $10.7 million. Each unit included one share of common stock and one common warrant to purchase 0.5 share of common stock at an exercise price of $3.25 per share. Each pre-funded unit included one pre-funded warrant to purchase one share of common stock for an exercise price of $0.01 per share, and one common warrant to purchase 0.5 share of common stock at an exercise price of $3.25 per share. The common warrants are exercisable immediately and have a five-year term from the date of issuance. The 851,155 pre-funded warrants issued in the February 2018 Public Offering were exercised during the year ended December 31, 2018.

•

On September 13, 2016, the Company entered into the Sales Agreement (the “Sales Agreement”) with Cowen and Company LLC (“Cowen”) pursuant to which the Company could offer and sell from time to time, up to an aggregate of $25 million of shares of its common stock through Cowen, as sales agent, with initial sales limited to an aggregate of $11.5 million. During the year ended December 31, 2018, the Company sold 318,236 shares of its common stock under this at the market offering resulting in aggregate net proceeds to the Company of approximately $0.6 million, and gross proceeds of $0.6 million. The at the market offering was terminated in connection with the October 2018 Public Offering.

To meet its capital needs, the Company is considering multiple alternatives, including, but not limited to, strategic financings or other transactions, additional equity financings, debt financings and other funding transactions, licensing and/or partnering arrangements and business combination transactions. There can be no assurance that the Company will be able to complete any such transaction on acceptable terms or otherwise. The Company believes that current cash will be sufficient to fund operations into the third quarter of 2019. This has led management to conclude that substantial doubt about the Company’s ability to continue as a going concern exists. In the event the Company is unable to successfully raise additional capital during or before the end of the third quarter of 2019, the Company will not have sufficient cash flows and liquidity to finance its business operations as currently contemplated. Accordingly, in such circumstances the Company would be compelled to immediately reduce general and administrative expenses and delay research and development projects, including the purchase of scientific equipment and supplies, until it is able to obtain sufficient financing. If such sufficient financing is not received on a timely basis, the Company would then need to pursue a plan to license or sell its assets, seek to be acquired by another entity, cease operations and/or seek bankruptcy protection.

Note 2 - Going Concern and Management’s Plans

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Since inception, the Company has incurred, and continues to incur, significant losses from operations. The Company has funded its operations primarily through external investor financing arrangements and significant actions taken by the Company to reduce costs, including:

•

On June 11, 2018, the Company executed an Allonge (the “Allonge”) to its Second Amended and Restated Senior Secured Promissory Note, dated June 28, 2017, with a principal amount of $1,000,000 issued to Merck Global Health Innovation Fund, LLC (“MGHIF”). The Allonge provided that accrued and unpaid interest of $285,512 due as of July 14, 2018, the original maturity date, be paid through the issuance of shares of OpGen’s common stock in a private placement transaction. In addition, the Allonge revised and extended the maturity date for payment of the Note to six semi-annual payments of $166,667 plus accrued and unpaid interest beginning on January 2, 2019 and ending on July 1, 2021. On July 30, 2018, the Company issued 144,238 shares of common stock to MGHIF in a private placement transaction for $285,512 of accrued and unpaid interest due as of July 14, 2018 under the MGHIF Note.

•

On February 6, 2018, the Company closed a public offering (the “February 2018 Public Offering”) of 2,841,152 units at $3.25 per unit, and 851,155 pre-funded units at $3.24 per pre-funded unit, raising gross proceeds of approximately $12 million and net proceeds of approximately $10.7 million. Each unit included one share of common stock and one common warrant to purchase 0.5 share of common stock at an exercise price of $3.25 per share. Each pre-funded unit included one pre-funded warrant to purchase one share of common stock for an exercise price of $0.01 per share, and one common warrant to purchase 0.5 share of common stock at an exercise price of $3.25 per share. The common warrants are exercisable immediately and have a five-year term from the date of issuance. As of April 19, 2018, all 851,155 pre-funded warrants issued in the February 2018 Public Offering have been exercised.

•

On July 18, 2017, the Company closed a public offering (the “July 2017 Public Offering”) of 18,164,195 units at $0.40 per unit, and 6,835,805 pre-funded units at $0.39 per pre-funded unit, raising gross proceeds of approximately $10 million and net proceeds of approximately $8.8 million. jVen Capital, LLC (“jVen Capital”) was one of the investors participating in the offering. jVen Capital is an affiliate of Evan Jones, the Company’s Chairman of the Board and Chief Executive Officer. Each unit included one twenty-fifth of a share of common stock and one common warrant to purchase one twenty-fifth of a share of common stock at an exercise price of $10.625 per share. Each pre-funded unit included one pre-funded warrant to purchase one twenty-fifth of a share of common stock for an exercise price of $0.25 per share, and one common warrant to purchase one twenty-fifth of a share of common stock at an exercise price of $10.625 per share. The common warrants are exercisable immediately and have a five-year term from the date of issuance. Approximately $1 million of the gross proceeds was used to repay the outstanding Bridge Financing Notes to jVen Capital in July 2017.

•

In early June 2017, the Company commenced a restructuring of its operations to improve efficiency and reduce its cost structure. Under the restructuring plan the Company is consolidating its operations, including manufacturing, for its FDA-cleared and CE marked QuickFISH and PNA FISH families of products and research and development activities for the Acuitas AMR Gene Panel products and services, in Gaithersburg, Maryland, and reducing the size of its commercial organization while the Company works to complete the development of its Acuitas AMR Gene Panel and Acuitas Lighthouse Knowledgebase products and services in development.

•

On May 31, 2017, the Company entered into a Note Purchase Agreement with jVen Capital, under which jVen Capital agreed to provide bridge financing in an aggregate principal amount of up to $1,500,000 to the Company in up to three separate tranches of $500,000 (each, a “Bridge Financing Note” and collectively, the “Bridge Financing Notes”). In connection with the issuance of Bridge Financing Notes, in June and July 2017, the Company issued jVen Capital stock purchase warrants to acquire 5,634 shares with an exercise price of $19.50 per share, and warrants to acquire 6,350 shares with an exercise price of $17.25 per share. The Company drew down on two of three Bridge Financing Notes during June and July 2017, and repaid such outstanding Bridge Financing Notes in full upon the closing of the July 2017 Public Offering.

•

On September 13, 2016, the Company entered into the Sales Agreement (the “Sales Agreement”) with Cowen and Company LLC (“Cowen”) pursuant to which the Company may offer and sell from time to time, up to an aggregate of $25 million of shares of its common stock through Cowen, as sales agent, with initial sales limited to an aggregate of $11.5 million. As of December 31, 2018, the Company sold an aggregate of 690,247 shares of its common stock under this at the market offering resulting in aggregate net proceeds to the Company of approximately $8.8 million, and gross proceeds of $9.4 million. During the year ended December 31, 2018, the Company has sold 318,236 shares of its common stock under this at the market offering resulting in aggregate net proceeds to the Company of approximately $0.6 million, and gross proceeds of $0.6 million. In connection with the October 2018 Public Offering, the Company terminated the at the market offering.

To meet its capital needs, the Company is considering multiple alternatives, including, but not limited to, strategic financings or other transactions, additional equity financings, debt financings and other funding transactions, licensing and/or partnering arrangements and business combination transactions. There can be no assurance that the Company will be able to complete any such transaction on acceptable terms or otherwise. The Company believes that current cash will be sufficient to fund operations into the second quarter of 2019. This has led management to conclude that substantial doubt about the Company’s ability to continue as a going concern exists. In the event the Company is unable to successfully raise additional capital during or before the second quarter of 2019, the Company will not have sufficient cash flows and liquidity to finance its business operations as currently contemplated. Accordingly, in such circumstances the Company would be compelled to immediately reduce general and administrative expenses and delay research and development projects, including the purchase of scientific equipment and supplies, until it is able to obtain sufficient financing. If such sufficient financing is not received on a timely basis, the Company would then need to pursue a plan to license or sell its assets, seek to be acquired by another entity, cease operations and/or seek bankruptcy protection.

Summary of significant accounting policies

6 Months Ended

12 Months Ended

Jun. 30, 2019

Dec. 31, 2018

Accounting Policies [Abstract]

Summary of significant accounting policies

Note 3 – Summary of significant accounting policies

Basis of presentation and consolidation

The Company has prepared the accompanying unaudited condensed consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and the standards of accounting measurement set forth in the Interim Reporting Topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”). Certain information and note disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted, although the Company believes that the disclosures made are adequate to make the information not misleading. The Company recommends that the unaudited condensed consolidated financial statements be read in conjunction with the audited consolidated financial statements and the notes thereto included in the Company’s 2018 Annual Report on Form 10-K. In the opinion of management, all adjustments that are necessary for a fair presentation of the Company’s financial position for the periods presented have been reflected. All adjustments are of a normal, recurring nature, unless otherwise stated. The interim condensed consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. The December 31, 2018 consolidated balance sheet included herein was derived from the audited consolidated financial statements, but does not include all disclosures including notes required by GAAP for complete financial statements.

The accompanying unaudited condensed consolidated financial statements include the accounts of OpGen and its wholly-owned subsidiaries; all intercompany transactions and balances have been eliminated.

Foreign currency

The Company has subsidiaries located in Copenhagen, Denmark, and Bogota, Colombia, both of which use currencies other than the U.S dollar as their functional currency. As a result, all assets and liabilities are translated into U.S. dollars based on exchange rates at the end of the reporting period. Income and expense items are translated at the average exchange rates prevailing during the reporting period. Translation adjustments are reported in accumulated other comprehensive loss, a component of stockholders’ equity. Foreign currency translation adjustments are the sole component of accumulated other comprehensive loss at June 30, 2019 and December 31, 2018.

Foreign currency transaction gains and losses, excluding gains and losses on intercompany balances where there is no current intent to settle such amounts in the foreseeable future, are included in the determination of net loss. Unless otherwise noted, all references to “$” or “dollar” refer to the U.S. dollar.

Use of estimates

In preparing financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In the accompanying unaudited condensed consolidated financial statements, estimates are used for, but not limited to, liquidity assumptions, revenue recognition, stock-based compensation, allowances for doubtful accounts and inventory obsolescence, discount rates used to discount unpaid lease payments to present values, valuation of derivative financial instruments measured at fair value on a recurring basis, deferred tax assets and liabilities and related valuation allowance, the estimated useful lives of long-lived assets, and the recoverability of long-lived assets. Actual results could differ from those estimates.

Fair value of financial instruments

Financial instruments classified as current assets and liabilities (including cash and cash equivalent, receivables, accounts payable, deferred revenue and short-term notes) are carried at cost, which approximates fair value, because of the short-term maturities of those instruments.

Cash, cash equivalents and restricted cash

The Company considers all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company has cash and cash equivalents deposited in financial institutions in which the balances occasionally exceed the federal government agency (“FDIC”) insured limit of $250,000. The Company has not experienced any losses in such accounts and management believes it is not exposed to any significant credit risk.

At June 30, 2019, the Company has funds totaling $185,380, which are required as collateral for letters of credit benefiting its landlords and for credit card processors. At December 31, 2018, the Company had funds totaling $164,720, which are required as collateral for letters of credit benefiting its landlords and for credit card processors. These funds are reflected in other noncurrent assets on the accompanying unaudited condensed consolidated balance sheets.

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the statements of cash flows:

	June 30, 2019		December 31, 2018		June 30, 2018		December 31, 2017
Cash and cash equivalents	$	3,055,894	$	4,572,487	$	7,428,993	$	1,847,171
Restricted cash		185,380		164,720		181,490		243,380
Total cash, cash equivalents and restricted cash in the condensed consolidated statement of cash flows	$	3,241,274	$	4,737,207	$	7,610,483	$	2,090,551

Accounts receivable

The Company’s accounts receivable result from revenues earned but not yet collected from customers. Credit is extended based on an evaluation of a customer’s financial condition and, generally, collateral is not required. Accounts receivable are due within 30 to 60 days and are stated at amounts due from customers. The Company evaluates if an allowance is necessary by considering a number of factors, including the length of time accounts receivable are past due, the Company’s previous loss history and the customer’s current ability to pay its obligation. If amounts become uncollectible, they are charged to operations when that determination is made. The allowance for doubtful accounts was $22,309 and $18,332 as of June 30, 2019 and December 31, 2018, respectively.

One individual customer represented 50% and 19% of revenues for the three months ended June 30, 2019 and 2018, respectively. One individual customer represented 49% and 21% of revenues for the six months ended June 30, 2019 and 2018, respectively. At June 30, 2019, one individual customer represented 65% of total accounts receivable. At December 31, 2018, one individual customer represented 12% of total accounts receivable.

Inventory

Inventories are valued using the first-in, first-out method and stated at the lower of cost or net realizable value and consist of the following:

	June 30, 2019		December 31, 2018
Raw materials and supplies	$	237,500	$	368,438
Work-in-process		135,916		58,402
Finished goods		194,006		116,907
Total	$	567,422	$	543,747

Inventory includes reagents and components for QuickFISH and PNA FISH kit products, and reagents and supplies used for the Company’s laboratory services. Inventory reserves for obsolescence and expirations were $114,327 and $71,270 at June 30, 2019 and December 31, 2018, respectively.

Long-lived assets

Property and equipment

Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. Recoverability measurement and estimating of undiscounted cash flows is done at the lowest possible level for which we can identify assets. If such assets are considered to be impaired, impairment is recognized as the amount by which the carrying amount of assets exceeds the fair value of the assets. During the three and six months ended June 30, 2019 and 2018, the Company determined that its property and equipment was not impaired.

Leases

The Company determines if an arrangement is a lease at inception. For leases where the Company is the lessee, right-of-use (“ROU”) assets represent the Company’s right to use the underlying asset for the term of the lease and the lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the future lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date of the underlying lease arrangement to determine the present value of lease payments. The ROU asset also includes any prepaid lease payments and any lease incentives received. The lease term to calculate the ROU asset and related lease liability includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option. The Company’s lease agreements generally do not contain any material variable lease payments, residual value guarantees or restrictive covenants.

Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while expense for financing leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition. The Company has made certain accounting policy elections whereby the Company (i) does not recognize ROU assets or lease liabilities for short-term leases (those with original terms of 12 months or less) and (ii) combines lease and non-lease elements of our operating leases.

ROU assets

ROU assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. Recoverability measurement and estimating of undiscounted cash flows is done at the lowest possible level for which the Company can identify assets. If such assets are considered to be impaired, impairment is recognized as the amount by which the carrying amount of assets exceeds the fair value of the assets. In conjunction with adoption of Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842) (“ASC 842”), the Company determined that the ROU asset associated with its Woburn, Massachusetts office lease may not be recoverable. As a result, the Company recorded an impairment charge of $520,759 during the six months ended June 30, 2019.

Intangible assets and goodwill

Intangible assets and goodwill as of June 30, 2019 consist of finite-lived intangible assets and goodwill.

Finite-lived intangible assets

Finite-lived intangible assets include trademarks, developed technology and customer relationships and consisted of the following as of June 30, 2019 and December 31, 2018:

			June 30, 2019					December 31, 2018
	Cost		Accumulated Amortization			Net Balance		Accumulated Amortization			Net Balance
Trademarks and trade names	$	461,000	$	(182,835	)	$	278,165	$	(159,783	)	$	301,217
Developed technology		458,000		(259,458	)		198,542		(226,746	)		231,254
Customer relationships		1,094,000		(619,249	)		474,751		(541,105	)		552,895
	$	2,013,000	$	(1,061,542	)	$	951,458	$	(927,634	)	$	1,085,366

Finite-lived intangible assets are amortized over their estimated useful lives. The estimated useful life of trademarks is 10 years, developed technology is 7 years, and customer relationships is 7 years. The Company reviews the useful lives of intangible assets when events or changes in circumstances occur which may potentially impact the estimated useful life of the intangible assets.

Total amortization expense of intangible assets was $66,954 for each of the three months ended June 30, 2019 and 2018. Total amortization expense of intangible assets was $133,908 for each of the six months ended June 30, 2019 and 2018.

Finite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. If any indicators were present, the Company would test for recoverability by comparing the carrying amount of the asset to the net undiscounted cash flows expected to be generated from the asset. If those net undiscounted cash flows do not exceed the carrying amount (i.e., the asset is not recoverable), the Company would perform the next step, which is to determine the fair value of the asset and record an impairment loss, if any. During the three and six months ended June 30, 2019 and 2018, the Company determined that its finite-lived intangible assets were not impaired.

In accordance with ASC 360-10, Property, Plant and Equipment, the Company records impairment losses on long-lived assets used in operations when events and circumstances indicate that long-lived assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amounts of those assets. During the fourth quarter of 2018, events and circumstances indicated the Company’s intangible assets might be impaired. However, management’s estimate of undiscounted cash flows indicated that such carrying amounts were expected to be recovered. Nonetheless, it is reasonably possible that the estimate of undiscounted cash flows may change in the near term resulting in the need to write down those assets to fair value. Management’s estimate of cash flows might change if there is an unfavorable development of sales trends.

Goodwill

Goodwill represents the excess of the purchase price paid in a July 2015 merger transaction in which the Company acquired AdvanDx, Inc. and its subsidiary (the “Merger”) over the fair values of the acquired tangible or intangible assets and assumed liabilities. Goodwill is not tax deductible in any relevant jurisdictions. The Company’s goodwill balance as of June 30, 2019 and December 31, 2018 was $600,814.

The Company conducts an impairment test of goodwill on an annual basis as of October 1 of each year, and will also conduct tests if events occur or circumstances change that would, more likely than not, reduce the Company’s fair value below its net equity value. During the three and six months ended June 30, 2019 and 2018, the Company determined that its goodwill was not impaired.

Revenue recognition

The Company derives revenues from (i) the sale of QuickFISH and PNA FISH diagnostic test products and Acuitas AMR Gene Panel RUO test products, (ii) providing laboratory services, and (iii) providing collaboration services including funded software arrangements, and license arrangements.

The Company analyzes contracts to determine the appropriate revenue recognition using the following steps: (i) identification of contracts with customers, (ii) identification of distinct performance obligations in the contract, (iii) determination of contract transaction price, (iv) allocation of contract transaction price to the performance obligations and (v) determination of revenue recognition based on timing of satisfaction of the performance obligation.

The Company recognizes revenues upon the satisfaction of its performance obligation (upon transfer of control of promised goods or services to our customers) in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services.

The Company defers incremental costs of obtaining a customer contract and amortizes the deferred costs over the period that the goods and services are transferred to the customer. The Company had no material incremental costs to obtain customer contracts in any period presented.

Deferred revenue results from amounts billed in advance to customers or cash received from customers in advance of services being provided.

Research and development costs

Research and development costs are expensed as incurred. Research and development costs primarily consist of salaries and related expenses for personnel, other resources, laboratory supplies, and fees paid to consultants and outside service partners.

Stock-based compensation

Stock-based compensation expense is recognized at fair value. The fair value of stock-based compensation to employees and directors is estimated, on the date of grant, using the Black-Scholes model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. For all time-vesting awards granted, expense is amortized using the straight-line attribution method. The Company accounts for forfeitures as they occur.

Option valuation models, including the Black-Scholes model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award.

Income taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the expected future tax consequences attributable to temporary differences between financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred income tax assets to the amount expected to be realized.

Tax benefits are initially recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions are initially, and subsequently, measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement with the tax authority, assuming full knowledge of the position and all relevant facts.

The Company had federal net operating loss (“NOL”) carryforwards of $178.2 million at December 31, 2018. Despite the NOL carryforwards, which begin to expire in 2022, the Company may have future tax liability due to alternative minimum tax or state tax requirements. Also, use of the NOL carryforwards may be subject to an annual limitation as provided by Section 382 of the Internal Revenue Code of 1986, as amended (the “Code”). To date, the Company has not performed a formal study to determine if any of its remaining NOL and credit attributes might be further limited due to the ownership change rules of Section 382 or Section 383 of the Code. The Company will continue to monitor this matter going forward. There can be no assurance that the NOL carryforwards will ever be fully utilized.

Loss per share

Basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period.

For periods of net income, and when the effects are not anti-dilutive, diluted earnings per share is computed by dividing net income available to common stockholders by the weighted average number of shares outstanding plus the impact of all potential dilutive common shares, consisting primarily of common stock options and stock purchase warrants using the treasury stock method, and convertible preferred stock and convertible debt using the if-converted method.

For periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive. The number of anti-dilutive shares, consisting of (i) common stock options, (ii) stock purchase warrants, and (iii) restricted stock units representing the right to acquire shares of common stock which have been excluded from the computation of diluted loss per share, was 4.0 million shares and 3.8 million shares as of June 30, 2019 and 2018, respectively.

Adopted accounting pronouncements

There have been no developments to the Recent Accounting Pronouncements discussion included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, including the expected dates of adoption and estimated effects on the Company’s condensed consolidated financial statements, except for the following:

In February 2016, the FASB issued ASC 842, which amends the existing accounting standards for leases. The guidance requires lessees to recognize assets and liabilities related to long-term leases on the balance sheet and expands disclosure requirements regarding leasing arrangements. The Company adopted this guidance effective January 1, 2019 using the modified retrospective transition method and the following practical expedients:

•

The Company did not reassess if any expired or existing contracts are or contain leases.

•

The Company did not reassess the classification of any expired or existing leases.

Additionally, the Company made ongoing accounting policy elections whereby the Company (i) does not recognize ROU assets or lease liabilities for short-term leases (those with original terms of 12 months or less) and (ii) combines lease and non-lease elements of our operating leases.

Upon adoption of the new guidance on January 1, 2019, the Company recorded an operating lease right of use asset of approximately $2.2 million (net of existing deferred rent) and recognized a lease liability of approximately $2.5 million.

In June 2018, the FASB issued ASU 2018-07: Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. This ASU expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from non-employees, and as a result, the accounting for share-based payments to non-employees will be substantially aligned. ASU 2018-07 is effective for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year, early adoption is permitted but no earlier than an entity’s adoption date of ASC 606. The adoption of this new guidance did not have a material impact on the Company’s condensed consolidated financial statements.

In August 2018, the SEC issued a final rule that amends certain disclosure requirements that were duplicative, outdated or superseded. In addition, the final rule expanded the financial reporting requirements for changes in stockholders’ equity for interim reporting periods. The Company adopted the new guidance on January 1, 2019 with no material impact to the condensed consolidated financial statements.

The Company has evaluated all other issued and unadopted ASUs and believes the adoption of these standards will not have a material impact on its results of operations, financial position or cash flows.

Note 3 - Summary of Significant Accounting Policies

Basis of Presentation

The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The consolidated financial statements consolidate the operations of all controlled subsidiaries; all intercompany activity is eliminated.

Foreign Currency

The Company has subsidiaries located in Copenhagen, Denmark, and Bogota, Colombia, both of which use currencies other than the U.S. dollar as their functional currency. As a result, all assets and liabilities are translated into U.S. dollars based on exchange rates at the end of the reporting period. Income and expense items are translated at the average exchange rates prevailing during the reporting period. Translation adjustments are reported in accumulated other comprehensive (loss)/income, a component of stockholders’ equity. Foreign currency translation adjustments are the sole component of accumulated other comprehensive (loss)/income at December 31, 2018 and 2017.

Use of Estimates

In preparing financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In the accompanying consolidated financial statements, estimates are used for, but not limited to, liquidity assumptions, revenue recognition, share-based compensation, allowances for doubtful accounts and inventory obsolescence, and valuation of derivative financial instruments measured at fair value on a recurring basis, deferred tax assets and liabilities and related valuation allowance, depreciation and amortization and estimated useful lives of long-lived assets. Actual results could differ from those estimates.

Fair value of financial instruments

For additional fair value disclosures, see Note 12.

Cash and cash equivalents and restricted cash

The Company considers all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company has cash and cash equivalents deposited in financial institutions in which the balances occasionally exceed the federal government agency (FDIC) insured limits of $250,000. The Company has not experienced any losses in such accounts, and management believes it is not exposed to any significant credit risk.

As of December 31, 2018 and 2017, the Company had funds totaling $164,720 and $243,380, respectively, which are required as collateral for letters of credit benefiting its landlords and for credit card processors. These funds are reflected in other noncurrent assets on the accompanying consolidated balance sheets.

Accounts Receivable

The Company’s accounts receivable result from revenues earned but not collected from customers. Credit is extended based on an evaluation of a customer’s financial condition and, generally, collateral is not required. Accounts receivable are due within 30 to 60 days and are stated at amounts due from customers. The Company evaluates if an allowance is necessary by considering a number of factors, including the length of time accounts receivable are past due, the Company’s previous loss history and the customer’s current ability to pay its obligation. If amounts become uncollectible, they are charged to operations when that determination is made. The allowance for doubtful accounts was $18,332 and $31,278 as of December 31, 2018 and 2017, respectively.

At December 31, 2018, the Company had accounts receivable from one customer which individually represented 12% of total accounts receivable. At December 31, 2017, the Company had accounts receivable from one customer which individually represented 41% of total accounts receivable. For the year ended December 31, 2018, revenue earned from one customer represented 17% of total revenues. For the year ended December 31, 2017, revenue earned from one customer represented 11% of total revenues.

Inventory

Inventories are valued using the first-in, first-out method and stated at the lower of cost or net realizable value and consist of the following:

	December 31,
	2018		2017
Raw materials and supplies	$	368,438	$	360,134
Work-in process		58,402		51,233
Finished goods		116,907		122,058
Total	$	543,747	$	533,425

Inventory includes reagents and components for QuickFISH and PNA FISH kit products, and reagents and supplies used for the Company’s laboratory services. Inventory reserves for obsolescence and expirations were $71,270 and $155,507 at December 31, 2018 and 2017, respectively.

Long-lived assets

Property and equipment

Property and equipment is stated at cost and depreciated on a straight-line basis over the estimated useful lives of the related assets. The estimated service lives approximate three to five years. Depreciation expense was $463,068 and $401,272 for the years ended December 31, 2018 and 2017, respectively. Property and equipment consisted of the following at December 31, 2018 and 2017:

	December 31,
	2018			2017
Laboratory and manufacturing equipment	$	4,829,323		$	4,109,367
Office furniture and equipment		700,299			700,299
Computers and network equipment		1,520,713			1,505,651
Leasehold improvements		745,800			729,504
		7,796,135			7,044,821
Less accumulated depreciation		(6,574,308	)		(6,209,284	)
Property and equipment, net	$	1,221,827		$	835,537

Property and equipment is reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. Recoverability measurement and estimating of undiscounted cash flows is done at the lowest possible level for which we can identify assets. If such assets are considered to be impaired, impairment is recognized as the amount by which the carrying amount of assets exceeds the fair value of the assets. During the years ended December 31, 2018 and 2017, the Company determined that its property and equipment was not impaired.

Intangible assets and goodwill

Intangible assets and goodwill as of December 31, 2018 and 2017 were acquired as part of a July 2015 merger transaction in which the Company acquired AdvanDx, Inc. and its subsidiary (the “Merger”) and consist of finite-lived intangible assets and goodwill.

Finite-lived intangible assets

Finite-lived intangible assets include trademarks, developed technology and customer relationships, and consisted of the following as of December 31, 2018 and 2017:

			December 31, 2018					December 31, 2017
	Cost		Accumulated Amortization			Net Balance		Accumulated Amortization			Net Balance
Trademarks and tradenames	$	461,000	$	(159,783	)	$	301,217	$	(113,679	)	$	347,321
Developed technology		458,000		(226,746	)		231,254		(161,322	)		296,678
Customer relationships		1,094,000		(541,105	)		552,895		(384,817	)		709,183
	$	2,013,000	$	(927,634	)	$	1,085,366	$	(659,818	)	$	1,353,182

Total amortization expense of intangible assets was $267,816 and $267,816 for the years ended December 31, 2018 and 2017, respectively. Expected amortization of intangible assets for each of the next five fiscal years is as follows.

Year Ending December 31,
2019	$	267,816
2020		267,816
2021		267,816
2022		165,117
2023		46,104
Thereafter		70,697
Total	$	1,085,366

Finite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. If any indicators were present, the Company would test for recoverability by comparing the carrying amount of the asset to the net undiscounted cash flows expected to be generated from the asset. If those net undiscounted cash flows do not exceed the carrying amount (i.e., the asset is not recoverable), the Company would perform the next step, which is to determine the fair value of the asset and record an impairment loss, if any. During the years ended December 31, 2018 and 2017, the Company determined that its finite-lived intangible assets were not impaired.

In accordance with ASC 360-10, the Company records impairment losses on long-lived assets used in operations when events and circumstances indicate that long-lived assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amounts of those assets. During 2018, events and circumstances indicated the Company’s intangible assets might be impaired. However, management’s estimate of undiscounted cash flows indicated that such carrying amounts were expected to be recovered. Nonetheless, it is reasonably possible that the estimate of undiscounted cash flows may change in the near term, resulting in the need to write down those assets to fair value.

Goodwill

Goodwill represents the excess of the purchase price for AdvanDx, Inc. and subsidiary (collectively, “AdvanDx”) over the fair values of the acquired tangible or intangible assets and assumed liabilities. Goodwill is not tax deductible in any relevant jurisdictions.

The Company conducts an impairment test of goodwill on an annual basis as of October 1 of each year, and will also conduct tests if events occur or circumstances change that would, more likely than not, reduce the Company’s fair value below its net equity value. As of December 31, 2018, the Company determined that its goodwill was not impaired.

Deferred rent

Deferred rent is recorded and amortized to the extent the total minimum rental payments allocated to the current period on a straight-line basis exceed or are less than the cash payments required.

Revenue recognition

Subsequent to the Adoption of Accounting Standards Codification Revenue from Contracts with Customers (“ASC 606”) on January 1, 2018

The Company derives revenues from (i) the sale of QuickFISH and PNA FISH diagnostic test products and Acuitas AMR Gene Panel (RUO) test products, (ii) providing laboratory services, and (iii) providing collaboration services including funded software arrangements, and license arrangements.

Deferred revenue results from amounts billed in advance to customers or cash received from customers in advance of services being provided.

For details about the Company’s revenue recognition policy prior to the adoption of ASC 606, refer to the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.

Research and development costs

Research and development costs are expensed as incurred. Research and development costs primarily consist of salaries and related expenses for personnel, other resources, laboratory supplies, fees paid to consultants and outside service partners.

Share-based compensation

Share-based compensation expense is recognized at fair value. The fair value of share-based compensation to employees and directors is estimated, on the date of grant, using the Black-Scholes model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. For all time-vesting awards granted, expense is amortized using the straight-line attribution method. The Company accounts for forfeitures as they occur.

Fair value of common stock

For periods prior to the Company’s IPO in May 2015, given the lack of an active public market for the common stock, the Company’s board of directors determined the fair value of the common stock. In the absence of a public market, and as an emerging company with no significant revenues, the Company believed that it was appropriate to consider a range of factors to determine the fair market value of the common stock at each grant date. The factors included: (1) the achievement of clinical and operational milestones by the Company; (2) the status of strategic relationships with collaborators; (3) the significant risks associated with the Company’s stage of development; (4) capital market conditions for life science and medical diagnostic companies, particularly similarly situated, privately held, early stage companies; (5) the Company’s available cash, financial condition and results of operations; (6) the most recent sales of the Company’s preferred stock; and (7) the preferential rights of the outstanding preferred stock. Since the IPO, the Company uses the quoted market price of its common stock as its fair value.

Expected volatility

Volatility is a measure of the amount by which a financial variable such as a share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. Until a significant trading history for its common stock develops, the Company has identified several public entities of similar size, complexity and stage of development; accordingly, historical volatility has been calculated using the volatility of this peer group.

Expected dividend yield

The Company has never declared or paid dividends on its common stock and has no plans to do so in the foreseeable future.

Risk-free interest rate

This is the U.S. Treasury rate for the day of each option grant during the year, having a term that most closely resembles the expected term of the option.

Expected term

This is the period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of 10 years. The Company estimates the expected term of the option to be 6.25 years for options with a standard four-year vesting period, using the simplified method. Over time, management will track actual terms of the options and adjust their estimate accordingly so that estimates will approximate actual behavior for similar options.

Income taxes

The Company had federal net operating loss (“NOL”) carryforwards of $178,163,456 and $165,981,195 at December 31, 2018 and 2017, respectively. Despite the NOL carryforwards, which begin to expire in 2022, the Company may have future tax liability due to alternative minimum tax or state tax requirements. Also, use of the NOL carryforwards may be subject to an annual limitation as provided by Section 382 of the Internal Revenue Code of 1986, as amended (the “Code”). To date, the Company has not performed a formal study to determine if any of its remaining NOL and credit attributes might be further limited due to the ownership change rules of Section 382 or Section 383 of the Code. The Company will continue to monitor this matter going forward. There can be no assurance that the NOL carryforwards will ever be fully utilized.

Loss per share

Basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period.

For periods of net income, and when the effects are not anti-dilutive, diluted earnings per share is computed by dividing net income available to common stockholders by the weighted-average number of shares outstanding plus the impact of all potential dilutive common shares, consisting primarily of common stock options and stock purchase warrants using the treasury stock method, and convertible preferred stock and convertible debt using the if-converted method.

For periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive. The number of anti-dilutive shares, consisting of (i) common stock options, (ii) stock purchase warrants, and (iii) restricted stock units representing the right to acquire shares of common stock which have been excluded from the computation of diluted loss per share, was 3.7 million shares and 1.6 million shares as of December 31, 2018 and 2017, respectively.

Adopted accounting pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) and International Accounting Standards Board (“IASB”) jointly issued a new revenue recognition standard, Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (“ASC 606”) that is designed to improve financial reporting by creating common recognition guidance for U.S. GAAP and International Financial Reporting Standards (“IFRS”). This guidance provides a robust framework for addressing revenue issues, improves the comparability of revenue recognition practices across industries, provides useful information to users of financial statements through improved disclosure requirements and simplifies the presentation of financial statements. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. From March to December 2016, amendments to the new revenue recognition standard were issued to clarify numerous accounting topics, including, but not limited to (i) the implementation guidance on principal versus agent considerations, (ii) the identification of performance obligations, (iii) the licensing implementation guidance, (iv) the objective of the collectability criterion, (v) the application of the variable consideration guidance and modified retrospective transition method, (vi) the way in which impairment testing is performed and (vii) the disclosure requirements for revenue recognized from performance obligations. This guidance permits the use of either a full retrospective method or a modified retrospective approach. The modified retrospective approach is applied only to the most current period presented along with a cumulative-effect adjustment at the date of adoption. This guidance became effective for annual reporting periods beginning after December 15, 2017.

On January 1, 2018, the Company adopted ASC 606, using the modified retrospective method. Results for reporting periods beginning subsequent to December 31, 2017 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported in accordance with the Company’s historical accounting policies prior to adoption. In adopting the guidance, the Company applied the guidance to all contracts and used available practical expedients including assessing contracts with similar terms and conditions on a “portfolio” basis. The adoption of this new guidance did not have a material impact on the Company’s condensed consolidated financial statements.

In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows: Restricted Cash, which addresses classification and presentation of changes in restricted cash on the statement of cash flows. The standard requires that restricted cash and restricted cash equivalents be included as components of total cash and cash equivalents as presented on the statement of cash flows. The Company adopted ASU 2016-18 using a retrospective transition method effective January 1, 2018 and applied to the periods presented on the condensed consolidated statements of cash flows. Restricted cash includes cash and cash equivalents that is restricted through legal contracts, regulations or the Company’s intention to use the cash for a specific purpose. The Company’s restricted cash primarily related to funds held as collateral for letters of credit.

	December 31, 2018		December 31, 2017		December 31, 2016
Cash and cash equivalents	$	4,572,487	$	1,847,171	$	4,117,324
Restricted cash		164,720		243,380		243,380
Total cash, cash equivalents and restricted cash in the consolidated statements of cash flows	$	4,737,207	$	2,090,551	$	4,360,704

Accounting pronouncements not yet adopted

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) (“ASC 842”), which amends the existing accounting standards for leases. The new standard requires lessees to record a right-of-use (“ROU”) asset and a corresponding lease liability on the balance sheet (with the exception of short-term leases), whereas under current accounting standards, the Company’s lease portfolio consists of operating leases and is not recognized on its consolidated balance sheets. The new standard also requires expanded disclosures regarding leasing arrangements. The new standard is effective for the Company beginning January 1, 2019. In July 2018, the FASB issued ASU 2018-11, Leases (Topic 842): Targeted Improvements, which provides an alternative modified transition method. Under this method, the cumulative-effect adjustment to the opening balance of retained earnings is recognized on the date of adoption with prior periods not restated.

The new standard provides a number of optional practical expedients in transition. The Company expects to elect: (1) the ‘package of practical expedients’, which permits it not to reassess under the new standard its prior conclusions about lease identification, lease classification, and initial direct costs; (2) the use-of-hindsight; and (3) the practical expedient pertaining to land easements. In addition, the new standard provides practical expedients for an entity’s ongoing accounting that the Company anticipates making, such as the (1) the election for certain classes of underlying asset to not separate non-lease components from lease components and (2) the election for short-term lease recognition exemption for all leases that qualify.

The Company will adopt ASC 842 as of January 1, 2019, using the alternative modified transition method. In preparation of adopting ASC 842, the Company is implementing additional internal controls to enable future preparation of financial information in accordance with ASC 842. The Company has also substantially completed its evaluation of the impact on the Company’s lease portfolio. The Company believes the largest impact will be on the consolidated balance sheets for the accounting of facilities-related leases, which represents a majority of its operating leases it has entered into as a lessee. These leases will be recognized under the new standard as ROU assets and operating lease liabilities. The Company will also be required to provide expanded disclosures for its leasing arrangements. As of December 31, 2018, the Company had $2.8 million of undiscounted future minimum operating lease commitments that are not recognized on its consolidated balance sheets as determined under the current standard. For a lessor, the results of operations are not expected to significantly change after adoption of the new standard.

While substantially complete, the Company is still in the process of finalizing its evaluation of the effect of ASC 842 on the Company’s consolidated financial statements and disclosures. The Company will finalize its accounting assessment and quantitative impact of the adoption during the first quarter of fiscal year 2019. As the Company completes its evaluation of this new standard, new information may arise that could change the Company’s current understanding of the impact to leases. Additionally, the Company will continue to monitor industry activities and any additional guidance provided by regulators, standards setters, or the accounting profession, and adjust the Company’s assessment and implementation plans accordingly.

In June 2018, the FASB issued ASU 2018-07: Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. This ASU expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from non-employees, and as a result, the accounting for share-based payments to non-employees will be substantially aligned. ASU 2018-07 is effective for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year, and early adoption is permitted but no earlier than an entity’s adoption date of ASC 606. The Company does not expect this new guidance will have a material impact on its financial statements and related disclosures.

Revenue from contracts with customers

6 Months Ended

12 Months Ended

Jun. 30, 2019

Dec. 31, 2018

Revenue from Contract with Customer [Abstract]

Revenue from contracts with customers

Note 4 – Revenue from contracts with customers

Disaggregated revenue

The Company provides diagnostic test products, laboratory services to hospitals, clinical laboratories and other healthcare provider customers, and enters into collaboration agreements with government agencies and healthcare providers. The revenues by type of service consist of the following:

	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
Product sales	$	504,293	$	632,525	$	1,024,470	$	1,266,021
Laboratory services		5,250		1,100		5,250		9,790
Collaboration revenue		500,000		155,276		1,000,000		359,316
Total revenue	$	1,009,543	$	788,901	$	2,029,720	$	1,635,127

Deferred revenue

Changes in deferred revenue for the period were as follows:

Balance at December 31, 2018	$	15,824
Revenue recognized in the current period from the amounts in the beginning balance		(5,831	)
New deferrals, net of amounts recognized in the current period		—
Balance at June 30, 2019	$	9,993

Contract assets

The Company had no contract assets as of June 30, 2019, which are generated when contractual billing schedules differ from revenue recognition timing. Contract assets represent a conditional right to consideration for satisfied performance obligations that becomes a billed receivable when the conditions are satisfied.

Unsatisfied performance obligations

Remaining contract consideration for which revenue has not been recognized due to unsatisfied performance obligations was $575,000 at June 30, 2019, which the Company expects to recognize over the next six months.

Note 4 - Revenue from Contracts with Customers

Disaggregated Revenue

	December 31,
	2018		2017
Product sales	$	2,395,626	$	2,771,869
Laboratory services		34,665		41,960
Collaboration revenue		516,016		397,178
Total revenue	$	2,946,307	$	3,211,007

Deferred Revenue

Changes in deferred revenue for the period were as follows:

Balance at December 31, 2017	$	24,442
Revenue recognized in the current period from the amounts in the beginning balance		(14,450	)
New deferrals, net of amounts recognized in the current period		5,832
Balance at December 31, 2018	$	15,824

Contract Assets

The Company had no contract assets as of December 31, 2018, which are generated when contractual billing schedules differ from revenue recognition timing. Contract assets represent a conditional right to consideration for satisfied performance obligations that becomes a billed receivable when the conditions are satisfied.

Unsatisfied Performance Obligations

The Company had no unsatisfied performance obligations related to its contracts with customers at December 31, 2018.

MGHIF financing

6 Months Ended

12 Months Ended

Jun. 30, 2019

Dec. 31, 2018

Common Stock And Note Purchase Agreement [Abstract]

MGHIF financing

Note 5 – MGHIF financing

On June 28, 2017, the MGHIF Note was amended and restated, and the maturity date of the MGHIF Note was extended by one year to July 14, 2018. As consideration for the agreement to extend the maturity date, the Company issued an amended and restated secured promissory note to MGHIF that (1) increased the interest rate to ten percent (10%) per annum and (2) provided for the issuance of common stock warrants to purchase 13,120 shares of its common stock to MGHIF.

On June 11, 2018, the Company executed an Allonge to the MGHIF Note. The Allonge provided that accrued and unpaid interest of $285,512 due as of July 14, 2018, the original maturity date, be paid through the issuance of shares of OpGen’s common stock in a private placement transaction. In addition, the Allonge revised and extended the maturity date for payment of the Note to six semi-annual payments of $166,667 plus accrued and unpaid interest beginning on January 2, 2019 and ending on July 1, 2021.

On July 30, 2018, the Company issued 144,238 shares of common stock to MGHIF in a private placement transaction for $285,512 of accrued and unpaid interest due as of July 14, 2018 under the MGHIF Note.

The Allonge to the MGHIF Note was treated as a debt modification and as such the unamortized issuance costs of approximately $7,000 as of June 11, 2018 are deferred and amortized as incremental expense over the term of the MGHIF Note.

Note 5 - MGHIF Financing

In July 2015, in connection with the Merger, the Company entered into a Purchase Agreement with MGHIF, pursuant to which MGHIF purchased 45,454 shares of common stock of the Company at $110.00 per share for gross proceeds of $5.0 million. Pursuant to the Purchase Agreement, the Company also issued to MGHIF an 8% Senior Secured Promissory Note (the “MGHIF Note”) in the principal amount of $1.0 million with a two-year maturity date from the date of issuance. Also in July 2015, the Company entered into a Registration Rights Agreement with MGHIF and certain stockholders, which will require the Company to register for resale by such holders in the future, such shares of Company common stock that cannot be sold under an exemption from such registration. The Company’s obligations under the MGHIF Note are secured by a lien on all of the Company’s assets.

The Allonge to the MGHIF Note was treated as a debt modification and as such the unamortized issuance costs of approximately $7,000 as of June 11, 2018 is deferred and amortized as incremental expense over the term of the MGHIF Note.

Fair value measurements

6 Months Ended

12 Months Ended

Jun. 30, 2019

Dec. 31, 2018

Fair Value Disclosures [Abstract]

Fair value measurements

Note 6 – Fair value measurements

The Company classifies its financial instruments using a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:

•

Level 1 - defined as observable inputs such as quoted prices in active markets;

•

Level 2 - defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and

•

Level 3 - defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions such as expected revenue growth and discount factors applied to cash flow projections.

For the six months ended June 30, 2019, the Company has not transferred any assets between fair value measurement levels.

Financial assets and liabilities measured at fair value on a recurring basis

The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the hierarchy.

As part of the Company’s bridge financing and amendment to the MGHIF Note, the Company issued stock purchase warrants that the Company considers to be mark-to-market liabilities due to certain put features that allow the holder to put the warrant back to the Company for cash equal to the Black-Scholes value of the warrant upon a change of control or fundamental transaction. The Company determines the fair value of the warrant liabilities using the Black-Scholes option pricing model. Using this model, level 3 unobservable inputs include the estimated volatility of the Company’s common stock, estimated terms of the instruments, and estimated risk-free interest rates.

The following table sets forth a summary of changes in the fair value of level 3 liabilities measured at fair value on a recurring basis for the six months ended June 30, 2019:

Description

Balance at

December 31,

2018

Change in

Fair Value

Balance at

June 30, 2019

Warrant liability

(67

)

—

Financial assets and liabilities carried at fair value on a non-recurring basis

The Company does not have any financial assets and liabilities measured at fair value on a non-recurring basis.

Non-financial assets and liabilities carried at fair value on a recurring basis

The Company does not have any non-financial assets and liabilities measured at fair value on a recurring basis.

Non-financial assets and liabilities carried at fair value on a non-recurring basis

The Company measures its long-lived assets, including property and equipment and intangible assets (including goodwill), at fair value on a non-recurring basis when they are deemed to be impaired. No such fair value impairment was recognized in the three and six months ended June 30, 2019 and 2018.

Note 12 - Fair Value Measurements

The Company classifies its financial instruments using a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:

•

Level 1 - defined as observable inputs such as quoted prices in active markets;

•

Level 2 - defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and

•

Financial assets and liabilities measured at fair value on a recurring basis

The Company originally accounted for the conversion option embedded in the Bridge Financing Notes as a mark-to-market derivative financial instrument. The Company determined the fair value of the embedded conversion option liability using a probability-weighted expected return method. Using this method, level 3 unobservable inputs include the probability of default, the probability of a qualified financing, the probability of conversion, the estimated volatility of the Company’s common stock, estimated terms of the instruments, and estimated risk-free interest rates, among other inputs. The fair value of the conversion option was expensed at the time of repayment of the Bridge Financing Notes.

The following table sets forth a summary of changes in the fair value of level 3 liabilities measured at fair value on a recurring basis for the year ended December 31, 2018:

Description

Balance at

December 31,

2017

Change in

Fair Value

Balance at

December 31,

2018

Warrant liability

8,453

(8,386

)

Financial assets and liabilities carried at fair value on a non-recurring basis

The Company does not have any financial assets and liabilities measured at fair value on a non-recurring basis.

Non-financial assets and liabilities carried at fair value on a recurring basis

The Company does not have any non-financial assets and liabilities measured at fair value on a recurring basis.

Non-financial assets and liabilities carried at fair value on a non-recurring basis

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Debt

6 Months Ended

12 Months Ended

Jun. 30, 2019

Dec. 31, 2018

Debt Disclosure [Abstract]

Debt

Note 7 – Debt

As of June 30, 2019, the Company’s outstanding short-term debt consisted of approximately $333,000 due under the MGHIF Note, as well as the financing arrangements for the Company’s insurance with note balances of approximately $10,000 with a final payment scheduled for February 2020. The Company’s outstanding long-term debt as of June 30, 2019 consisted of approximately $495,000 due under the MGHIF Note (see Note 5 “MGHIF financing”). As of December 31, 2018, the Company’s outstanding short-term debt consisted of $333,000 due under the MGHIF Note, net of discounts and financing costs, as well as the financing arrangements for the Company’s insurance with note balances of approximately $65,000. The Company’s outstanding long-term debt as of December 31, 2018 consisted of approximately $660,000 due under the MGHIF Note, net of discounts and financing costs. Total principal payments of approximately $333,000 are due annually in 2019, 2020, and 2021.

Total interest expense (including amortization of debt discounts and financing fees) on all debt instruments was $37,129 and $54,533 for the three months ended June 30, 2019 and 2018, respectively. Total interest expense (including amortization of debt discounts and financing fees) on all debt instruments was $93,573 and $112,379 for the six months ended June 30, 2019 and 2018, respectively.

Note 6 - Debt

As of December 31, 2018, the Company’s outstanding short-term debt consisted of approximately $333,000 due under the MGHIF Note, as well as, the financing arrangements for the Company’s insurance with note balances of approximately $65,000 with a final payment scheduled for April 2019. The Company’s outstanding long-term debt as of December 31, 2018 consisted of approximately $660,000 due under the MGHIF Note, net of discounts and financing costs (see Note 5 “MGHIF Financing”). As of December 31, 2017, the Company’s outstanding short-term debt consisted of the $1.0 million MGHIF Note, net of discounts and financing costs, as well as the financing arrangements for the Company’s insurance with note balances of approximately $56,000. The Company did not have any long-term debt as of December 31, 2017. Total principal payments of approximately $333,000 are due annually in 2019, 2020, and 2021.

The Company drew down on two of three Bridge Financing Notes (see discussion in Note 2 "Going Concern and Management’s Plans”) during June and July of 2017. The outstanding Bridge Financing Notes were repaid in full subsequent to the closing of the July 2017 Public Offering.

The Company accounted for the embedded conversion option granted to jVen Capital in the Bridge Financing Notes as a mark-to-market derivative financial instrument carried at fair value. Changes in fair value of the embedded conversion option were reflected in earnings during the period of change. The embedded conversion option was expensed along with the remaining unamortized discount at the date of the Bridge Financing Notes repayment. The warrants issued to jVen Capital and MGHIF are classified as mark-to-market liabilities under ASC 480 due to certain put features that allow the holder to put the warrant back to the Company for cash equal to the Black-Scholes value of the warrant upon a change of control or fundamental transaction.

Total interest expense (including amortization of debt discounts and financing fees) on all debt instruments was $191,195 and $233,505 for the years ended December 31, 2018 and 2017, respectively.

Stockholders' equity

6 Months Ended

12 Months Ended

Jun. 30, 2019

Dec. 31, 2018

Stockholders' Equity Note [Abstract]

Stockholders' equity

Note 8 – Stockholders’ equity

As of June 30, 2019, the Company has 50,000,000 authorized shares of common stock and 17,645,720 shares issued and outstanding, and 10,000,000 authorized shares of preferred stock, of which none were issued or outstanding.

In September 2016, the Company entered into the Sales Agreement with Cowen pursuant to which the Company could offer and sell from time to time, up to an aggregate of $25 million of shares of its common stock through Cowen, as sales agent, with initial sales limited to an aggregate of $11.5 million. During the year ended December 31, 2018, the Company sold 318,236 shares of its common stock under this at the market offering resulting in aggregate net proceeds to the Company of approximately $0.6 million, and gross proceeds of $0.6 million. In connection with the October 2018 Public Offering, the Company terminated the at the market offering.

In the February 2018 Public Offering, the Company issued 2,841,152 units at $3.25 per unit, and 851,155 pre-funded units at $3.24 per pre-funded unit, raising gross proceeds of approximately $12 million and net proceeds of approximately $10.7 million. Each unit included one share of common stock and one common warrant to purchase 0.5 share of common stock at an exercise price of $3.25 per share. Each pre-funded unit included one pre-funded warrant to purchase one share of common stock for an exercise price of $0.01 per share, and one common warrant to purchase 0.5 share of common stock at an exercise price of $3.25 per share. The common warrants were exercisable immediately and have a five-year term from the date of issuance. The 851,155 pre-funded warrants issued in the February 2018 Public Offering were exercised during the year ended December 31, 2018.

In connection with the February 2018 Public Offering, the Company issued to its placement agent warrants to purchase 184,615 shares of common stock. The warrants issued to the placement agent have an exercise price of $4.0625 per share and are exercisable for five years.

On October 22, 2018, the Company closed the October 2018 Public Offering of 2,220,000 shares of its common stock at a public offering price of $1.45 per share. The offering raised gross proceeds of approximately $3.2 million and net proceeds of approximately $2.8 million.

On March 29, 2019, the Company closed the March 2019 Public Offering of 9,000,000 shares of its common stock at a public offering price of $0.60 per share. The offering raised gross proceeds of $5.4 million and net proceeds of approximately $4.8 million.

Stock options

In 2008, the Company adopted the 2008 Stock Option and Restricted Stock Plan (the “2008 Plan”), pursuant to which the Company’s Board of Directors could grant either incentive or non-qualified stock options or shares of restricted stock to directors, key employees, consultants and advisors.

In April 2015, the Company adopted, and the Company’s stockholders approved, the 2015 Equity Incentive Plan (the “2015 Plan”); the 2015 Plan became effective upon the execution and delivery of the underwriting agreement for the Company’s initial public offering in May 2015. Following the effectiveness of the 2015 Plan, no further grants will be made under the 2008 Plan. The 2015 Plan provides for the granting of incentive stock options within the meaning of Section 422 of the Code to employees and the granting of non-qualified stock options to employees, non-employee directors and consultants. The 2015 Plan also provides for the grants of restricted stock, restricted stock units, stock appreciation rights, dividend equivalents and stock payments to employees, non-employee directors and consultants.

Under the 2015 Plan, the aggregate number of shares of the common stock authorized for issuance may not exceed (1) 54,200 plus (2) the sum of the number of shares subject to outstanding awards under the 2008 Plan as of the 2015 Plan’s effective date, that are subsequently forfeited or terminated for any reason before being exercised or settled, plus (3) the number of shares subject to vesting restrictions under the 2008 Plan as of the 2015 Plan’s effective date that are subsequently forfeited. In addition, the number of shares that have been authorized for issuance under the 2015 Plan will be automatically increased on the first day of each fiscal year beginning on January 1, 2016 and ending on (and including) January 1, 2025, in an amount equal to the lesser of (1) 4% of the outstanding shares of common stock on the last day of the immediately preceding fiscal year, or (2) another lesser amount determined by the Company’s Board of Directors. Shares subject to awards granted under the 2015 Plan that are forfeited or terminated before being exercised or settled, or are not delivered to the participant because such award is settled in cash, will again become available for issuance under the 2015 Plan. However, shares that have actually been issued shall not again become available unless forfeited. As of June 30, 2019, 84,412 shares remain available for issuance under the 2015 Plan, which includes 345,828 shares automatically added to the 2015 Plan on January 1, 2019.

For the three and six months ended June 30, 2019 and 2018, the Company recognized stock-based compensation expense as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
Cost of services	$	524	$	1,341	$	562	$	3,731
Research and development		18,333		61,080		35,460		130,551
General and administrative		61,365		140,158		137,378		292,340
Sales and marketing		5,749		11,311		10,604		25,458
	$	85,971	$	213,890	$	184,004	$	452,080

No income tax benefit for stock-based compensation arrangements was recognized in the condensed consolidated statements of operations and comprehensive loss due to the Company’s net loss position.

The Company did not grant any stock options during the three months ended June 30, 2019. During the three months ended June 30, 2019, 720 options were forfeited and no options expired. The Company did not grant any stock options during the six months ended June 30, 2019. During the six months ended June 30, 2019, 720 options were forfeited and 5 options expired. The Company had total stock options to acquire 210,834 shares of common stock outstanding at June 30, 2019.

Restricted stock units

During the six months ended June 30, 2019, 313,000 restricted stock units were granted, no restricted stock units vested and no restricted stock units were forfeited. The Company had 313,250 total restricted stock units outstanding at June 30, 2019.

Stock purchase warrants

At June 30, 2019 and December 31, 2018, the following warrants to purchase shares of common stock were outstanding:

				Outstanding at
Issuance	Exercise Price		Expiration	June 30, 2019		December 31, 2018
November 2009	$	197.75	November 2019		270		270
January 2010	$	197.75	January 2020		270		270
March 2010	$	197.75	March 2020		55		55
November 2011	$	197.75	November 2021		212		212
December 2011	$	197.75	December 2021		27		27
March 2012	$	2,747.50	March 2019		—		165
February 2015	$	165.00	February 2025		9,001		9,001
May 2015	$	165.00	May 2020		138,310		138,310
May 2016	$	32.81	May 2021		189,577		189,577
June 2016	$	32.81	May 2021		82,035		82,035
June 2017	$	19.50	June 2022		18,754		18,754
July 2017	$	17.25	July 2022		6,350		6,350
July 2017	$	12.50	July 2022		50,000		50,000
July 2017	$	10.63	July 2022		1,000,003		1,000,003
February 2018	$	4.06	February 2023		184,615		184,615
February 2018	$	3.25	February 2023		1,846,153		1,846,153
					3,525,632		3,525,797

The warrants listed above were issued in connection with various debt, equity or development contract agreements.

Note 7 - Stockholders’ Equity

As of December 31, 2018, the Company has 50,000,000 shares of authorized common shares and 8,645,720 shares issued and outstanding, and 10,000,000 of authorized preferred shares, of which none were issued or outstanding.

In September 2016, the Company entered into the Sales Agreement with Cowen pursuant to which the Company may offer and sell from time to time, up to an aggregate of $25 million of shares of its common stock through Cowen, as sales agent, with initial sales limited to an aggregate of $11.5 million. Pursuant to the Sales Agreement, Cowen may sell the shares of common stock by any method permitted by law deemed to be an “at the market” offering as defined in Rule 415 of the Securities Act, including, without limitation, sales made by means of ordinary brokers’ transactions on The Nasdaq Capital Market or otherwise at market prices prevailing at the time of sale, in block transactions, or as otherwise directed by the Company. The Company pays Cowen compensation equal to 3.0% of the gross proceeds from the sales of common stock pursuant to the terms of the Sales Agreement. As of December 31, 2018, the Company has sold an aggregate of 690,247 shares of its common stock under this at the market offering resulting in aggregate net proceeds to the Company of approximately $8.8 million, and gross proceeds of $9.4 million. During the year ended December 31, 2018, the Company sold 318,236 shares of its common stock under this at the market offering resulting in aggregate net proceeds to the Company of approximately $0.6 million, and gross proceeds of $0.6 million. In connection with the October 2018 Public Offering, the Company terminated the at the market offering.

In the July 2017 Public Offering, the Company issued 18,164,195 units at $0.40 per unit, and 6,835,805 pre-funded units at $0.39 per pre-funded unit, raising gross proceeds of approximately $10 million and net proceeds of approximately $8.8 million. jVen Capital was one of the investors participating in the offering. Each unit included one twenty-fifth of a share of common stock and one common warrant to purchase one twenty-fifth of a share of common stock at an exercise price of $10.625 per share. Each pre-funded unit included one pre-funded warrant to purchase one twenty-fifth of a share of common stock for an exercise price of $0.25 per share, and one common warrant to purchase one twenty-fifth of a share of common stock at an exercise price of $10.625 per share. The common warrants are exercisable immediately and have a five-year term from the date of issuance. At closing, the outstanding Bridge Financing Notes issued to jVen Capital, were repaid in the principal amount of $1 million plus accrued interest of $6,438. All pre-funded warrants issued in the July 2017 Public Offering were exercised during the year ended December 31, 2017.

In connection with the July 2017 Public Offering, the Company issued to its placement agent warrants to purchase 50,000 shares of common stock. The warrants issued to the Placement Agent have an exercise price of $12.50 per share and are exercisable for five years.

In September 2017, the Company issued 15,843 shares of its common stock with an aggregate value of $110,000 to settle a dispute related to pre-Merger AdvanDx activities. In October 2017, the Company issued 2,898 shares of its common stock with an aggregate value of $23,245 to a vendor in exchange for consulting services.

Following receipt of approval from stockholders at a special meeting of stockholders held on January 17, 2018, the Company filed an amendment to its Amended and Restated Certificate of Incorporation to effect a reverse stock split of the issued and outstanding shares of common stock, at a ratio of one share for twenty-five shares, and to reduce the authorized shares of common stock from 200,000,000 to 50,000,000 shares. All share amounts and per share prices in this Annual Report have been adjusted to reflect the reverse stock split.

In the February 2018 Public Offering, the Company issued 2,841,152 units at $3.25 per unit, and 851,155 pre-funded units at $3.24 per pre-funded unit, raising gross proceeds of approximately $12 million and net proceeds of approximately $10.7 million. Each unit included one share of common stock and one common warrant to purchase 0.5 share of common stock at an exercise price of $3.25 per share. Each pre-funded unit included one pre-funded warrant to purchase one share of common stock for an exercise price of $0.01 per share, and one common warrant to purchase 0.5 share of common stock at an exercise price of $3.25 per share. The common warrants are exercisable immediately and have a five-year term from the date of issuance. All 851,155 pre-funded warrants issued in the February 2018 Public Offering were exercised during the year ended December 31, 2018.

In connection with the February 2018 Public Offering, the Company issued to its placement agent warrants to purchase 184,615 shares of common stock. The warrants issued to the Placement Agent have an exercise price of $4.0625 per share and are exercisable for five years.

Stock options

In 2008, the Board adopted, and the stockholders approved, the 2008 Stock Option and Restricted Stock Plan (the “2008 Plan”), pursuant to which the Company’s Board of Directors may grant either incentive or non-qualified stock options or shares of restricted stock to directors, key employees, consultants and advisors.

In April 2015, the Board adopted, and the Company’s stockholders approved, the 2015 Equity Incentive Plan (the “2015 Plan”); the 2015 Plan became effective upon the execution and delivery of the underwriting agreement for the Company’s IPO. Following the effectiveness of the 2015 Plan, no further grants have been made under the 2008 Plan. The 2015 Plan provides for the granting of incentive stock options within the meaning of Section 422 of the Code to employees and the granting of non-qualified stock options to employees, non-employee directors and consultants. The 2015 Plan also provides for the grants of restricted stock, restricted stock units, stock appreciation rights, dividend equivalents and stock payments to employees, non-employee directors and consultants.

Under the 2015 Plan, the aggregate number of shares of the common stock authorized for issuance may not exceed (1) 54,200 plus (2) the sum of the number of shares subject to outstanding awards under the 2008 Plan as of the 2015 Plan’s effective date, that are subsequently forfeited or terminated for any reason before being exercised or settled, plus (3) the number of shares subject to vesting restrictions under the 2008 Plan as of the 2015 Plan’s effective date that are subsequently forfeited. In addition, the number of shares that have been authorized for issuance under the 2015 Plan will be automatically increased on the first day of each fiscal year beginning on January 1, 2016 and ending on (and including) January 1, 2025, in an amount equal to the lesser of (1) 4% of the outstanding shares of common stock on the last day of the immediately preceding fiscal year, or (2) another lesser amount determined by the Company’s Board of Directors. Shares subject to awards granted under the 2015 Plan that are forfeited or terminated before being exercised or settled, or are not delivered to the participant because such award is settled in cash, will again become available for issuance under the 2015 Plan. However, shares that have actually been issued shall not again become available unless forfeited. As of December 31, 2018, 50,863 shares remain available for issuance under the 2015 Plan.

For the years ended December 31, 2018 and 2017, the Company recognized stock compensation expense as follows:

	Year Ended December 31,
	2018		2017
Cost of services	$	964	$	13,776
Research and development		241,122		237,103
General and administrative		574,244		603,787
Sales and marketing		45,951		56,732
	$	862,281	$	911,398

No income tax benefit for stock-based compensation arrangements was recognized in the consolidated statements of operations due to the Company’s net loss position.

As of December 31, 2018, the Company had unrecognized expense related to its stock options of $0.5 million, which will be recognized over a weighted average period of 7.6 years.

A summary of the status of options granted is presented below as of and for the years ended December 31, 2018 and 2017:

	Number of Options			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life (in years)		Aggregate Intrinsic Value
Outstanding at January 1, 2017		119,106		$	44.00		8.6	$	663,298
Granted		58,324		$	17.58
Exercised		(1,167	)	$	7.01			$	11,256
Forfeited		(24,538	)	$	36.31
Expired		(12,330	)	$	83.49
Outstanding at December 31, 2017		139,395		$	31.16		8.3	$	37,339
Granted		95,800		$	3.84
Exercised		—			—
Forfeited		(18,812	)	$	11.98
Expired		(4,824	)	$	56.12
Outstanding at December 31, 2018		211,559		$	20.58		7.6	$	522
Vested and expected to vest		211,559		$	20.58		7.6	$	522
Exercisable at December 31, 2018		10,445		$	1.25		5.3	$	522

The total fair value of options vested in the years ended December 31, 2018 and 2017 was $930,921 and $2,086,843, respectively. The fair value of each option grant was estimated at the date of grant using the Black-Scholes option pricing model based on the assumptions below:

	Year Ended December 31,
	2018		2017
Annual dividend		—		—
Expected life (in years)	5.25 - 6.25		5.25 - 6.25
Risk free interest rate	2.5 - 2.9%		1.8 - 2.3%
Expected volatility	46.0 - 49.6%		44.2 - 53.0%

Restricted stock units

A summary of the status of restricted stock units granted is presented below as of and for the years ended December 31, 2018 and 2017:

	Number of Options			Weighted- Average Grant Date Fair Value
Unvested at January 1, 2017		750		$	42.50
Granted		11,175		$	6.93
Vested		(6,025	)	$	8.01
Forfeited		—			—
Unvested at December 31, 2017		5,900		$	31.16
Granted		—			—
Vested		(5,650	)	$	8.93
Forfeited		—			—
Unvested at December 31, 2018		250		$	42.50

As of December 31, 2018, there was approximately $9,000 of unrecognized compensation cost related to restricted stock units, which is expected to be recognized over a weighted average period of 0.92 years.

Stock purchase warrants

At December 31, 2018 and 2017, the following warrants to purchase shares of common stock were outstanding:

				Outstanding at December 31,
Issuance	Exercise Price		Expiration	2018 (1)		2017 (1)
March 2008	$	19,763.50	March 2018		—		2
November 2009	$	197.75	November 2019		270		270
January 2010	$	197.75	January 2020		270		270
March 2010	$	197.75	March 2020		55		55
November 2011	$	197.75	November 2021		212		212
December 2011	$	197.75	December 2021		27		27
March 2012	$	2,747.50	March 2019		165		165
February 2015	$	165.00	February 2025		9,001		9,001
May 2015	$	165.00	May 2020		138,310		138,310
May 2016	$	32.81	May 2021		189,577		189,577
June 2016	$	32.81	May 2021		82,035		82,035
June 2017	$	19.50	June 2022		18,754		18,754
July 2017	$	17.25	July 2022		6,350		6,350
July 2017	$	12.50	July 2022		50,000		50,000
July 2017	$	10.625	July 2022		1,000,003		1,000,003
February 2018	$	4.06	February 2023		184,615		—
February 2018	$	3.25	February 2023		1,846,153		—
					3,525,797		1,495,031

The warrants listed above were issued in connection with various equity, debt, preferred stock or development contract agreements.

(1)	Warrants to purchase fractional shares of common stock resulting from the reverse stock split on January 17, 2018 were rounded up to the next whole share of common stock on a holder by holder basis.

Income Taxes

12 Months Ended

Dec. 31, 2018

Income Tax Disclosure [Abstract]

Income Taxes

Note 8 - Income Taxes

At December 31, 2018 and 2017, the Company had net deferred tax assets of $52,348,036 and $49,251,408, respectively, primarily consisting of NOL carryforwards, research and experimental (“R&E”) credits, and differences between depreciation and amortization recorded for financial statement and tax purposes. The Company’s net deferred tax assets at December 31, 2018 and 2017 have been offset by a valuation allowance of $52,348,036 and $49,251,408, respectively. The valuation allowance has been recorded due to the uncertainty of realization of the deferred tax assets. The Company’s deferred tax assets and liabilities as of December 31, 2018 and 2017 are as follows:

	December 31,
	2018			2017
Deferred tax assets:
NOL carryforward	$	49,480,731		$	46,326,407
R&E credit carryforward		2,559,479			2,559,479
Share-based compensation		329,796			345,088
Inventory reserve		19,068			45,338
Depreciation		—			71,756
Interest expense		51,152			—
Accruals and other		284,662			247,093
Total deferred tax assets		52,724,888			49,595,161
Valuation allowance		(52,348,036	)		(49,251,408	)
Deferred tax liabilities:
Intangible assets		(256,011	)		(343,753	)
Depreciation		(120,841	)		—
Net	$	—		$	—

The difference between the Company’s expected income tax provision (benefit) from applying federal statutory tax rates to the pre-tax loss and actual income tax provision (benefit) relates to the effect of the following:

	2018			2017
Federal income tax benefit at statutory rates		21.0	%		34.0	%
Permanent adjustment		(1.4	)%		—
Provision to return adjustment		(0.2	)%		—
State income tax benefit, net of Federal benefit		(6.4	)%		6.8	%
Tax reform impact		—			(134.5	)%
Change in valuation allowance		(13.0	)%		93.0	%
Change in state tax rates and other		—			0.7	%
		0.0	%		0.0	%

The Company has federal NOL carryforwards of $178,163,456 and $165,981,195 at December 31, 2018 and 2017, respectively. The NOL carryforwards incurred prior to 2018 begin to expire in 2022. Under the Tax Cuts and Jobs Act (the Tax Act), the amount of post 2017 NOLs that we are permitted to deduct in any taxable year is limited to 80% of our taxable income in such year, where taxable income is determined without regard to the NOL deduction itself. In addition, the Tax Act generally eliminates the ability to carry back any NOL to prior taxable years, while allowing post 2017 unused NOLs to be carried forward indefinitely. Utilization of the NOL carryforward may be subject to an annual limitation as provided by Section 382 of the Internal Revenue Code. There can be no assurance that the NOL carryforward will ever be fully utilized. To date, the Company has not performed a formal study to determine if any of its remaining NOL and credit attributes might be further limited due to the ownership change rules of Section 382 or Section 383 of the Internal Revenue Code of 1986, as amended. The Company will continue to monitor this matter going forward. There can be no assurance that the NOL carryforwards will ever be fully utilized.

In December 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the "Tax Act"), most of the provisions of which took effect starting in 2018. The Tax Act made broad and complex changes to the U.S. tax code, including, but not limited to: (i) reducing the U.S. federal corporate tax rate from 35 percent to 21 percent; (ii) eliminating the corporate alternative minimum tax (AMT) and changing how existing AMT credits can be realized; (iii) creating a new limitation on deductible interest expense; and (iv) changing rules related to uses and limitations of net operating loss carryforwards created in tax years beginning after December 31, 2017; and (v) changing the U.S. federal taxation of earnings of foreign subsidiaries. The U.S. change in federal taxation for foreign subsidiary earnings included a one-time toll charge on deemed repatriated earnings of foreign subsidiaries as of December 31, 2017. As a result of the accumulated losses in the Company’s foreign subsidiary, the Company had no toll tax liability for the tax year ended December 31, 2017. For 2018, the Company considered in its estimated annual effective tax rate additional provisions of Tax Reform including changes to the deduction for interest expense pursuant to IRC Section 163(j) interest limitation.

As a result, the most significant impact on the Company’s consolidated financial statements was the reduction of approximately $14.6 million of the deferred tax assets related to net operating losses and other deferred tax assets. Such reduction is offset by a change in the Company’s valuation allowance. Additionally, the Company has foreign subsidiaries. At December 31, 2017 and November 2, 2017, the cumulative earnings and profits of these entities were negative. Accordingly, the Company was not liable for the transition tax on foreign earnings enacted under the Tax Act.

Commitments

6 Months Ended

12 Months Ended

Jun. 30, 2019

Dec. 31, 2018

Commitments and Contingencies Disclosure [Abstract]

Commitments

Note 9 – Commitments

Registration and other stockholder rights

In connection with the various investment transactions, the Company entered into registration rights agreements with stockholders, pursuant to which the investors were granted certain demand registration rights and/or piggyback and/or resale registration rights in connection with subsequent registered offerings of the Company’s common stock.

Supply agreements

In June 2017, the Company entered into an agreement with Life Technologies Corporation (“LTC”) to supply the Company with QuantStudio 5 Real-Time PCR Systems (“QuantStudio 5”) to be used to run OpGen’s Acuitas AMR Gene Panel tests. Under the terms of the agreement, the Company must notify LTC of the number of QuantStudio 5s that it commits to purchase in the following quarter. As of June 30, 2019, the Company has acquired twenty-one QuantStudio 5s including six in the six months ended June 30, 2019. As of June 30, 2019, the Company has committed to acquiring an additional three QuantStudio 5s at a total cost of approximately $135,000 in the next three months.

Note 9 - Commitments

Operating leases

The Company leases a facility in Gaithersburg, Maryland under an operating lease that expires January 31, 2021, with one additional five-year renewal at the Company’s election. The Company also leases a facility in Woburn, Massachusetts under an operating lease that expires January 30, 2022. Additionally, the Company leases office space in Denmark; this lease is currently on a month-to-month basis.

Rent expense under the Company’s facility operating leases for the year ended December 31, 2018 and 2017 was $984,639 and $949,244, respectively.

Capital leases

The Company leases lab equipment, office furniture, and computer equipment under various capital leases. The leases expire at various dates through 2021. The leases require monthly principal and interest payments. Following is a schedule by year of the estimated future minimum payments under all operating and capital leases as of December 31, 2018:

Year ending December 31,	Capital Leases			Operating Leases		Total
2019	$	508,114		$	1,107,565	$	1,615,679
2020		408,264			1,125,940		1,534,204
2021		104,579			535,250		639,829
2022		—			40,080		40,080
2023 and thereafter		—			—		—
Total		1,020,957		$	2,808,835	$	3,829,792
Less: amount representing interest		(96,251	)
Less: amount representing service costs		(88,172	)
Net present value of future minimum lease payments		836,534
Current maturities		(399,345	)
Long-term maturities	$	437,189

Assets under capital leases were included in the following balance sheet categories as of December 31:

	2018			2017
Laboratory and manufacturing equipment	$	1,563,346		$	850,792
Office furniture and equipment		64,790			64,790
Computers and network equipment		24,350			24,350
Less accumulated amortization		(749,480	)		(454,471	)
Capital lease assets, net	$	903,006		$	485,461

Amortization expense associated with equipment under capital leases for the years ended December 31, 2018 and 2017 was $295,009 and $161,606, respectively, and is included within depreciation and amortization expense in the consolidated statements of operations.

Registration and other stockholder rights

Restructuring

In early June 2017, the Company commenced a restructuring of its operations to improve efficiency and reduce its cost structure. The restructuring plans anticipate that the Company will consolidate operations for FDA-cleared and CE marked products and research and development activities for the Acuitas Rapid Test in Gaithersburg, Maryland, and reduce the size of its commercial organization while the Company works to complete the development of its Acuitas Rapid Test and Acuitas Lighthouse Knowledgebase products and services in development.

There were approximately $121,000 of one-time termination benefits that were recognized during the year ended December 31, 2017 related to the restructuring. The Company does not anticipate any further one-time termination benefits related to the restructuring plan. Retention agreements were issued to certain employees in which retention bonuses are earned and paid upon the completion of a designated service period. The service periods ended in December 2017. The Company incurred total retention expense of approximately $68,000 during the year ended December 31, 2017. The future minimum lease payments for the Woburn facility were approximately $1.4 million as of December 31, 2018. A liability for costs that will continue to be incurred under a contract for its remaining term without economic benefit to the entity shall be recognized at the cease-use date. If the contract is an operating lease the fair value of the liability at the cease-use date shall be determined based on the remaining lease rentals, adjusted for the effects of any prepaid or deferred items recognized under the lease, and reduced by estimated sublease rentals that could be reasonably obtained for the property. The Company expects the cease-use date for the Woburn facility to be in the first quarter of 2019. We do not believe there will be significant additional costs related to restructuring outside of what is described herein.

Supply Agreements

In June 2017, the Company entered into an agreement with Life Technologies Corporation, a subsidiary of Thermo Fisher Scientific (“LTC”) to supply the Company with Thermo Fisher Scientific’s QuantStudio 5 Real-Time PCR Systems (“QuantStudio 5”) to be used to run OpGen’s Acuitas AMR Gene Panel tests. Under the terms of the agreement the Company must notify LTC of the number of QuantStudio 5s that it commits to purchase in the following quarter. As of December 31, 2018 the Company has acquired fifteen QuantStudio 5s including eleven in the twelve months ended December 31, 2018. As of December 31, 2018 the Company has committed to acquiring an additional three QuantStudio 5s at a total cost of approximately $135,000 in the next three months.

Leases

6 Months Ended

Jun. 30, 2019

Leases [Abstract]

Leases

Note 10 – Leases

The following table presents the Company’s ROU assets and lease liabilities as of June 30, 2019:

Lease Classification	June 30, 2019
ROU Assets:
Operating	$	1,381,830
Financing		984,742
Total ROU assets	$	2,366,572
Liabilities
Current:
Operating	$	958,992
Finance		576,322
Noncurrent:
Operating		1,071,677
Finance		379,825
Total lease liabilities	$	2,986,816

Maturities of lease liabilities as of June 30, 2019 by fiscal year are as follows:

Maturity of Lease Liabilities	Operating			Finance			Total
2019	$	558,109		$	332,786		$	890,895
2020		1,128,138			520,947			1,649,085
2021		536,819			166,318			703,137
2022		40,080			11,240			51,320
2023		—			3,644			3,644
Thereafter		—			—			—
Total lease payments		2,263,146			1,034,935			3,298,081
Less: Interest		(232,477	)		(78,788	)		(311,265	)
Present value of lease liabilities	$	2,030,669		$	956,147		$	2,986,816

Statement of operations classification of lease costs are as follows:

		June 30, 2019
Lease Cost	Classification	Three months ended		Six months ended
Operating	Operating expenses	$	218,673	$	439,595
Finance:
Amortization	Operating expenses		107,496		204,689
Interest expense	Other expenses		19,297		41,778
Total lease costs		$	345,466	$	686,062

Other Information	Total
Weighted average remaining lease term (in years)
Operating leases		2.1
Finance leases		1.8
Weighted average discount rate:
Operating leases		10.0	%
Finance leases		9.2	%

Supplemental Cash Flow Information	Total
Cash paid for amounts included in the measurement of lease liabilities
Cash used in operating activities
Operating leases	$	439,595
Finance leases	$	41,778
Cash used in financing activities
Finance leases	$	235,600
ROU assets obtained in exchange for lease obligations:
Finance leases	$	355,536

Lease Commitments as of December 31, 2018

Minimum lease payments for future years as of December 31, 2018 were as follows:

Year ending December 31,	Total
2019	$	1,615,679
2020		1,534,204
2021		639,829
2022		40,080
2023 and thereafter		—
Total	$	3,829,792

License Agreements, Research Collaborations and Development Agreements

6 Months Ended

12 Months Ended

Jun. 30, 2019

Dec. 31, 2018

License Agreements Research Collaborations And Development Agreements [Abstract]

License Agreements, Research Collaborations and Development Agreements

Note 11 – License agreements, research collaborations and development agreements

In 2018, the Company announced a collaboration with the New York State Department of Health (“DOH”) and ILÚM Health Solutions, LLC (“ILÚM”), a wholly-owned subsidiary of Merck’s Healthcare Services and Solutions division, to develop a state-of-the-art research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions statewide. The Company is working together with DOH’s Wadsworth Center and ILÚM to develop an infectious disease digital health and precision medicine platform that connects healthcare institutions to DOH and uses genomic microbiology for statewide surveillance and control of antimicrobial resistance. As part of the collaboration, the Company will receive $1.6 million over the 12 month demonstration portion of the project. The demonstration project began in early 2019. During the three and six months ended June 30, 2019, the Company recognized $500,000 and $1.0 million of revenue related to the contract, respectively.

The Company is a party to one license agreement to acquire certain patent rights and technologies related to its FISH product line. Royalties are incurred upon the sale of a product or service which utilizes the licensed technology. The Company recognized net royalty expense of $62,500 for each of the three months ended June 30, 2019 and 2018. The Company recognized net royalty expense of $125,000 for each of the six months ended June 30, 2019 and 2018. Annual future minimum royalty fees are $250,000 under this agreement.

Note 10 - License Agreements, Research Collaborations and Development Agreements

The Company is a party to one license agreement to acquire certain patent rights and technologies related to its FISH product line. Royalties are incurred upon the sale of a product or service which utilizes the licensed technology. Certain of the agreements require the Company to pay minimum royalties or license maintenance fees. The Company recognized net royalty expense of $250,000 and $257,186 for the years ended December 31, 2018 and 2017, respectively. Annual future minimum royalty fees are $250,000 under these agreements.

In September 2017, the Company was awarded a contract from the Centers for Disease Control and Prevention (“CDC”) to develop smartphone-based clinical decision support solutions for antimicrobial stewardship, or AMS, and infection control in low- and middle-income countries. The one-year $860,000 award began September 30, 2017 and funds development and evaluation of cloud-based mobile software. The Company worked with subcontractors Ilúm, LLC, an affiliate of Merck, and Universidad El Bosque (“UEB”) of Bogota, Colombia under this CDC contract. During the years ended December 31, 2018 and 2017, the Company recognized $503,881 and $357,178 of revenue related to the contract, respectively.

In June 2016, the Company entered into a license agreement with Hitachi, pursuant to which it resolved various matters with respect to previously delivered milestones under the technology development agreement and provided a development license and commercial products license to certain technology. The license agreement contains non-contingent multiple elements (the licenses) that the Company determined did not have stand alone value, and a contingent substantive milestone. The licenses are treated as a single unit of accounting and the Company will recognize the revenue associated with that unit of accounting over the applicable license period. During the years ended December 31, 2018 and 2017, the Company recognized $12,397 and $25,000 of revenue related to the license agreement, respectively.

Related Party Transactions

6 Months Ended

12 Months Ended

Jun. 30, 2019

Dec. 31, 2018

Related Party Transactions

Note 12 – Related party transactions

In October 2016, the Company entered into an agreement with Merck Sharp & Dohme Corp. (“MSD”), a wholly-owned subsidiary of Merck, and an affiliate of MGHIF, a principal stockholder of the Company and a related party to the Company. Under the agreement, MSD provided access to its archive of over 200,000 bacterial pathogens. The Company is initially performing molecular analyses on up to 10,000 pathogens to identify markers of resistance to support rapid decision making using the Acuitas Lighthouse, and to speed development of its rapid diagnostic products. MSD gains access to the high-resolution genotype data for the isolates as well as access to the Acuitas Lighthouse informatics to support internal research and development programs. The Company is required to expend up to $175,000 for the procurement of materials related to the activities contemplated by the agreement. Contract life-to-date, the Company has incurred $171,646 of procurement costs which have been recognized as research and development expense. The Company recognized research and development expense of $0 and $22,604 related to the agreement in the three months ended June 30, 2019 and 2018, respectively. The Company recognized research and development expense of $0 and $22,604 related to the agreement in the six months ended June 30, 2019 and 2018, respectively.

In December 2017, the Company entered into a subcontractor agreement with ILÚM, whereby ILÚM will provide services to the Company in the performance of the Company’s CDC contract to deploy ILÚM’s commercially-available cloud- and mobile-based software platform for infectious disease management in up to three medical sites in Colombia with the aim of improving antibiotic use in resource-limited settings. The Company recognized $0 and $84,853 of cost of services expense related to the contract in the three months ended June 30, 2019 and 2018, respectively. The Company recognized $0 and $198,665 of cost of services expense related to the contract in the six months ended June 30, 2019 and 2018, respectively.

Note 11 - Related Party Transactions

In October 2016, the Company entered into an agreement with Merck Sharp & Dohme, a wholly-owned subsidiary of Merck Co. & Inc. (“Merck”), an affiliate of MGHIF, a principal stockholder of the Company and a related party to the Company. Under the agreement, Merck provided access to its archive of over 200,000 bacterial pathogens. The Company is initially performing molecular analyses on up to 10,000 pathogens to identify markers of resistance to support rapid decision making using the Acuitas Lighthouse, and to speed development of its rapid diagnostic products. Merck gains access to the high-resolution genotype data for the isolates as well as access to the Acuitas Lighthouse informatics to support internal research and development programs. The Company is required to expend up to $175,000 for the procurement of materials related to the activities contemplated by the agreement. Contract life-to-date, the Company has incurred $171,646 of procurement costs which have been recognized as research and development expense, including $22,603 and $146,177 during the years ended December 31, 2018 and 2017.

In December 2017, we entered into a subcontractor agreement with ILÚM Health Solutions, LLC, an entity created by Merck’s Healthcare Services and Solutions division, whereby ILÚM Health Solutions provided services to the Company in the performance of the Company’s CDC contract to deploy ILÚM’s commercially-available cloud- and mobile-based software platform for infectious disease management in up to three medical sites in Colombia with the aim of improving antibiotic use in resource-limited settings. During the years ended December 31, 2018 and 2017, the Company recognized $329,162 and $210,180 of cost of services expense related to the contract, respectively.

Subsequent events	12 Months Ended
Subsequent events	Dec. 31, 2018
Subsequent Events [Abstract]
Subsequent events

Summary of significant accounting policies (Policies)

6 Months Ended

12 Months Ended

Jun. 30, 2019

Dec. 31, 2018

Accounting Policies [Abstract]

Basis of presentation and consolidation

Basis of Presentation

Foreign currency

Foreign Currency

Use of estimates

Use of Estimates

Fair value of financial instruments

For additional fair value disclosures, see Note 12.

Cash, cash equivalents and restricted cash

	June 30, 2019		December 31, 2018		June 30, 2018		December 31, 2017
Cash and cash equivalents	$	3,055,894	$	4,572,487	$	7,428,993	$	1,847,171
Restricted cash		185,380		164,720		181,490		243,380
Total cash, cash equivalents and restricted cash in the condensed consolidated statement of cash flows	$	3,241,274	$	4,737,207	$	7,610,483	$	2,090,551

Cash and cash equivalents and restricted cash

The Company considers all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company has cash and cash equivalents deposited in financial institutions in which the balances occasionally exceed the federal government agency (FDIC) insured limits of $250,000. The Company has not experienced any losses in such accounts, and management believes it is not exposed to any significant credit risk.

Accounts receivable

Accounts Receivable

Inventory

Inventories are valued using the first-in, first-out method and stated at the lower of cost or net realizable value and consist of the following:

	June 30, 2019		December 31, 2018
Raw materials and supplies	$	237,500	$	368,438
Work-in-process		135,916		58,402
Finished goods		194,006		116,907
Total	$	567,422	$	543,747

Inventory

Inventories are valued using the first-in, first-out method and stated at the lower of cost or net realizable value and consist of the following:

	December 31,
	2018		2017
Raw materials and supplies	$	368,438	$	360,134
Work-in process		58,402		51,233
Finished goods		116,907		122,058
Total	$	543,747	$	533,425

Inventory includes reagents and components for QuickFISH and PNA FISH kit products, and reagents and supplies used for the Company’s laboratory services. Inventory reserves for obsolescence and expirations were $71,270 and $155,507 at December 31, 2018 and 2017, respectively.

Property and equipment

	December 31,
	2018			2017
Laboratory and manufacturing equipment	$	4,829,323		$	4,109,367
Office furniture and equipment		700,299			700,299
Computers and network equipment		1,520,713			1,505,651
Leasehold improvements		745,800			729,504
		7,796,135			7,044,821
Less accumulated depreciation		(6,574,308	)		(6,209,284	)
Property and equipment, net	$	1,221,827		$	835,537

Leases

ROU assets

Intangible assets and goodwill

Finite-lived intangible assets

Finite-lived intangible assets include trademarks, developed technology and customer relationships, and consisted of the following as of December 31, 2018 and 2017:

			December 31, 2018					December 31, 2017
	Cost		Accumulated Amortization			Net Balance		Accumulated Amortization			Net Balance
Trademarks and tradenames	$	461,000	$	(159,783	)	$	301,217	$	(113,679	)	$	347,321
Developed technology		458,000		(226,746	)		231,254		(161,322	)		296,678
Customer relationships		1,094,000		(541,105	)		552,895		(384,817	)		709,183
	$	2,013,000	$	(927,634	)	$	1,085,366	$	(659,818	)	$	1,353,182

Year Ending December 31,
2019	$	267,816
2020		267,816
2021		267,816
2022		165,117
2023		46,104
Thereafter		70,697
Total	$	1,085,366

Finite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. If any indicators were present, the Company would test for recoverability by comparing the carrying amount of the asset to the net undiscounted cash flows expected to be generated from the asset. If those net undiscounted cash flows do not exceed the carrying amount (i.e., the asset is not recoverable), the Company would perform the next step, which is to determine the fair value of the asset and record an impairment loss, if any. During the years ended December 31, 2018 and 2017, the Company determined that its finite-lived intangible assets were not impaired.

Goodwill

The Company conducts an impairment test of goodwill on an annual basis as of October 1 of each year, and will also conduct tests if events occur or circumstances change that would, more likely than not, reduce the Company’s fair value below its net equity value. As of December 31, 2018, the Company determined that its goodwill was not impaired.

Intangible assets and goodwill

Intangible assets and goodwill as of June 30, 2019 consist of finite-lived intangible assets and goodwill.

Finite-lived intangible assets

Finite-lived intangible assets include trademarks, developed technology and customer relationships and consisted of the following as of June 30, 2019 and December 31, 2018:

			June 30, 2019					December 31, 2018
	Cost		Accumulated Amortization			Net Balance		Accumulated Amortization			Net Balance
Trademarks and trade names	$	461,000	$	(182,835	)	$	278,165	$	(159,783	)	$	301,217
Developed technology		458,000		(259,458	)		198,542		(226,746	)		231,254
Customer relationships		1,094,000		(619,249	)		474,751		(541,105	)		552,895
	$	2,013,000	$	(1,061,542	)	$	951,458	$	(927,634	)	$	1,085,366

Goodwill

Deferred rent

Deferred rent is recorded and amortized to the extent the total minimum rental payments allocated to the current period on a straight-line basis exceed or are less than the cash payments required.

Revenue recognition

Deferred revenue results from amounts billed in advance to customers or cash received from customers in advance of services being provided.

Revenue recognition

Subsequent to the Adoption of Accounting Standards Codification Revenue from Contracts with Customers (“ASC 606”) on January 1, 2018

Deferred revenue results from amounts billed in advance to customers or cash received from customers in advance of services being provided.

For details about the Company’s revenue recognition policy prior to the adoption of ASC 606, refer to the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.

Research and development costs

Research and development costs are expensed as incurred. Research and development costs primarily consist of salaries and related expenses for personnel, other resources, laboratory supplies, fees paid to consultants and outside service partners.

Stock-based compensation

Share-based compensation

Fair value of common stock

Expected volatility

Expected dividend yield

The Company has never declared or paid dividends on its common stock and has no plans to do so in the foreseeable future.

Risk-free interest rate

This is the U.S. Treasury rate for the day of each option grant during the year, having a term that most closely resembles the expected term of the option.

Expected term

Income taxes

Loss per share

Basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period.

Loss per share

Basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period.

For periods of net income, and when the effects are not anti-dilutive, diluted earnings per share is computed by dividing net income available to common stockholders by the weighted-average number of shares outstanding plus the impact of all potential dilutive common shares, consisting primarily of common stock options and stock purchase warrants using the treasury stock method, and convertible preferred stock and convertible debt using the if-converted method.

For periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive. The number of anti-dilutive shares, consisting of (i) common stock options, (ii) stock purchase warrants, and (iii) restricted stock units representing the right to acquire shares of common stock which have been excluded from the computation of diluted loss per share, was 3.7 million shares and 1.6 million shares as of December 31, 2018 and 2017, respectively.

Accounting pronouncements adopted and not yet adopted

Adopted accounting pronouncements

•

The Company did not reassess if any expired or existing contracts are or contain leases.

•

The Company did not reassess the classification of any expired or existing leases.

Adopted accounting pronouncements

	December 31, 2018		December 31, 2017		December 31, 2016
Cash and cash equivalents	$	4,572,487	$	1,847,171	$	4,117,324
Restricted cash		164,720		243,380		243,380
Total cash, cash equivalents and restricted cash in the consolidated statements of cash flows	$	4,737,207	$	2,090,551	$	4,360,704

Accounting pronouncements not yet adopted

In June 2018, the FASB issued ASU 2018-07: Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. This ASU expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from non-employees, and as a result, the accounting for share-based payments to non-employees will be substantially aligned. ASU 2018-07 is effective for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year, and early adoption is permitted but no earlier than an entity’s adoption date of ASC 606. The Company does not expect this new guidance will have a material impact on its financial statements and related disclosures.

Summary of Significant Accounting Policies (Tables)

6 Months Ended

12 Months Ended

Jun. 30, 2019

Dec. 31, 2018

Accounting Policies [Abstract]

Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash

	June 30, 2019		December 31, 2018		June 30, 2018		December 31, 2017
Cash and cash equivalents	$	3,055,894	$	4,572,487	$	7,428,993	$	1,847,171
Restricted cash		185,380		164,720		181,490		243,380
Total cash, cash equivalents and restricted cash in the condensed consolidated statement of cash flows	$	3,241,274	$	4,737,207	$	7,610,483	$	2,090,551

	December 31, 2018		December 31, 2017		December 31, 2016
Cash and cash equivalents	$	4,572,487	$	1,847,171	$	4,117,324
Restricted cash		164,720		243,380		243,380
Total cash, cash equivalents and restricted cash in the consolidated statements of cash flows	$	4,737,207	$	2,090,551	$	4,360,704

Schedule of Inventories

Inventories are valued using the first-in, first-out method and stated at the lower of cost or net realizable value and consist of the following:

	June 30, 2019		December 31, 2018
Raw materials and supplies	$	237,500	$	368,438
Work-in-process		135,916		58,402
Finished goods		194,006		116,907
Total	$	567,422	$	543,747

Inventories are valued using the first-in, first-out method and stated at the lower of cost or net realizable value and consist of the following:

	December 31,
	2018		2017
Raw materials and supplies	$	368,438	$	360,134
Work-in process		58,402		51,233
Finished goods		116,907		122,058
Total	$	543,747	$	533,425

Property, Plant and Equipment

Property and equipment consisted of the following at December 31, 2018 and 2017:

	December 31,
	2018			2017
Laboratory and manufacturing equipment	$	4,829,323		$	4,109,367
Office furniture and equipment		700,299			700,299
Computers and network equipment		1,520,713			1,505,651
Leasehold improvements		745,800			729,504
		7,796,135			7,044,821
Less accumulated depreciation		(6,574,308	)		(6,209,284	)
Property and equipment, net	$	1,221,827		$	835,537

Schedule of Finite-Lived Intangible Assets

Finite-lived intangible assets include trademarks, developed technology and customer relationships and consisted of the following as of June 30, 2019 and December 31, 2018

			June 30, 2019					December 31, 2018
	Cost		Accumulated Amortization			Net Balance		Accumulated Amortization			Net Balance
Trademarks and trade names	$	461,000	$	(182,835	)	$	278,165	$	(159,783	)	$	301,217
Developed technology		458,000		(259,458	)		198,542		(226,746	)		231,254
Customer relationships		1,094,000		(619,249	)		474,751		(541,105	)		552,895
	$	2,013,000	$	(1,061,542	)	$	951,458	$	(927,634	)	$	1,085,366

Finite-lived intangible assets include trademarks, developed technology and customer relationships, and consisted of the following as of December 31, 2018 and 2017:

			December 31, 2018					December 31, 2017
	Cost		Accumulated Amortization			Net Balance		Accumulated Amortization			Net Balance
Trademarks and tradenames	$	461,000	$	(159,783	)	$	301,217	$	(113,679	)	$	347,321
Developed technology		458,000		(226,746	)		231,254		(161,322	)		296,678
Customer relationships		1,094,000		(541,105	)		552,895		(384,817	)		709,183
	$	2,013,000	$	(927,634	)	$	1,085,366	$	(659,818	)	$	1,353,182

Schedule of Expected Amortization of Intangible Assets

Expected amortization of intangible assets for each of the next five fiscal years is as follows.

Year Ending December 31,
2019	$	267,816
2020		267,816
2021		267,816
2022		165,117
2023		46,104
Thereafter		70,697
Total	$	1,085,366

Revenue from Contracts with Customers (Tables)

6 Months Ended

12 Months Ended

Jun. 30, 2019

Dec. 31, 2018

Revenue from Contract with Customer [Abstract]

Schedule of Revenues by Type of Service

	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
Product sales	$	504,293	$	632,525	$	1,024,470	$	1,266,021
Laboratory services		5,250		1,100		5,250		9,790
Collaboration revenue		500,000		155,276		1,000,000		359,316
Total revenue	$	1,009,543	$	788,901	$	2,029,720	$	1,635,127

	December 31,
	2018		2017
Product sales	$	2,395,626	$	2,771,869
Laboratory services		34,665		41,960
Collaboration revenue		516,016		397,178
Total revenue	$	2,946,307	$	3,211,007

Summary of Changes in Deferred Revenue

Changes in deferred revenue for the period were as follows:

Balance at December 31, 2018	$	15,824
Revenue recognized in the current period from the amounts in the beginning balance		(5,831	)
New deferrals, net of amounts recognized in the current period		—
Balance at June 30, 2019	$	9,993

Changes in deferred revenue for the period were as follows:

Balance at December 31, 2017	$	24,442
Revenue recognized in the current period from the amounts in the beginning balance		(14,450	)
New deferrals, net of amounts recognized in the current period		5,832
Balance at December 31, 2018	$	15,824

Fair value measurements (Tables)

6 Months Ended

12 Months Ended

Jun. 30, 2019

Dec. 31, 2018

Fair Value Disclosures [Abstract]

Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following table sets forth a summary of changes in the fair value of level 3 liabilities measured at fair value on a recurring basis for the six months ended June 30, 2019:

Description

Balance at

December 31,

2018

Change in

Fair Value

Balance at

June 30, 2019

Warrant liability

(67

)

—

The following table sets forth a summary of changes in the fair value of level 3 liabilities measured at fair value on a recurring basis for the year ended December 31, 2018:

Description

Balance at

December 31,

2017

Change in

Fair Value

Balance at

December 31,

2018

Warrant liability

8,453

(8,386

)

Stockholders' equity (Tables)

6 Months Ended

12 Months Ended

Jun. 30, 2019

Dec. 31, 2018

Stockholders' Equity Note [Abstract]

Schedule of Company Recognized Stock-Based Compensation Expense

For the three and six months ended June 30, 2019 and 2018, the Company recognized stock-based compensation expense as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
Cost of services	$	524	$	1,341	$	562	$	3,731
Research and development		18,333		61,080		35,460		130,551
General and administrative		61,365		140,158		137,378		292,340
Sales and marketing		5,749		11,311		10,604		25,458
	$	85,971	$	213,890	$	184,004	$	452,080

For the years ended December 31, 2018 and 2017, the Company recognized stock compensation expense as follows:

	Year Ended December 31,
	2018		2017
Cost of services	$	964	$	13,776
Research and development		241,122		237,103
General and administrative		574,244		603,787
Sales and marketing		45,951		56,732
	$	862,281	$	911,398

Summary of Status of Options Granted

A summary of the status of options granted is presented below as of and for the years ended December 31, 2018 and 2017:

	Number of Options			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life (in years)		Aggregate Intrinsic Value
Outstanding at January 1, 2017		119,106		$	44.00		8.6	$	663,298
Granted		58,324		$	17.58
Exercised		(1,167	)	$	7.01			$	11,256
Forfeited		(24,538	)	$	36.31
Expired		(12,330	)	$	83.49
Outstanding at December 31, 2017		139,395		$	31.16		8.3	$	37,339
Granted		95,800		$	3.84
Exercised		—			—
Forfeited		(18,812	)	$	11.98
Expired		(4,824	)	$	56.12
Outstanding at December 31, 2018		211,559		$	20.58		7.6	$	522
Vested and expected to vest		211,559		$	20.58		7.6	$	522
Exercisable at December 31, 2018		10,445		$	1.25		5.3	$	522

Schedule of Fair Value of Option Grant Estimated Using Black-Scholes Option Pricing Model

The fair value of each option grant was estimated at the date of grant using the Black-Scholes option pricing model based on the assumptions below:

	Year Ended December 31,
	2018		2017
Annual dividend		—		—
Expected life (in years)	5.25 - 6.25		5.25 - 6.25
Risk free interest rate	2.5 - 2.9%		1.8 - 2.3%
Expected volatility	46.0 - 49.6%		44.2 - 53.0%

Summary of Status of Restricted Stock Unit Granted

A summary of the status of restricted stock units granted is presented below as of and for the years ended December 31, 2018 and 2017:

	Number of Options			Weighted- Average Grant Date Fair Value
Unvested at January 1, 2017		750		$	42.50
Granted		11,175		$	6.93
Vested		(6,025	)	$	8.01
Forfeited		—			—
Unvested at December 31, 2017		5,900		$	31.16
Granted		—			—
Vested		(5,650	)	$	8.93
Forfeited		—			—
Unvested at December 31, 2018		250		$	42.50

Schedule of Warrants to Purchase Shares of Common Stock

At June 30, 2019 and December 31, 2018, the following warrants to purchase shares of common stock were outstanding:

				Outstanding at
Issuance	Exercise Price		Expiration	June 30, 2019		December 31, 2018
November 2009	$	197.75	November 2019		270		270
January 2010	$	197.75	January 2020		270		270
March 2010	$	197.75	March 2020		55		55
November 2011	$	197.75	November 2021		212		212
December 2011	$	197.75	December 2021		27		27
March 2012	$	2,747.50	March 2019		—		165
February 2015	$	165.00	February 2025		9,001		9,001
May 2015	$	165.00	May 2020		138,310		138,310
May 2016	$	32.81	May 2021		189,577		189,577
June 2016	$	32.81	May 2021		82,035		82,035
June 2017	$	19.50	June 2022		18,754		18,754
July 2017	$	17.25	July 2022		6,350		6,350
July 2017	$	12.50	July 2022		50,000		50,000
July 2017	$	10.63	July 2022		1,000,003		1,000,003
February 2018	$	4.06	February 2023		184,615		184,615
February 2018	$	3.25	February 2023		1,846,153		1,846,153
					3,525,632		3,525,797

At December 31, 2018 and 2017, the following warrants to purchase shares of common stock were outstanding:

				Outstanding at December 31,
Issuance	Exercise Price		Expiration	2018 (1)		2017 (1)
March 2008	$	19,763.50	March 2018		—		2
November 2009	$	197.75	November 2019		270		270
January 2010	$	197.75	January 2020		270		270
March 2010	$	197.75	March 2020		55		55
November 2011	$	197.75	November 2021		212		212
December 2011	$	197.75	December 2021		27		27
March 2012	$	2,747.50	March 2019		165		165
February 2015	$	165.00	February 2025		9,001		9,001
May 2015	$	165.00	May 2020		138,310		138,310
May 2016	$	32.81	May 2021		189,577		189,577
June 2016	$	32.81	May 2021		82,035		82,035
June 2017	$	19.50	June 2022		18,754		18,754
July 2017	$	17.25	July 2022		6,350		6,350
July 2017	$	12.50	July 2022		50,000		50,000
July 2017	$	10.625	July 2022		1,000,003		1,000,003
February 2018	$	4.06	February 2023		184,615		—
February 2018	$	3.25	February 2023		1,846,153		—
					3,525,797		1,495,031

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2018

Income Tax Disclosure [Abstract]

Deferred Tax Assets and Liabilities

The Company’s deferred tax assets and liabilities as of December 31, 2018 and 2017 are as follows:

	December 31,
	2018			2017
Deferred tax assets:
NOL carryforward	$	49,480,731		$	46,326,407
R&E credit carryforward		2,559,479			2,559,479
Share-based compensation		329,796			345,088
Inventory reserve		19,068			45,338
Depreciation		—			71,756
Interest expense		51,152			—
Accruals and other		284,662			247,093
Total deferred tax assets		52,724,888			49,595,161
Valuation allowance		(52,348,036	)		(49,251,408	)
Deferred tax liabilities:
Intangible assets		(256,011	)		(343,753	)
Depreciation		(120,841	)		—
Net	$	—		$	—

Expected Income Tax Provision (Benefit) from Applying Federal Statutory Tax Rates to the Pre-Tax Loss and Actual Income Tax Provision (Benefit)

	2018			2017
Federal income tax benefit at statutory rates		21.0	%		34.0	%
Permanent adjustment		(1.4	)%		—
Provision to return adjustment		(0.2	)%		—
State income tax benefit, net of Federal benefit		(6.4	)%		6.8	%
Tax reform impact		—			(134.5	)%
Change in valuation allowance		(13.0	)%		93.0	%
Change in state tax rates and other		—			0.7	%
		0.0	%		0.0	%

Commitments (Tables)

12 Months Ended

Dec. 31, 2018

Commitments and Contingencies Disclosure [Abstract]

Schedule of Future Minimum Lease Payments For Capital Leases

Following is a schedule by year of the estimated future minimum payments under all operating and capital leases as of December 31, 2018:

Year ending December 31,	Capital Leases			Operating Leases		Total
2019	$	508,114		$	1,107,565	$	1,615,679
2020		408,264			1,125,940		1,534,204
2021		104,579			535,250		639,829
2022		—			40,080		40,080
2023 and thereafter		—			—		—
Total		1,020,957		$	2,808,835	$	3,829,792
Less: amount representing interest		(96,251	)
Less: amount representing service costs		(88,172	)
Net present value of future minimum lease payments		836,534
Current maturities		(399,345	)
Long-term maturities	$	437,189

Schedule of Capital Leased Assets

Assets under capital leases were included in the following balance sheet categories as of December 31:

	2018			2017
Laboratory and manufacturing equipment	$	1,563,346		$	850,792
Office furniture and equipment		64,790			64,790
Computers and network equipment		24,350			24,350
Less accumulated amortization		(749,480	)		(454,471	)
Capital lease assets, net	$	903,006		$	485,461

Leases (Tables)

6 Months Ended

Jun. 30, 2019

Leases [Abstract]

Schedule of ROU Assets and Lease Liabilities

The following table presents the Company’s ROU assets and lease liabilities as of June 30, 2019:

Lease Classification	June 30, 2019
ROU Assets:
Operating	$	1,381,830
Financing		984,742
Total ROU assets	$	2,366,572
Liabilities
Current:
Operating	$	958,992
Finance		576,322
Noncurrent:
Operating		1,071,677
Finance		379,825
Total lease liabilities	$	2,986,816

Schedule of Maturities of Lease Liabilities

Maturities of lease liabilities as of June 30, 2019 by fiscal year are as follows:

Maturity of Lease Liabilities	Operating			Finance			Total
2019	$	558,109		$	332,786		$	890,895
2020		1,128,138			520,947			1,649,085
2021		536,819			166,318			703,137
2022		40,080			11,240			51,320
2023		—			3,644			3,644
Thereafter		—			—			—
Total lease payments		2,263,146			1,034,935			3,298,081
Less: Interest		(232,477	)		(78,788	)		(311,265	)
Present value of lease liabilities	$	2,030,669		$	956,147		$	2,986,816

Schedule of Statement of Operations Classification of Lease Costs and Other Information

Statement of operations classification of lease costs are as follows:

		June 30, 2019
Lease Cost	Classification	Three months ended		Six months ended
Operating	Operating expenses	$	218,673	$	439,595
Finance:
Amortization	Operating expenses		107,496		204,689
Interest expense	Other expenses		19,297		41,778
Total lease costs		$	345,466	$	686,062

Other Information	Total
Weighted average remaining lease term (in years)
Operating leases		2.1
Finance leases		1.8
Weighted average discount rate:
Operating leases		10.0	%
Finance leases		9.2	%

Schedule of Supplemental Cash Flow Information

Supplemental Cash Flow Information	Total
Cash paid for amounts included in the measurement of lease liabilities
Cash used in operating activities
Operating leases	$	439,595
Finance leases	$	41,778
Cash used in financing activities
Finance leases	$	235,600
ROU assets obtained in exchange for lease obligations:
Finance leases	$	355,536

Schedule of Future Minimum Lease Payments

Minimum lease payments for future years as of December 31, 2018 were as follows:

Year ending December 31,	Total
2019	$	1,615,679
2020		1,534,204
2021		639,829
2022		40,080
2023 and thereafter		—
Total	$	3,829,792

Organization - Additional Information (Details) - Segment	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of operating business segment	1	1

Liquidity and Management's Plans - Additional Information (Details) - USD ($)										1 Months Ended	3 Months Ended			6 Months Ended		12 Months Ended		28 Months Ended
	Mar. 29, 2019	Oct. 22, 2018	Jul. 30, 2018	Jul. 14, 2018	Jun. 11, 2018	Apr. 19, 2018	Feb. 06, 2018	Sep. 13, 2016	Sep. 13, 2016	Jul. 31, 2015	Mar. 31, 2019	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018
Conversion of Stock [Line Items]
Proceeds from issuance of common stock, net of issuance costs														$ 4,782,509	$ 192,320	$ 597,743	$ 3,808,836
Net proceeds from sale of common stock and warrants														$ 0	$ 10,728,131	$ 13,530,401	$ 8,754,882
M G H I F Financing Agreement [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues										45,454
Shares issued, price per share										$ 110.00
Proceeds from issuance of common stock, net of issuance costs										$ 5,000,000
Aggregate principal amount										$ 1,000,000
At The Market Offering [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues																318,236	227,216	690,247
Stock issued during period, value, new issues									$ 115			$ 192,320				$ 597,743	$ 3,808,836
February Two Thousand Eighteen Public Offering [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues							2,841,152
Shares issued, price per share							$ 3.25
Gross proceeds from sale of common stock and warrants							$ 12,000,000
Net proceeds from sale of common stock and warrants							$ 10,700,000
Sale of stock, description of transaction														Each unit included one share of common stock and one common warrant to purchase 0.5 share of common stock at an exercise price of $3.25 per share. Each pre-funded unit included one pre-funded warrant to purchase one share of common stock for an exercise price of $0.01 per share, and one common warrant to purchase 0.5 share of common stock at an exercise price of $3.25 per share.		Each unit included one share of common stock and one common warrant to purchase 0.5 share of common stock at an exercise price of $3.25 per share. Each pre-funded unit included one pre-funded warrant to purchase one share of common stock for an exercise price of $0.01 per share, and one common warrant to purchase 0.5 share of common stock at an exercise price of $3.25 per share.
Class of warrant or right, number of securities called by each warrant or right							0.5
Class of warrant or right, exercise price of warrants or rights							$ 3.25
Warrants exercisable period							5 years
Public Placement [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues																5,912,307	1,000,000
Stock issued during period, value, new issues											$ 4,782,509	$ 6,731	$ 10,721,400			$ 13,530,401	$ 8,823,242
Common Stock [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues																318,236	227,216	690,247
Stock issued during period, value, new issues																$ 3,182	$ 2,272
Common Stock [Member] \| October Two Thousand Eighteen Public Offering [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues		2,220,000														318,236	227,216	690,247
Shares issued, price per share		$ 1.45
Gross proceeds from sale of common stock		$ 3,200,000
Proceeds from issuance of common stock, net of issuance costs		$ 2,800,000
Stock issued during period, value, new issues																$ 3,182	$ 2,272
Common Stock [Member] \| At The Market Offering [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues												104,043				318,236	227,216	690,247
Stock issued during period, value, new issues									115			$ 1,040				$ 597,743	$ 3,808,836
Common Stock [Member] \| March Two Thousand Nineteen Public Offering [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues	9,000,000
Shares issued, price per share	$ 0.60
Gross proceeds from sale of common stock	$ 5,400,000
Proceeds from issuance of common stock, net of issuance costs	$ 4,800,000
Common Stock [Member] \| Public Placement [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues											9,000,000	673,077	3,019,230			318,236	227,216	690,247
Stock issued during period, value, new issues											$ 90,000	$ 6,731	$ 30,192			$ 3,182	$ 2,272
Prefunded Units [Member] \| February Two Thousand Eighteen Public Offering [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues							851,155
Shares issued, price per share							$ 3.24
Additional Paid In Capital [Member]
Conversion of Stock [Line Items]
Stock issued during period, value, new issues																$ 594,561	$ 3,806,564
Additional Paid In Capital [Member] \| At The Market Offering [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues																318,236	227,216	690,247
Stock issued during period, value, new issues									115			$ 191,280				$ 597,743	$ 3,808,836
Additional Paid In Capital [Member] \| Public Placement [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues																5,912,307	1,000,000
Stock issued during period, value, new issues											$ 4,692,509		$ 10,691,208			$ 594,561	$ 3,806,564
Pre Funded Warrant [Member] \| February Two Thousand Eighteen Public Offering [Member]
Conversion of Stock [Line Items]
Class of warrant or right, exercise price of warrants or rights							$ 0.01
Warrants exercised						851,155										851,155
Cowen And Company Limited Liability Company [Member] \| At The Market Offering [Member] \| Sales Agreement [Member]
Conversion of Stock [Line Items]
Gross proceeds from sale of common stock																$ 600,000
Proceeds from issuance of common stock, net of issuance costs																600,000
Aggregate gross proceeds from issuance of common stock																$ 9,400,000		$ 9,400,000
Stock issued during period, value, new issues								$ 11,500,000	11,500,000
Cowen And Company Limited Liability Company [Member] \| Common Stock [Member] \| At The Market Offering [Member] \| Sales Agreement [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues																318,236		690,247
Second Amended And Restated Senior Secured Promissory Note [Member] \| M G H I F Financing Agreement [Member]
Conversion of Stock [Line Items]
Aggregate principal amount					$ 1,000,000
Accrued and unpaid interest				$ 285,512
Revised and extended maturity date for payment, terms					Six semi-annual payments
Principal payments includes accrued and unpaid interest					$ 166,667
Beginning date of debt maturity					Jan. 02, 2019
Ending date of debt maturity					Jul. 01, 2021
Second Amended And Restated Senior Secured Promissory Note [Member] \| Common Stock [Member] \| Private Placement [Member] \| M G H I F Financing Agreement [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues			144,238
Accrued and unpaid interest			$ 285,512
Accrued and unpaid interest due date			Jul. 14, 2018
Maximum [Member] \| Cowen And Company Limited Liability Company [Member] \| At The Market Offering [Member] \| Sales Agreement [Member]
Conversion of Stock [Line Items]
Aggregate gross proceeds from issuance of common stock								$ 25,000,000	$ 2,500,000,000,000

Liquidity and Management's Plans - Additional Information (Details 1) - USD ($)										1 Months Ended			3 Months Ended			6 Months Ended		12 Months Ended		28 Months Ended
	Oct. 22, 2018	Jul. 30, 2018	Jul. 14, 2018	Jun. 11, 2018	Apr. 19, 2018	Feb. 06, 2018	Jul. 18, 2017	Sep. 13, 2016	Sep. 13, 2016	Oct. 31, 2017	Jul. 31, 2017	Jul. 31, 2015	Mar. 31, 2019	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Jun. 30, 2017	Jun. 28, 2017	May 31, 2017
Conversion of Stock [Line Items]
Proceeds from issuance of common stock, net of issuance costs																$ 4,782,509	$ 192,320	$ 597,743	$ 3,808,836
Net proceeds from sale of common stock and warrants																$ 0	$ 10,728,131	$ 13,530,401	$ 8,754,882
M G H I F Financing Agreement [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues												45,454
Shares issued, price per share												$ 110.00
Proceeds from issuance of common stock, net of issuance costs												$ 5,000,000
Aggregate principal amount												$ 1,000,000
Amended And Restated M G H I F Financing Agreement [Member]
Conversion of Stock [Line Items]
Class of warrant or right, number of securities called by warrants or rights																						13,120
February Two Thousand Eighteen Public Offering [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues						2,841,152
Shares issued, price per share						$ 3.25
Gross proceeds from sale of common stock and warrants						$ 12,000,000
Net proceeds from sale of common stock and warrants						$ 10,700,000
Sale of stock, description of transaction																Each unit included one share of common stock and one common warrant to purchase 0.5 share of common stock at an exercise price of $3.25 per share. Each pre-funded unit included one pre-funded warrant to purchase one share of common stock for an exercise price of $0.01 per share, and one common warrant to purchase 0.5 share of common stock at an exercise price of $3.25 per share.		Each unit included one share of common stock and one common warrant to purchase 0.5 share of common stock at an exercise price of $3.25 per share. Each pre-funded unit included one pre-funded warrant to purchase one share of common stock for an exercise price of $0.01 per share, and one common warrant to purchase 0.5 share of common stock at an exercise price of $3.25 per share.
Class of warrant or right, number of securities called by each warrant or right						0.5
Class of warrant or right, exercise price of warrants or rights						$ 3.25
Warrants exercisable period						5 years
July Two Thousand Seventeen Public Offering [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues							18,164,195
Shares issued, price per share							$ 0.40
Gross proceeds from sale of common stock and warrants							$ 1,000,000
Net proceeds from sale of common stock and warrants							$ 8,800,000
Sale of stock, description of transaction																		Each unit included one twenty-fifth of a share of common stock and one common warrant to purchase one twenty-fifth of a share of common stock at an exercise price of $10.625 per share. Each pre-funded unit included one pre-funded warrant to purchase one twenty-fifth of a share of common stock for an exercise price of $0.25 per share, and one common warrant to purchase one twenty-fifth of a share of common stock at an exercise price of $10.625 per share.
Class of warrant or right, number of securities called by each warrant or right							0.04
Class of warrant or right, exercise price of warrants or rights							$ 10.625
Warrants exercisable period							5 years
At The Market Offering [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues																		318,236	227,216	690,247
Stock issued during period, value, new issues									$ 115					$ 192,320				$ 597,743	$ 3,808,836
Public Placement [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues																		5,912,307	1,000,000
Stock issued during period, value, new issues													$ 4,782,509	$ 6,731	$ 10,721,400			$ 13,530,401	$ 8,823,242
Common Stock [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues																		318,236	227,216	690,247
Stock issued during period, value, new issues																		$ 3,182	$ 2,272
Common Stock [Member] \| Vendor Consulting Services [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues										2,898
Stock issued during period, value, new issues										$ 2,324,500,000
Common Stock [Member] \| October Two Thousand Eighteen Public Offering [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues	2,220,000																	318,236	227,216	690,247
Shares issued, price per share	$ 1.45
Gross proceeds from sale of common stock	$ 3,200,000
Proceeds from issuance of common stock, net of issuance costs	$ 2,800,000
Stock issued during period, value, new issues																		$ 3,182	$ 2,272
Common Stock [Member] \| At The Market Offering [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues														104,043				318,236	227,216	690,247
Stock issued during period, value, new issues									115					$ 1,040				$ 597,743	$ 3,808,836
Common Stock [Member] \| Public Placement [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues													9,000,000	673,077	3,019,230			318,236	227,216	690,247
Stock issued during period, value, new issues													$ 90,000	$ 6,731	$ 30,192			$ 3,182	$ 2,272
Pre Funded Warrant [Member] \| February Two Thousand Eighteen Public Offering [Member]
Conversion of Stock [Line Items]
Class of warrant or right, exercise price of warrants or rights						$ 0.01
Warrants exercised					851,155													851,155
Pre Funded Warrant [Member] \| July Two Thousand Seventeen Public Offering [Member]
Conversion of Stock [Line Items]
Class of warrant or right, number of securities called by each warrant or right							0.04
Class of warrant or right, exercise price of warrants or rights							$ 0.25
Prefunded Units [Member] \| February Two Thousand Eighteen Public Offering [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues						851,155
Shares issued, price per share						$ 3.24
Prefunded Units [Member] \| July Two Thousand Seventeen Public Offering [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues							6,835,805
Shares issued, price per share							$ 0.39
Additional Paid In Capital [Member]
Conversion of Stock [Line Items]
Stock issued during period, value, new issues																		$ 594,561	$ 3,806,564
Additional Paid In Capital [Member] \| At The Market Offering [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues																		318,236	227,216	690,247
Stock issued during period, value, new issues									115					$ 191,280				$ 597,743	$ 3,808,836
Additional Paid In Capital [Member] \| Public Placement [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues																		5,912,307	1,000,000
Stock issued during period, value, new issues													$ 4,692,509		$ 10,691,208			$ 594,561	$ 3,806,564
Bridge Financing Notes [Member] \| July Two Thousand Seventeen Public Offering [Member]
Conversion of Stock [Line Items]
Repayment of outstanding debt							$ 100,000				$ 100,000
Bridge Financing Notes [Member] \| Warrant [Member] \| Note Purchase Agreement [Member]
Conversion of Stock [Line Items]
Class of warrant or right, exercise price of warrants or rights											$ 17.25
Class of warrant or right, number of securities called by warrants or rights											6,350
Bridge Financing Notes [Member] \| Stock Purchase Warrants [Member] \| Note Purchase Agreement [Member]
Conversion of Stock [Line Items]
Class of warrant or right, exercise price of warrants or rights																					$ 19.50
Class of warrant or right, number of securities called by warrants or rights																					5,634
Bridge Financing Note Two [Member] \| Note Purchase Agreement [Member]
Conversion of Stock [Line Items]
Aggregate principal amount																							$ 50,000,000,000
Bridge Financing Note One [Member] \| Note Purchase Agreement [Member]
Conversion of Stock [Line Items]
Aggregate principal amount																							50,000,000,000
Bridge Financing Note Three [Member] \| Note Purchase Agreement [Member]
Conversion of Stock [Line Items]
Aggregate principal amount																							50,000,000,000
Cowen And Company Limited Liability Company [Member] \| At The Market Offering [Member] \| Sales Agreement [Member]
Conversion of Stock [Line Items]
Gross proceeds from sale of common stock																		600,000
Proceeds from issuance of common stock, net of issuance costs																		600,000
Aggregate gross proceeds from issuance of common stock																		9,400,000		$ 9,400,000
Stock issued during period, value, new issues								$ 11,500,000	11,500,000
Aggregate net proceeds from sale of common stock																		$ 8,800,000		$ 8,800,000
Cowen And Company Limited Liability Company [Member] \| Common Stock [Member] \| At The Market Offering [Member] \| Sales Agreement [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues																		318,236		690,247
Second Amended And Restated Senior Secured Promissory Note [Member] \| M G H I F Financing Agreement [Member]
Conversion of Stock [Line Items]
Aggregate principal amount				$ 1,000,000
Accrued and unpaid interest			$ 285,512
Revised and extended maturity date for payment, terms				Six semi-annual payments
Principal payments includes accrued and unpaid interest				$ 166,667
Beginning date of debt maturity				Jan. 02, 2019
Ending date of debt maturity				Jul. 01, 2021
Second Amended And Restated Senior Secured Promissory Note [Member] \| Common Stock [Member] \| Private Placement [Member] \| M G H I F Financing Agreement [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues		144,238
Accrued and unpaid interest		$ 285,512
Accrued and unpaid interest due date		Jul. 14, 2018
Maximum [Member] \| Bridge Financing Notes [Member] \| Note Purchase Agreement [Member]
Conversion of Stock [Line Items]
Aggregate principal amount																							$ 150,000,000,000
Maximum [Member] \| Cowen And Company Limited Liability Company [Member] \| At The Market Offering [Member] \| Sales Agreement [Member]
Conversion of Stock [Line Items]
Aggregate gross proceeds from issuance of common stock								$ 25,000,000	$ 2,500,000,000,000

Summary of Significant Accounting Policies - Additional Information (Details)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2019 USD ($) Note	Jun. 30, 2018 USD ($) Note	Jun. 30, 2019 USD ($) Note shares	Jun. 30, 2018 USD ($) Note shares	Dec. 31, 2018 USD ($) Note shares	Dec. 31, 2017 USD ($) Note shares	Jan. 01, 2019 USD ($)
Significant Accounting Policies [Line Items]
FDIC limit of insurable cash	$ 250,000		$ 250,000		$ 250,000
Letters of credit outstanding, amount	185,380		185,380		164,720	$ 243,380
Allowance for doubtful accounts receivable	$ 22,309		$ 22,309		$ 18,332	$ 31,278
Number of individual customers accounting for more than 10% of revenue \| Note	1	1	1	1	1	1
Number of individual customers accounting for more than 10% of accounts receivable \| Note	1		1		1	1
Inventory valuation reserves	$ 114,327		$ 114,327		$ 71,270	$ 155,507
Amortization of intangible assets	66,954	$ 66,954	133,908	$ 133,908	267,816	267,816
Impairment of finite-lived intangible assets	0	0	0	0	0	0
Goodwill	600,814		600,814		600,814	$ 600,814
Impairment of goodwill	0	$ 0	$ 0	$ 0	$ 0
Antidilutive securities excluded from computation of earnings per share, amount \| shares			4,000,000	3,800,000	37	16
Operating lease right of use asset	1,381,830		$ 1,381,830		$ 0		$ 2,200,000
Operating lease liability	$ 2,030,669		$ 2,030,669				$ 2,500,000
Domestic Country [Member]
Significant Accounting Policies [Line Items]
Operating loss carryforwards					$ 178,200,000	$ 165,981,195
Operating loss carryforwards, expiration terms			begin to expire in 2022		begin to expire in 2022
Customer Relationships [Member]
Significant Accounting Policies [Line Items]
Finite-lived intangible asset, useful life			7 years		7 years
Developed Technology Rights [Member]
Significant Accounting Policies [Line Items]
Finite-lived intangible asset, useful life			7 years		7 years
Trademarks And Trade Names [Member]
Significant Accounting Policies [Line Items]
Finite-lived intangible asset, useful life			10 years		10 years
Accounting Standards Update201602 [Member]
Significant Accounting Policies [Line Items]
Impairment charge			$ 520,759
Maximum [Member]
Significant Accounting Policies [Line Items]
Accounts receivable period due			60 days		60 days
Minimum [Member]
Significant Accounting Policies [Line Items]
Accounts receivable period due			30 days		30 days
Customer One [Member] \| Sales Revenue Net [Member] \| Customer Concentration Risk [Member]
Significant Accounting Policies [Line Items]
Concentration risk, percentage	50.00%	19.00%			17.00%	11.00%
Customer One [Member] \| Accounts Receivable [Member] \| Customer Concentration Risk [Member]
Significant Accounting Policies [Line Items]
Concentration risk, percentage			65.00%		12.00%	41.00%
Customer Two [Member] \| Sales Revenue Net [Member] \| Customer Concentration Risk [Member]
Significant Accounting Policies [Line Items]
Concentration risk, percentage			49.00%	21.00%

Summary of Significant Accounting Policies - Additional Information (Details 1)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2019 USD ($) Note	Jun. 30, 2018 USD ($) Note	Jun. 30, 2019 USD ($) Note shares	Jun. 30, 2018 USD ($) Note shares	Dec. 31, 2018 USD ($) Note shares	Dec. 31, 2017 USD ($) Note shares
Significant Accounting Policies [Line Items]
FDIC limit of insurable cash	$ 250,000		$ 250,000		$ 250,000
Letters of credit outstanding, amount	185,380		185,380		164,720	$ 243,380
Allowance for doubtful accounts receivable	$ 22,309		$ 22,309		$ 18,332	$ 31,278
Number of individual customers accounting for more than 10% of accounts receivable \| Note	1		1		1	1
Number of individual customers accounting for more than 10% of revenue \| Note	1	1	1	1	1	1
Inventory valuation reserves	$ 114,327		$ 114,327		$ 71,270	$ 155,507
Depreciation expense					463,068	401,272
Amortization of intangible assets	66,954	$ 66,954	133,908	$ 133,908	267,816	267,816
Impairment of finite-lived intangible assets	0	0	0	0	0	$ 0
Impairment of goodwill	0	$ 0	$ 0	$ 0	$ 0
Share-based compensation arrangement by share-based payment award, award vesting period					4 years
Antidilutive securities excluded from computation of earnings per share, amount \| shares			4,000,000	3,800,000	37	16
Undiscounted future minimum operating lease commitments	$ 2,263,146		$ 2,263,146
Domestic Country [Member]
Significant Accounting Policies [Line Items]
Operating loss carryforwards					$ 178,200,000	$ 165,981,195
Operating loss carryforwards, expiration terms			begin to expire in 2022		begin to expire in 2022
Customer Relationships [Member]
Significant Accounting Policies [Line Items]
Finite-lived intangible asset, useful life			7 years		7 years
Trademarks And Trade Names [Member]
Significant Accounting Policies [Line Items]
Finite-lived intangible asset, useful life			10 years		10 years
Developed Technology Rights [Member]
Significant Accounting Policies [Line Items]
Finite-lived intangible asset, useful life			7 years		7 years
Accounting Standards Update201602 [Member]
Significant Accounting Policies [Line Items]
Undiscounted future minimum operating lease commitments					$ 28
Minimum [Member]
Significant Accounting Policies [Line Items]
Accounts receivable period due			30 days		30 days
Estimated useful lives of related assets					3 years
Fair value assumptions, expected term					5 years 3 months	5 years 3 months
Minimum [Member] \| Employee Stock Option [Member]
Significant Accounting Policies [Line Items]
Fair value assumptions, expected term					6 years 3 months
Maximum [Member]
Significant Accounting Policies [Line Items]
Accounts receivable period due			60 days		60 days
Estimated useful lives of related assets					5 years
Fair value assumptions, expected term					6 years 3 months	6 years 3 months
Maximum [Member] \| Employee Stock Option [Member]
Significant Accounting Policies [Line Items]
Fair value assumptions, expected term					10 years
Customer One [Member] \| Accounts Receivable [Member] \| Customer Concentration Risk [Member]
Significant Accounting Policies [Line Items]
Concentration risk, percentage			65.00%		12.00%	41.00%
Customer One [Member] \| Sales Revenue Net [Member] \| Customer Concentration Risk [Member]
Significant Accounting Policies [Line Items]
Concentration risk, percentage	50.00%	19.00%			17.00%	11.00%

Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash Cash Equivalents and Restricted Cash (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018	Jun. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Accounting Policies [Abstract]
Cash and cash equivalents	$ 3,055,894	$ 4,572,487	$ 7,428,993	$ 1,847,171	$ 4,117,324
Restricted cash	185,380	164,720	181,490	243,380	243,380
Total cash, cash equivalents and restricted cash in the condensed consolidated statement of cash flows	$ 3,241,274	$ 4,737,207	$ 7,610,483	$ 2,090,551	$ 4,360,704

Summary of Significant Accounting Policies - Schedule of Inventories (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Inventories
Raw materials and supplies	$ 237,500	$ 368,438	$ 360,134
Work-in-process	135,916	58,402	51,233
Finished goods	194,006	116,907	122,058
Total	$ 567,422	$ 543,747	$ 533,425

Summary of Significant Accounting Policies - Property and Equipment (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Significant Accounting Policies [Line Items]
Property and equipment, Gross		$ 7,796,135	$ 7,044,821
Less accumulated depreciation		(6,574,308)	(6,209,284)
Property and equipment, net	$ 197,502	1,221,827	835,537
Leasehold Improvements [Member]
Significant Accounting Policies [Line Items]
Property and equipment, Gross		745,800	729,504
Laboratory And Manufacturing Equipment [Member]
Significant Accounting Policies [Line Items]
Property and equipment, Gross		4,829,323	4,109,367
Computer Equipment [Member]
Significant Accounting Policies [Line Items]
Property and equipment, Gross		1,520,713	1,505,651
Office Equipment [Member]
Significant Accounting Policies [Line Items]
Property and equipment, Gross		$ 700,299	$ 700,299

Summary of Significant Accounting Policies - Schedule of Finite-Lived Intangible Assets (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]
Cost	$ 2,013,000	$ 2,013,000	$ 2,013,000
Accumulated Amortization	(1,061,542)	(927,634)	(659,818)
Net Balance	951,458	1,085,366	1,353,182
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	1,094,000	1,094,000	1,094,000
Accumulated Amortization	(619,249)	(541,105)	(384,817)
Net Balance	474,751	552,895	709,183
Trademarks And Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	461,000	461,000	461,000
Accumulated Amortization	(182,835)	(159,783)	(113,679)
Net Balance	278,165	301,217	347,321
Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	458,000	458,000	458,000
Accumulated Amortization	(259,458)	(226,746)	(161,322)
Net Balance	$ 198,542	$ 231,254	$ 296,678

Summary of Significant Accounting Policies - Schedule of Expected Amortization of Intangible Assets (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
2019		$ 267,816
2020		267,816
2021		267,816
2022		165,117
2023		46,104
Thereafter		70,697
Net Balance	$ 951,458	$ 1,085,366	$ 1,353,182

Revenue from Contracts with Customers - Schedule of Revenues by Type of Service (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Disaggregation of Revenue [Line Items]
Total revenue	$ 1,009,543	$ 788,901	$ 2,029,720	$ 1,635,127	$ 2,946,307	$ 3,211,007
Product [Member]
Disaggregation of Revenue [Line Items]
Total revenue	504,293	632,525	1,024,470	1,266,021	2,395,626	2,771,869
Collaborations Revenue [Member]
Disaggregation of Revenue [Line Items]
Total revenue	500,000	155,276	1,000,000	359,316	516,016	397,178
Laboratory Service Revenue [Member]
Disaggregation of Revenue [Line Items]
Total revenue	$ 5,250	$ 1,100	$ 5,250	$ 9,790	$ 34,665	$ 41,960

Revenue from Contracts with Customers - Summary of Changes in Deferred Revenue (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Revenue Recognition and Deferred Revenue [Abstract]
Beginning balance	$ 15,824	$ 24,442
Revenue recognized in the current period from the amounts in the beginning balance	(5,831)	(14,450)
New deferrals, net of amounts recognized in the current period		5,832
Ending balance	$ 9,993	$ 15,824

Revenue from Contracts with Customers - Additional Information (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Revenue from Contract with Customer [Abstract]
Contract with customers, asset	$ 0	$ 0
Unsatisfied performance obligations related to contracts with customers		$ 0

MGHIF financing - Additional Information (Details) - USD ($)									1 Months Ended	3 Months Ended			6 Months Ended		12 Months Ended		28 Months Ended
	Mar. 29, 2019	Oct. 22, 2018	Jul. 30, 2018	Jul. 14, 2018	Jun. 11, 2018	Feb. 06, 2018	Jun. 28, 2017	Jun. 28, 2017	Jul. 31, 2015	Mar. 31, 2019	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018
Common Stock And Note Purchase Agreement [Line Items]
Proceeds from issuance of common stock, net of issuance costs													$ 4,782,509	$ 192,320	$ 597,743	$ 3,808,836
M G H I F Financing Agreement [Member]
Common Stock And Note Purchase Agreement [Line Items]
Stock issued during period, shares, new issues									45,454
Shares issued, price per share									$ 110.00
Proceeds from issuance of common stock, net of issuance costs									$ 5,000,000
Debt instrument, interest rate, stated percentage									8.00%
Debt instrument, face amount									$ 1,000,000
Unamortized debt issuance costs					$ 7,000
Amended And Restated M G H I F Financing Agreement [Member]
Common Stock And Note Purchase Agreement [Line Items]
Debt instrument, interest rate, stated percentage							10.00%	10.00%
Debt instrument, extended maturity date							Jul. 14, 2018	Jul. 14, 2018
Issuance of common stock warrants to purchase							13,120	13,120
February Two Thousand Eighteen Public Offering [Member]
Common Stock And Note Purchase Agreement [Line Items]
Stock issued during period, shares, new issues						2,841,152
Shares issued, price per share						$ 3.25
Public Placement [Member]
Common Stock And Note Purchase Agreement [Line Items]
Stock issued during period, shares, new issues															5,912,307	1,000,000
At The Market Offering [Member]
Common Stock And Note Purchase Agreement [Line Items]
Stock issued during period, shares, new issues															318,236	227,216	690,247
Common Stock [Member]
Common Stock And Note Purchase Agreement [Line Items]
Stock issued during period, shares, new issues															318,236	227,216	690,247
Common Stock [Member] \| October Two Thousand Eighteen Public Offering [Member]
Common Stock And Note Purchase Agreement [Line Items]
Stock issued during period, shares, new issues		2,220,000													318,236	227,216	690,247
Shares issued, price per share		$ 1.45
Proceeds from issuance of common stock, net of issuance costs		$ 2,800,000
Common Stock [Member] \| March Two Thousand Nineteen Public Offering [Member]
Common Stock And Note Purchase Agreement [Line Items]
Stock issued during period, shares, new issues	9,000,000
Shares issued, price per share	$ 0.60
Proceeds from issuance of common stock, net of issuance costs	$ 4,800,000
Common Stock [Member] \| Public Placement [Member]
Common Stock And Note Purchase Agreement [Line Items]
Stock issued during period, shares, new issues										9,000,000	673,077	3,019,230			318,236	227,216	690,247
Common Stock [Member] \| At The Market Offering [Member]
Common Stock And Note Purchase Agreement [Line Items]
Stock issued during period, shares, new issues											104,043				318,236	227,216	690,247
Prefunded Units [Member] \| February Two Thousand Eighteen Public Offering [Member]
Common Stock And Note Purchase Agreement [Line Items]
Stock issued during period, shares, new issues						851,155
Shares issued, price per share						$ 3.24
Second Amended And Restated Senior Secured Promissory Note [Member] \| M G H I F Financing Agreement [Member]
Common Stock And Note Purchase Agreement [Line Items]
Debt instrument, face amount					$ 1,000,000
Accrued and unpaid interest				$ 285,512
Revised and extended the maturity date, payment terms					Six semi-annual payments
Annual payments plus accrued and unpaid interest					$ 166,667
Beginning date of debt maturity					Jan. 02, 2019
Ending date of debt maturity					Jul. 01, 2021
Second Amended And Restated Senior Secured Promissory Note [Member] \| Common Stock [Member] \| Private Placement [Member] \| M G H I F Financing Agreement [Member]
Common Stock And Note Purchase Agreement [Line Items]
Stock issued during period, shares, new issues			144,238
Accrued and unpaid interest			$ 285,512
Stock issued during period, accrued and unpaid interest due			$ 285,512
Accrued and unpaid interest due date			Jul. 14, 2018

MGHIF Financing - Additional Information (Details 1) - USD ($)									1 Months Ended	3 Months Ended			6 Months Ended		12 Months Ended		28 Months Ended
	Oct. 22, 2018	Jul. 30, 2018	Jul. 14, 2018	Jun. 11, 2018	Feb. 06, 2018	Jul. 18, 2017	Jun. 28, 2017	Jun. 28, 2017	Jul. 31, 2015	Mar. 31, 2019	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018
Common Stock And Note Purchase Agreement [Line Items]
Proceeds from issuance of common stock, net of issuance costs													$ 4,782,509	$ 192,320	$ 597,743	$ 3,808,836
M G H I F Financing Agreement [Member]
Common Stock And Note Purchase Agreement [Line Items]
Stock issued during period, shares, new issues									45,454
Shares issued, price per share									$ 110.00
Proceeds from issuance of common stock, net of issuance costs									$ 5,000,000
Debt instrument, interest rate, stated percentage									8.00%
Debt instrument, face amount									$ 1,000,000
Unamortized debt issuance costs				$ 7,000
Amended And Restated M G H I F Financing Agreement [Member]
Common Stock And Note Purchase Agreement [Line Items]
Debt instrument, interest rate, stated percentage							10.00%	10.00%
Debt instrument, extended maturity date							Jul. 14, 2018	Jul. 14, 2018
Issuance of common stock warrants to purchase							13,120	13,120
February Two Thousand Eighteen Public Offering [Member]
Common Stock And Note Purchase Agreement [Line Items]
Stock issued during period, shares, new issues					2,841,152
Shares issued, price per share					$ 3.25
July Two Thousand Seventeen Public Offering [Member]
Common Stock And Note Purchase Agreement [Line Items]
Stock issued during period, shares, new issues						18,164,195
Shares issued, price per share						$ 0.40
Public Placement [Member]
Common Stock And Note Purchase Agreement [Line Items]
Stock issued during period, shares, new issues															5,912,307	1,000,000
At The Market Offering [Member]
Common Stock And Note Purchase Agreement [Line Items]
Stock issued during period, shares, new issues															318,236	227,216	690,247
Common Stock [Member]
Common Stock And Note Purchase Agreement [Line Items]
Stock issued during period, shares, new issues															318,236	227,216	690,247
Common Stock [Member] \| October Two Thousand Eighteen Public Offering [Member]
Common Stock And Note Purchase Agreement [Line Items]
Stock issued during period, shares, new issues	2,220,000														318,236	227,216	690,247
Shares issued, price per share	$ 1.45
Proceeds from issuance of common stock, net of issuance costs	$ 2,800,000
Common Stock [Member] \| Public Placement [Member]
Common Stock And Note Purchase Agreement [Line Items]
Stock issued during period, shares, new issues										9,000,000	673,077	3,019,230			318,236	227,216	690,247
Common Stock [Member] \| At The Market Offering [Member]
Common Stock And Note Purchase Agreement [Line Items]
Stock issued during period, shares, new issues											104,043				318,236	227,216	690,247
Prefunded Units [Member] \| February Two Thousand Eighteen Public Offering [Member]
Common Stock And Note Purchase Agreement [Line Items]
Stock issued during period, shares, new issues					851,155
Shares issued, price per share					$ 3.24
Prefunded Units [Member] \| July Two Thousand Seventeen Public Offering [Member]
Common Stock And Note Purchase Agreement [Line Items]
Stock issued during period, shares, new issues						6,835,805
Shares issued, price per share						$ 0.39
Second Amended And Restated Senior Secured Promissory Note [Member] \| M G H I F Financing Agreement [Member]
Common Stock And Note Purchase Agreement [Line Items]
Debt instrument, face amount				$ 1,000,000
Accrued and unpaid interest			$ 285,512
Revised and extended the maturity date, payment terms				Six semi-annual payments
Annual payments plus accrued and unpaid interest				$ 166,667
Beginning date of debt maturity				Jan. 02, 2019
Ending date of debt maturity				Jul. 01, 2021
Second Amended And Restated Senior Secured Promissory Note [Member] \| Common Stock [Member] \| Private Placement [Member] \| M G H I F Financing Agreement [Member]
Common Stock And Note Purchase Agreement [Line Items]
Stock issued during period, shares, new issues		144,238
Accrued and unpaid interest		$ 285,512
Stock issued during period, accrued and unpaid interest due		$ 285,512
Accrued and unpaid interest due date		Jul. 14, 2018

Fair value measurements - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets transferred between fair value measurement levels			$ 0
Fair Value Measurements Nonrecurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets measured at fair value	$ 0		0		$ 0
Financial liabilities measured at fair value	0		0		0
Impairment of non-financial assets and liabilities at fair value	0	$ 0	0	$ 0	0
Fair Value Measurements Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Non-financial assets measured at fair value	0		0		0
Non-financial liabilities measured at fair value	$ 0		$ 0		$ 0

Fair Value Measurements - Additional Information (Details 1) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Fair Value Measurements Nonrecurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets measured at fair value	$ 0		$ 0		$ 0
Financial liabilities measured at fair value	0		0		0
Impairment of non-financial assets and liabilities at fair value	0	$ 0	0	$ 0	0
Fair Value Measurements Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Non-financial assets measured at fair value	0		0		0
Non-financial liabilities measured at fair value	$ 0		$ 0		$ 0

Fair value measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Warrant [Member] - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Changes in the fair value of Level 3 liabilities measured at fair value on recurring basis
Balance at the beginning of the period	$ 67	$ 8,453
Change in Fair Value	(67)	(8,386)
Balance at the end of the period	$ 0	$ 67

Debt - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
Debt - Additional Information (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Short-term debt	$ 343,330		$ 343,330		$ 398,595	$ 1,010,961
Interest expense, debt	37,129	$ 54,533	93,573	$ 112,379	191,195	233,505
M G H I F Financing Agreement [Member]
Debt Instrument [Line Items]
Short-term debt	333,000		333,000		333,000	10
Long-term debt, outstanding	495,000		495,000		660,000
Notes Payable Other Payables [Member]
Debt Instrument [Line Items]
Short-term debt	10,000		10,000		65,000	$ 56,000
Due In Two Thousand Twenty [Member]
Debt Instrument [Line Items]
Debt instrument, annual principal payment	333,000		333,000		333
Due In Two Thousand Nineteen [Member]
Debt Instrument [Line Items]
Debt instrument, annual principal payment	333,000		333,000
Due In Two Thousand Twenty One [Member]
Debt Instrument [Line Items]
Debt instrument, annual principal payment	$ 333,000		$ 333,000		$ 333,000

Debt - Additional Information (Details 1)	3 Months Ended		6 Months Ended		12 Months Ended
Debt - Additional Information (Details 1)	Jun. 30, 2019 USD ($)	Jun. 30, 2018 USD ($)	Jun. 30, 2019 USD ($)	Jun. 30, 2018 USD ($)	Dec. 31, 2018 USD ($) Note	Dec. 31, 2017 USD ($)
Debt Instrument [Line Items]
Short-term debt	$ 343,330		$ 343,330		$ 398,595	$ 1,010,961
Interest expense, debt	37,129	$ 54,533	93,573	$ 112,379	191,195	233,505
M G H I F Financing Agreement [Member]
Debt Instrument [Line Items]
Short-term debt	333,000		333,000		333,000	10
Long-term debt, outstanding	495,000		495,000		$ 660,000
Bridge Financing Notes [Member]
Debt Instrument [Line Items]
Number of notes \| Note					3
Number of notes drew down \| Note					2
Notes Payable Other Payables [Member]
Debt Instrument [Line Items]
Short-term debt	10,000		10,000		$ 65,000	$ 56,000
Due In Two Thousand Twenty [Member]
Debt Instrument [Line Items]
Debt instrument, annual principal payment	333,000		333,000		333
Due In Two Thousand Ninteen [Member]
Debt Instrument [Line Items]
Debt instrument, annual principal payment					333
Due In Two Thousand Twenty One [Member]
Debt Instrument [Line Items]
Debt instrument, annual principal payment	$ 333,000		$ 333,000		$ 333,000

Stockholders' Equity - Additional Information (Details) - USD ($)								3 Months Ended				6 Months Ended		12 Months Ended		28 Months Ended
	Mar. 29, 2019	Jan. 01, 2019	Oct. 22, 2018	Apr. 19, 2018	Feb. 06, 2018	Sep. 13, 2016	Sep. 13, 2016	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Jan. 17, 2018	Jan. 16, 2018	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares authorized								50,000,000				50,000,000		50,000,000	50,000,000	50,000,000	50,000,000	200,000,000
Common stock, shares issued								17,645,720				17,645,720		8,645,720	2,265,320	8,645,720
Common stock, shares outstanding								17,645,720				17,645,720		8,645,720	2,265,320	8,645,720
Preferred stock, shares authorized								10,000,000				10,000,000		10,000,000	10,000,000	10,000,000
Preferred stock, shares issued								0				0		0	0	0
Preferred stock, shares outstanding								0				0		0	0	0
Proceeds from issuance of common stock, net of issuance costs												$ 4,782,509	$ 192,320	$ 597,743	$ 3,808,836
Net proceeds from sale of common stock and warrants												0	$ 10,728,131	13,530,401	$ 8,754,882
Stock-based compensation, tax benefit from compensation expense												$ 0		$ 0
Stock options, granted								0				0		95,800	58,324
Stock options, granted, weighted average exercise price														$ 3.84	$ 17.58
Stock options, forfeited								720				720		18,812	24,538
Stock options, outstanding								210,834				210,834		211,559	139,395	211,559			119,106
Stock options, expired								0				5		4,824	12,330
Share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period														0	11,175
Share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period														5,650	6,025
Share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period														0	0
Share-based compensation arrangement by share-based payment award, equity instruments other than options, non-vested, outstanding														250	5,900	250			750
At The Market Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, value, new issues							$ 115			$ 192,320				$ 597,743	$ 3,808,836
Stock issued during period, shares, new issues														318,236	227,216	690,247
February Two Thousand Eighteen Public Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, new issues					2,841,152
Shares issued, price per share					$ 3.25
Gross proceeds from sale of common stock and warrants					$ 12,000,000
Net proceeds from sale of common stock and warrants					$ 10,700,000
Sale of stock, description of transaction												Each unit included one share of common stock and one common warrant to purchase 0.5 share of common stock at an exercise price of $3.25 per share. Each pre-funded unit included one pre-funded warrant to purchase one share of common stock for an exercise price of $0.01 per share, and one common warrant to purchase 0.5 share of common stock at an exercise price of $3.25 per share.		Each unit included one share of common stock and one common warrant to purchase 0.5 share of common stock at an exercise price of $3.25 per share. Each pre-funded unit included one pre-funded warrant to purchase one share of common stock for an exercise price of $0.01 per share, and one common warrant to purchase 0.5 share of common stock at an exercise price of $3.25 per share.
Class of warrant or right, number of securities called by each warrant or right					0.5
Class of warrant or right, exercise price of warrants or rights					$ 3.25
Warrants exercisable period					5 years
February Two Thousand Eighteen Public Offering [Member] \| Placement Agent [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, exercise price of warrants or rights					$ 4.0625
Warrants exercisable period					5 years
Public Placement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, value, new issues									$ 4,782,509	6,731	$ 10,721,400			$ 13,530,401	$ 8,823,242
Stock issued during period, shares, new issues														5,912,307	1,000,000
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, value, new issues														$ 3,182	$ 2,272
Stock issued during period, shares, new issues														318,236	227,216	690,247
Common Stock [Member] \| October Two Thousand Eighteen Public Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, value, new issues														$ 3,182	$ 2,272
Stock issued during period, shares, new issues			2,220,000											318,236	227,216	690,247
Proceeds from issuance of common stock, net of issuance costs			$ 2,800,000
Gross proceeds from sale of common stock			$ 3,200,000
Shares issued, price per share			$ 1.45
Common Stock [Member] \| At The Market Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, value, new issues							115			$ 1,040				$ 597,743	$ 3,808,836
Stock issued during period, shares, new issues										104,043				318,236	227,216	690,247
Common Stock [Member] \| March Two Thousand Nineteen Public Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, new issues	9,000,000
Proceeds from issuance of common stock, net of issuance costs	$ 4,800,000
Gross proceeds from sale of common stock	$ 5,400,000
Shares issued, price per share	$ 0.60
Common Stock [Member] \| February Two Thousand Eighteen Public Offering [Member] \| Placement Agent [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of common stock warrants to purchase					184,615
Common Stock [Member] \| Public Placement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, value, new issues									$ 90,000	$ 6,731	$ 30,192			$ 3,182	$ 2,272
Stock issued during period, shares, new issues									9,000,000	673,077	3,019,230			318,236	227,216	690,247
Prefunded Units [Member] \| February Two Thousand Eighteen Public Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, new issues					851,155
Shares issued, price per share					$ 3.24
Additional Paid In Capital [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, value, new issues														$ 594,561	$ 3,806,564
Additional Paid In Capital [Member] \| At The Market Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, value, new issues							115			$ 191,280				$ 597,743	$ 3,808,836
Stock issued during period, shares, new issues														318,236	227,216	690,247
Additional Paid In Capital [Member] \| Public Placement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, value, new issues									$ 4,692,509		$ 10,691,208			$ 594,561	$ 3,806,564
Stock issued during period, shares, new issues														5,912,307	1,000,000
Pre Funded Warrant [Member] \| February Two Thousand Eighteen Public Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, exercise price of warrants or rights					$ 0.01
Warrants exercised				851,155										851,155
Cowen And Company Limited Liability Company [Member] \| At The Market Offering [Member] \| Sales Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate gross proceeds from issuance of common stock														$ 9,400,000		$ 9,400,000
Stock issued during period, value, new issues						$ 11,500,000	11,500,000
Proceeds from issuance of common stock, net of issuance costs														600,000
Gross proceeds from sale of common stock														$ 600,000
Cowen And Company Limited Liability Company [Member] \| Common Stock [Member] \| At The Market Offering [Member] \| Sales Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, new issues														318,236		690,247
Two Thousand Fifteen Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, number of shares authorized								54,200				54,200		54,200		54,200
Share-based compensation arrangement by share-based payment award, description												the number of shares that have been authorized for issuance under the 2015 Plan will be automatically increased on the first day of each fiscal year beginning on January 1, 2016 and ending on (and including) January 1, 2025, in an amount equal to the lesser of (1) 4% of the outstanding shares of common stock on the last day of the immediately preceding fiscal year, or (2) another lesser amount determined by the Company’s Board of Directors.		the number of shares that have been authorized for issuance under the 2015 Plan will be automatically increased on the first day of each fiscal year beginning on January 1, 2016 and ending on (and including) January 1, 2025, in an amount equal to the lesser of (1) 4% of the outstanding shares of common stock on the last day of the immediately preceding fiscal year, or (2) another lesser amount determined by the Company’s Board of Directors.
Share-based compensation arrangement by share-based payment award, number of shares available for grant								84,412				84,412		50,863		50,863
Share-based compensation arrangement by share-based payment award, common stock percentage												4.00%		4.00%
Share-based compensation arrangement by share-based payment award, number of additional shares added		345,828
Restricted Stock Units R S U [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period												313,000
Share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period												0
Share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period												0
Share-based compensation arrangement by share-based payment award, equity instruments other than options, non-vested, outstanding								313,250				313,250
Maximum [Member] \| Cowen And Company Limited Liability Company [Member] \| At The Market Offering [Member] \| Sales Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate gross proceeds from issuance of common stock						$ 25,000,000	$ 2,500,000,000,000

Stockholders' Equity - Additional Information (Details 1)								1 Months Ended			3 Months Ended			6 Months Ended		12 Months Ended		28 Months Ended
	Oct. 22, 2018 USD ($) $ / shares shares	Apr. 19, 2018 shares	Feb. 06, 2018 USD ($) $ / shares shares	Jan. 17, 2018 shares	Jul. 18, 2017 USD ($) $ / shares shares	Sep. 13, 2016 USD ($)	Sep. 13, 2016 USD ($)	Oct. 31, 2017 USD ($) shares	Sep. 30, 2017 USD ($) shares	Jul. 31, 2017 USD ($) $ / shares shares	Mar. 31, 2019 USD ($) shares	Jun. 30, 2018 USD ($) shares	Mar. 31, 2018 USD ($) shares	Jun. 30, 2019 USD ($) shares	Jun. 30, 2018 USD ($)	Dec. 31, 2018 USD ($) shares	Dec. 31, 2017 USD ($) shares	Dec. 31, 2018 USD ($) shares	Jan. 16, 2018 shares	Jun. 30, 2017 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares authorized \| shares				50,000,000										50,000,000		50,000,000	50,000,000	50,000,000	200,000,000
Common stock, shares issued \| shares														17,645,720		8,645,720	2,265,320	8,645,720
Common stock, shares outstanding \| shares														17,645,720		8,645,720	2,265,320	8,645,720
Preferred stock, shares authorized \| shares														10,000,000		10,000,000	10,000,000	10,000,000
Preferred stock, shares issued \| shares														0		0	0	0
Preferred stock, shares outstanding \| shares														0		0	0	0
Proceeds from issuance of common stock, net of issuance costs \| $														$ 4,782,509	$ 192,320	$ 597,743	$ 3,808,836
Net proceeds from sale of common stock and warrants \| $														0	$ 10,728,131	$ 13,530,401	8,754,882
Stock split																On January 17, 2018, the Company filed an amendment to its Amended and Restated Certificate of Incorporation to effect a reverse stock split of the issued and outstanding shares of common stock, at a ratio of one share for twenty-five shares, and to reduce the authorized shares of common stock from 200,000,000 to 50,000,000 shares. All share amounts and per share prices in this Annual Report have been adjusted to reflect the reverse stock split.
Reverse stock split conversion ratio				0.04
Share-based compensation, tax benefit from compensation expense \| $														$ 0		$ 0
Employee service share-based compensation, non-vested awards, compensation cost not yet recognized, total \| $																$ 500,000		$ 500,000
Employee service share-based compensation, non-vested awards, compensation cost not yet recognized, period for recognition																7 years 7 months 6 days
Share-based compensation arrangement by share-based payment award, options, vested in period, fair value \| $																$ 93,092,100,000	208,684,300,000
Restricted Stock Units R S U [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee service share-based compensation, non-vested awards, compensation cost not yet recognized, period for recognition																11 months 1 day
Employee service share-based compensation, non-vested awards, compensation cost not yet recognized, total \| $																$ 900,000,000		$ 900,000,000
Two Thousand Fifteen Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, number of shares authorized \| shares														54,200		54,200		54,200
Share-based compensation arrangement by share-based payment award, description														the number of shares that have been authorized for issuance under the 2015 Plan will be automatically increased on the first day of each fiscal year beginning on January 1, 2016 and ending on (and including) January 1, 2025, in an amount equal to the lesser of (1) 4% of the outstanding shares of common stock on the last day of the immediately preceding fiscal year, or (2) another lesser amount determined by the Company’s Board of Directors.		the number of shares that have been authorized for issuance under the 2015 Plan will be automatically increased on the first day of each fiscal year beginning on January 1, 2016 and ending on (and including) January 1, 2025, in an amount equal to the lesser of (1) 4% of the outstanding shares of common stock on the last day of the immediately preceding fiscal year, or (2) another lesser amount determined by the Company’s Board of Directors.
Share-based compensation arrangement by share-based payment award, number of shares available for grant \| shares														84,412		50,863		50,863
Share-based compensation arrangement by share-based payment award, common stock percentage														4.00%		4.00%
February Two Thousand Eighteen Public Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, new issues \| shares			2,841,152
Shares issued, price per share \| $ / shares			$ 3.25
Gross proceeds from sale of common stock and warrants \| $			$ 12,000,000
Net proceeds from sale of common stock and warrants \| $			$ 10,700,000
Sale of stock, description of transaction														Each unit included one share of common stock and one common warrant to purchase 0.5 share of common stock at an exercise price of $3.25 per share. Each pre-funded unit included one pre-funded warrant to purchase one share of common stock for an exercise price of $0.01 per share, and one common warrant to purchase 0.5 share of common stock at an exercise price of $3.25 per share.		Each unit included one share of common stock and one common warrant to purchase 0.5 share of common stock at an exercise price of $3.25 per share. Each pre-funded unit included one pre-funded warrant to purchase one share of common stock for an exercise price of $0.01 per share, and one common warrant to purchase 0.5 share of common stock at an exercise price of $3.25 per share.
Class of warrant or right, number of securities called by each warrant or right \| shares			0.5
Class of warrant or right, exercise price of warrants or rights \| $ / shares			$ 3.25
Warrants exercisable period			5 years
February Two Thousand Eighteen Public Offering [Member] \| Placement Agent [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, exercise price of warrants or rights \| $ / shares			$ 4.0625
Warrants exercisable period			5 years
July Two Thousand Seventeen Public Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, new issues \| shares					18,164,195
Shares issued, price per share \| $ / shares					$ 0.40
Gross proceeds from sale of common stock and warrants \| $					$ 1,000,000
Net proceeds from sale of common stock and warrants \| $					$ 8,800,000
Sale of stock, description of transaction																Each unit included one twenty-fifth of a share of common stock and one common warrant to purchase one twenty-fifth of a share of common stock at an exercise price of $10.625 per share. Each pre-funded unit included one pre-funded warrant to purchase one twenty-fifth of a share of common stock for an exercise price of $0.25 per share, and one common warrant to purchase one twenty-fifth of a share of common stock at an exercise price of $10.625 per share.
Class of warrant or right, number of securities called by each warrant or right \| shares					0.04
Class of warrant or right, exercise price of warrants or rights \| $ / shares					$ 10.625
Warrants exercisable period					5 years
July Two Thousand Seventeen Public Offering [Member] \| Bridge Financing Notes [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Repayment of principal amount of outstanding debt \| $					$ 100,000					$ 100,000
Repayments of accrued interest on outstanding debt \| $					$ 643,800,000
July Two Thousand Seventeen Public Offering [Member] \| Placement Agent [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, exercise price of warrants or rights \| $ / shares					$ 12.50
Warrants exercisable period					5 years
At The Market Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, value, new issues \| $							$ 115					$ 192,320				$ 597,743	$ 3,808,836
Stock issued during period, shares, new issues \| shares																318,236	227,216	690,247
At The Market Offering [Member] \| Cowen And Company Limited Liability Company [Member] \| Sales Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate gross proceeds from issuance of common stock \| $																$ 9,400,000		$ 9,400,000
Stock issued during period, value, new issues \| $						$ 11,500,000	$ 11,500,000
Maximum commission percentage on gross proceeds							3.00%
Aggregate net proceeds from issuance of common stock \| $																8,800,000		$ 8,800,000
Proceeds from issuance of common stock, net of issuance costs \| $																600,000
Gross proceeds from sale of common stock \| $																600,000
At The Market Offering [Member] \| Cowen And Company Limited Liability Company [Member] \| Sales Agreement [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate gross proceeds from issuance of common stock \| $						$ 25,000,000	$ 2,500,000,000,000
Public Placement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, value, new issues \| $											$ 4,782,509	6,731	$ 10,721,400			$ 13,530,401	$ 8,823,242
Stock issued during period, shares, new issues \| shares																5,912,307	1,000,000
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, value, new issues \| $																$ 3,182	$ 2,272
Stock issued during period, shares, new issues \| shares																318,236	227,216	690,247
Common Stock [Member] \| Premerger Dispute Settlement [Member] \| Advandx [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, value, new issues \| $									$ 11,000,000,000
Stock issued during period, shares, new issues \| shares									15,843
Common Stock [Member] \| Vendor Consulting Services [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, value, new issues \| $								$ 2,324,500,000
Stock issued during period, shares, new issues \| shares								2,898
Common Stock [Member] \| October Two Thousand Eighteen Public Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, value, new issues \| $																$ 3,182	$ 2,272
Stock issued during period, shares, new issues \| shares	2,220,000															318,236	227,216	690,247
Proceeds from issuance of common stock, net of issuance costs \| $	$ 2,800,000
Gross proceeds from sale of common stock \| $	$ 3,200,000
Shares issued, price per share \| $ / shares	$ 1.45
Common Stock [Member] \| February Two Thousand Eighteen Public Offering [Member] \| Placement Agent [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number of securities called by warrants or rights \| shares			184,615
Common Stock [Member] \| July Two Thousand Seventeen Public Offering [Member] \| Placement Agent [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number of securities called by warrants or rights \| shares					50,000
Common Stock [Member] \| At The Market Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, value, new issues \| $							115					$ 1,040				$ 597,743	$ 3,808,836
Stock issued during period, shares, new issues \| shares												104,043				318,236	227,216	690,247
Common Stock [Member] \| At The Market Offering [Member] \| Cowen And Company Limited Liability Company [Member] \| Sales Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, new issues \| shares																318,236		690,247
Common Stock [Member] \| Public Placement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, value, new issues \| $											$ 90,000	$ 6,731	$ 30,192			$ 3,182	$ 2,272
Stock issued during period, shares, new issues \| shares											9,000,000	673,077	3,019,230			318,236	227,216	690,247
Pre Funded Warrant [Member] \| February Two Thousand Eighteen Public Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, exercise price of warrants or rights \| $ / shares			$ 0.01
Warrants exercised \| shares		851,155														851,155
Pre Funded Warrant [Member] \| July Two Thousand Seventeen Public Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number of securities called by each warrant or right \| shares					0.04
Class of warrant or right, exercise price of warrants or rights \| $ / shares					$ 0.25
Prefunded Units [Member] \| February Two Thousand Eighteen Public Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, new issues \| shares			851,155
Shares issued, price per share \| $ / shares			$ 3.24
Prefunded Units [Member] \| July Two Thousand Seventeen Public Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, new issues \| shares					6,835,805
Shares issued, price per share \| $ / shares					$ 0.39
Additional Paid In Capital [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, value, new issues \| $																$ 594,561	$ 3,806,564
Additional Paid In Capital [Member] \| At The Market Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, value, new issues \| $							$ 115					$ 191,280				$ 597,743	$ 3,808,836
Stock issued during period, shares, new issues \| shares																318,236	227,216	690,247
Additional Paid In Capital [Member] \| Public Placement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, value, new issues \| $											$ 4,692,509		$ 10,691,208			$ 594,561	$ 3,806,564
Stock issued during period, shares, new issues \| shares																5,912,307	1,000,000
Warrant [Member] \| Bridge Financing Notes [Member] \| Note Purchase Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, exercise price of warrants or rights \| $ / shares										$ 17.25
Class of warrant or right, number of securities called by warrants or rights \| shares										6,350
Stock Purchase Warrants [Member] \| Bridge Financing Notes [Member] \| Note Purchase Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, exercise price of warrants or rights \| $ / shares																				$ 19.50
Class of warrant or right, number of securities called by warrants or rights \| shares																				5,634

Stockholders' Equity - Company Recognized Stock-Based Compensation Expense (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share-based compensation expense	$ 85,971	$ 213,890	$ 184,004	$ 452,080	$ 862,281	$ 911,398
General And Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share-based compensation expense	61,365	140,158	137,378	292,340	574,244	237,103
Cost Of Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share-based compensation expense	524	1,341	562	3,731	964	13,776
Selling And Marketing Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share-based compensation expense	5,749	11,311	10,604	25,458	45,951	56,732
Research And Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share-based compensation expense	$ 18,333	$ 61,080	$ 35,460	$ 130,551	$ 241,122	$ 603,787

Stockholders' Equity - Summary of Status of Options Granted (Details) - USD ($)	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Stockholders' Equity Note [Abstract]
Number of Options, Outstanding Balance		211,559	139,395	119,106
Number of Options, Granted	0	0	95,800	58,324
Number of Options, Exercised			0	(1,167)
Number of Options, Forfeited	(720)	(720)	(18,812)	(24,538)
Number of Options, Expired	0	(5)	(4,824)	(12,330)
Number of Options, Outstanding Balance	210,834	210,834	211,559	139,395	119,106
Number of Options, Vested and expected to vest			211,559
Number of Options, Exercisable			10,445
Weighted Average Exercise Price, Outstanding Balance		$ 20.58	$ 31.16	$ 44.00
Weighted Average Exercise Price, Granted			3.84	17.58
Weighted Average Exercise Price, Exercised			0	7.01
Weighted Average Exercise Price, Forfeited			11.98	36.31
Weighted Average Exercise Price, Expired			56.12	83.49
Weighted Average Exercise Price, Outstanding Balance			20.58	$ 31.16	$ 44.00
Weighted Average Exercise Price, Vested and expected to vest			20.58
Weighted Average Exercise Price, Exercisable			$ 1.25
Weighted-Average Remaining Contractual Life, Outstanding (in years)			7 years 7 months 6 days	8 years 3 months 18 days	8 years 7 months 6 days
Weighted-Average Remaining Contractual Life, Vested and expected to vest (in years)			7 years 7 months 6 days
Weighted-Average Remaining Contractual Life, Exercisable (in years)			5 years 3 months 18 days
Aggregate Intrinsic Value, Outstanding		$ 52,200	$ 3,733,900	$ 66,329,800
Aggregate Intrinsic Value, Exercised			0	1,125,600
Aggregate Intrinsic Value, Outstanding			52,200	$ 3,733,900	$ 66,329,800
Aggregate Intrinsic Value, Vested and expected to vest			52,200
Aggregate Intrinsic Value, Exercisable			$ 52,200

Stockholders' Equity - Schedule of Fair Value of Option Grant Estimated Using Black-Scholes Option Pricing Model (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Annual dividend	0.00%	0.00%
Risk free interest rate, minimum	2.50%	1.80%
Risk free interest rate, maximum	2.90%	2.30%
Expected volatility, minimum	46.00%	44.20%
Expected volatility, maximum	49.60%	53.00%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (in years)	6 years 3 months	6 years 3 months
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (in years)	5 years 3 months	5 years 3 months

Stockholders' Equity - Summary of Status of Restricted Stock Unit Granted (Details) - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Stockholders' Equity Note [Abstract]
Number of Options, Outstanding Balance	5,900	750
Number of Options, Granted	0	11,175
Number of Options, Vested	(5,650)	(6,025)
Number of Options, Forfeited	0	0
Number of Options, Outstanding Balance	250	5,900
Weighted Average Grant Date Fair Value, Outstanding Balance	$ 31.16	$ 42.50
Weighted Average Grant Date Fair Value, Granted	0	6.93
Weighted Average Grant Date Fair Value, Vested	8.93	8.01
Weighted Average Grant Date Fair Value, Forfeited	0	0
Weighted Average Grant Date Fair Value, Outstanding Balance	$ 42.50	$ 31.16

Stockholders' Equity - Warrants to Purchase Shares of Common Stock (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of Common Stock Subject to Warrants	3,525,632	3,525,797	1,495,031
November Two Thousand Nine [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 197.75	$ 197.75
Expiration	2019-11	2019-11
Shares of Common Stock Subject to Warrants	270	270	270
January Two Thousand Ten [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 197.75	$ 197.75
Expiration	2020-01	2020-01
Shares of Common Stock Subject to Warrants	270	270	270
March Two Thousand Ten [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 197.75	$ 197.75
Expiration	2020-03	2020-03
Shares of Common Stock Subject to Warrants	55	55	55
November Two Thousand Eleven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 197.75	$ 197.75
Expiration	2021-11	2021-11
Shares of Common Stock Subject to Warrants	212	212	212
December Two Thousand Eleven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 197.75	$ 197.75
Expiration	2021-12	2021-12
Shares of Common Stock Subject to Warrants	27	27	27
March Two Thousand Twelve [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 2,747.50	$ 2,747.50
Expiration	2019-03	2019-03
Shares of Common Stock Subject to Warrants		165	165
February Two Thousand Fifteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 165.00	$ 165.00
Expiration	2025-02	2025-02
Shares of Common Stock Subject to Warrants	9,001	9,001	9,001
May Two Thousand Fifteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 165.00	$ 165.00
Expiration	2020-05	2020-05
Shares of Common Stock Subject to Warrants	138,310	138,310	138,310
May Two Thousand Sixteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 32.81	$ 32.81
Expiration	2021-05	2021-05
Shares of Common Stock Subject to Warrants	189,577	189,577	189,577
June Two Thousand Sixteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 32.81	$ 32.81
Expiration	2021-05	2021-05
Shares of Common Stock Subject to Warrants	82,035	82,035	82,035
June Two Thousand Seventeen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 19.50	$ 19.50
Expiration	2022-06	2022-06
Shares of Common Stock Subject to Warrants	18,754	18,754	18,754
July Two Thousand Seventeen [Member] \| Warrants Exercise Price One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 17.25	$ 17.25
Expiration	2022-07	2022-07
Shares of Common Stock Subject to Warrants	6,350	6,350	6,350
July Two Thousand Seventeen [Member] \| Warrants Exercise Price Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 12.50	$ 12.50
Expiration	2022-07	2022-07
Shares of Common Stock Subject to Warrants	50,000	50,000	50,000
July Two Thousand Seventeen [Member] \| Warrants Exercise Price Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 10.63	$ 10.625
Expiration	2022-07	2022-07
Shares of Common Stock Subject to Warrants	1,000,003	1,000,003	1,000,003
February Two Thousand Eighteen [Member] \| Warrants Exercise Price Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 4.06	$ 4.06
Expiration	2023-02	2023-02
Shares of Common Stock Subject to Warrants	184,615	184,615
February Two Thousand Eighteen [Member] \| Warrants Exercise Price Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 3.25	$ 3.25
Expiration	2023-02	2023-02
Shares of Common Stock Subject to Warrants	1,846,153	1,846,153

Stockholders' Equity - Warrants to Purchase Shares of Common Stock (Details 1) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of Common Stock Subject to Warrants	3,525,632	3,525,797	1,495,031
March Two Thousand Eight [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price		$ 19,763.50
Expiration		2018-03
Shares of Common Stock Subject to Warrants			2
November Two Thousand Nine [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 197.75	$ 197.75
Expiration	2019-11	2019-11
Shares of Common Stock Subject to Warrants	270	270	270
January Two Thousand Ten [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 197.75	$ 197.75
Expiration	2020-01	2020-01
Shares of Common Stock Subject to Warrants	270	270	270
March Two Thousand Ten [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 197.75	$ 197.75
Expiration	2020-03	2020-03
Shares of Common Stock Subject to Warrants	55	55	55
November Two Thousand Eleven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 197.75	$ 197.75
Expiration	2021-11	2021-11
Shares of Common Stock Subject to Warrants	212	212	212
December Two Thousand Eleven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 197.75	$ 197.75
Expiration	2021-12	2021-12
Shares of Common Stock Subject to Warrants	27	27	27
March Two Thousand Twelve [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 2,747.50	$ 2,747.50
Expiration	2019-03	2019-03
Shares of Common Stock Subject to Warrants		165	165
February Two Thousand Fifteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 165.00	$ 165.00
Expiration	2025-02	2025-02
Shares of Common Stock Subject to Warrants	9,001	9,001	9,001
May Two Thousand Fifteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 165.00	$ 165.00
Expiration	2020-05	2020-05
Shares of Common Stock Subject to Warrants	138,310	138,310	138,310
May Two Thousand Sixteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 32.81	$ 32.81
Expiration	2021-05	2021-05
Shares of Common Stock Subject to Warrants	189,577	189,577	189,577
June Two Thousand Sixteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 32.81	$ 32.81
Expiration	2021-05	2021-05
Shares of Common Stock Subject to Warrants	82,035	82,035	82,035
June Two Thousand Seventeen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 19.50	$ 19.50
Expiration	2022-06	2022-06
Shares of Common Stock Subject to Warrants	18,754	18,754	18,754
July Two Thousand Seventeen [Member] \| Warrants Exercise Price One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 17.25	$ 17.25
Expiration	2022-07	2022-07
Shares of Common Stock Subject to Warrants	6,350	6,350	6,350
July Two Thousand Seventeen [Member] \| Warrants Exercise Price Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 12.50	$ 12.50
Expiration	2022-07	2022-07
Shares of Common Stock Subject to Warrants	50,000	50,000	50,000
July Two Thousand Seventeen [Member] \| Warrants Exercise Price Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 10.63	$ 10.625
Expiration	2022-07	2022-07
Shares of Common Stock Subject to Warrants	1,000,003	1,000,003	1,000,003
February Two Thousand Eighteen [Member] \| Warrants Exercise Price Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 4.06	$ 4.06
Expiration	2023-02	2023-02
Shares of Common Stock Subject to Warrants	184,615	184,615
February Two Thousand Eighteen [Member] \| Warrants Exercise Price Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 3.25	$ 3.25
Expiration	2023-02	2023-02
Shares of Common Stock Subject to Warrants	1,846,153	1,846,153

Income Taxes - Additional Information (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax [Line Items]
Deferred tax assets, net of valuation allowance, total		$ 52,348,036	$ 49,251,408
Deferred tax assets, valuation allowance		$ 52,348,036	$ 49,251,408
Maximum percentage of taxable income in which NOLs permitted to deduct		80.00%
U.S. federal corporate tax rate		21.00%	34.00%
Toll tax liability			$ 0
Reduction of deferred tax assets			146
Domestic Country [Member]
Income Tax [Line Items]
Operating loss carryforwards		$ 178,200,000	$ 165,981,195
Operating loss carryforwards incurred prior to 2018, expiration terms	begin to expire in 2022	begin to expire in 2022
Maximum [Member]
Income Tax [Line Items]
U.S. federal corporate tax rate			35.00%

Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Deferred tax assets:
NOL carryforward	$ 49,480,731	$ 46,326,407
R&E credit carryforward	2,559,479	2,559,479
Share-based compensation	329,796	345,088
Inventory reserve	19,068	45,338
Depreciation	0	71,756
Interest expense	51,152	0
Accruals and other	284,662	247,093
Total deferred tax assets	52,724,888	49,595,161
Valuation allowance	(52,348,036)	(49,251,408)
Deferred tax liabilities:
Intangible assets	(256,011)	(343,753)
Depreciation	(120,841)	0
Net	$ 0	$ 0

Income Taxes - Expected Income Tax Provision (Benefit) from Applying Federal Statutory Tax Rates to the Pre-Tax Loss and Actual Income Tax Provision (Benefit) (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Federal income tax benefit at statutory rates	21.00%	34.00%
Permanent adjustment	(1.40%)
Provision to return adjustment	(0.20%)
State income tax benefit, net of Federal benefit	(6.40%)	6.80%
Tax reform impact		(134.50%)
Change in valuation allowance	(13.00%)	93.00%
Change in state tax rates and other		0.70%
Total	0.00%	0.00%

Commitments - Additional Information (Details) - Life Technologies Corporation Supply Agreement [Member] - Quant Studio Five Real Time P C R Systems [Member]			6 Months Ended	12 Months Ended
	Jun. 30, 2019 USD ($) Product	Dec. 31, 2018 USD ($) Product	Jun. 30, 2019 USD ($) Product	Dec. 31, 2018 USD ($) Product
Other Commitments [Line Items]
Number of products acquired	21	15		11
Number of products acquired during period			6
Committed to acquire total cost of additional products in next three months \| $	$ 135,000,000	$ 135,000	$ 135,000,000	$ 135,000
Number of products committed to be acquired			3	3

Commitments - Additional Information (Details 1)			6 Months Ended	12 Months Ended
Commitments - Additional Information (Details 1)	Jun. 30, 2019 USD ($) Product	Dec. 31, 2018 USD ($) Product	Jun. 30, 2019 USD ($) Product	Dec. 31, 2018 USD ($) Product	Dec. 31, 2017 USD ($)
Other Commitments [Line Items]
Operating lease description				The Company leases a facility in Gaithersburg, Maryland under an operating lease that expires January 31, 2021, with one additional five-year renewal at the Company’s election. The Company also leases a facility in Woburn, Massachusetts under an operating lease that expires January 30, 2022. Additionally, the Company leases office space in Denmark; this lease is currently on a month-to-month basis.
Operating leases, rent expense, net, total				$ 984,639	$ 949,244
Capital leases description				The Company leases lab equipment, office furniture, and computer equipment under various capital leases. The leases expire at various dates through 2021. The leases require monthly principal and interest payments.
Capital leases expiration date description				The leases expire at various dates through 2021.
Restructuring benefits recognized					121,000
Retention expense incurred					68,000
Future minimum operating lease payments		$ 2,808,835		$ 2,808,835
Designated service period of employees, description				The service periods ended in December 2017
Capital Lease Obligations [Member]
Other Commitments [Line Items]
Capital leases, income statement, amortization expense				$ 295,009	$ 161,606
MARYLAND
Other Commitments [Line Items]
Operating leases expiration date				Jan. 31, 2021
Operating leases additional term		5 years		5 years
stpr:MA
Other Commitments [Line Items]
Future minimum operating lease payments		$ 14		$ 14
Life Technologies Corporation Supply Agreement [Member] \| Quant Studio Five Real Time P C R Systems [Member]
Other Commitments [Line Items]
Number of products acquired \| Product	21	15		11
Committed to acquire total cost of additional products in next three months	$ 135,000,000	$ 135,000	$ 135,000,000	$ 135,000
Number of products committed to be acquired \| Product			3	3
Advandx [Member] \| stpr:MA
Other Commitments [Line Items]
Operating leases expiration date				Jan. 30, 2022

Commitments - Schedule of Future Minimum Lease Payments For Capital Leases (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Capital Leases
2019	$ 508,114
2020	408,264
2021	104,579
Total	1,020,957
Less: amount representing interest	(96,251)
Less: amount representing service costs	(88,172)
Net present value of future minimum lease payments	836,534
Current maturities	(399,345)	$ (154,839)
Long-term maturities	437,189
Operating Leases
2019	1,107,565
2020	1,125,940
2021	535,250
2022	40,080
Total	2,808,835
Total
2019	1,615,679
2020	1,534,204
2021	639,829
2022	40,080
Total	$ 3,829,792

Commitments - Schedule of Capital Leased Assets (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Loss Contingencies [Line Items]
Less accumulated amortization	$ (749,480)	$ (454,471)
Capital lease assets, net	903,006	485,461
Furniture And Fixtures [Member]
Loss Contingencies [Line Items]
Capital leased assets gross	64,790	64,790
Equipment [Member]
Loss Contingencies [Line Items]
Capital leased assets gross	1,563,346	850,792
Computer Equipment [Member]
Loss Contingencies [Line Items]
Capital leased assets gross	$ 24,350	$ 24,350

Leases - Schedule of ROU Assets and Lease Liabilities (Details) - USD ($)	Jun. 30, 2019	Jan. 01, 2019	Dec. 31, 2018	Dec. 31, 2017
ROU Assets:
Operating	$ 1,381,830	$ 2,200,000	$ 0
Financing	984,742		0
Total ROU assets	2,366,572
Current:
Operating	958,992		0
Finance	576,322		399,345	$ 154,839
Noncurrent:
Operating	1,071,677		0
Finance	379,825		$ 437,189	$ 130,153
Total lease liabilities	$ 2,986,816

Leases - Schedule of Maturities of Lease Liabilities (Details) - USD ($)	Jun. 30, 2019	Jan. 01, 2019
Operating
2019	$ 558,109
2020	1,128,138
2021	536,819
2022	40,080
Total lease payments	2,263,146
Less: Interest	(232,477)
Present value of lease liabilities	2,030,669	$ 2,500,000
Finance
2019	332,786
2020	520,947
2021	166,318
2022	11,240
2023	3,644
Total lease payments	1,034,935
Less: Interest	(78,788)
Present value of lease liabilities	956,147
Total
2019	890,895
2020	1,649,085
2021	703,137
2022	51,320
2023	3,644
Total lease payments	3,298,081
Less: Interest	(311,265)
Present value of lease liabilities	$ 2,986,816

Leases - Schedule of Statement of Operations Classification of Lease Costs (Details) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2019
Lease Cost
Total lease costs	$ 345,466	$ 686,062
Other Expense [Member]
Lease Cost
Interest expense	19,297	41,778
Operating Expense [Member]
Lease Cost
Operating	218,673	439,595
Amortization	$ 107,496	$ 204,689

Leases - Schedule of Other Information (Details)	Jun. 30, 2019
Weighted average remaining lease term (in years)
Operating leases	2 years 1 month 6 days
Finance leases	1 year 9 months 18 days
Weighted average discount rate:
Operating leases	10.00%
Finance leases	9.20%

Leases - Schedule of Supplemental Cash Flow Information (Details) - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Cash used in operating activities
Operating leases	$ 439,595
Finance leases	41,778
Cash used in financing activities
Finance leases	235,600	$ 107,871	$ 292,722	$ 205,085
ROU assets obtained in exchange for lease obligations
Finance leases	$ 355,536

Leases - Schedule of Future Minimum Lease Payments (Details)	Dec. 31, 2018 USD ($)
Leases [Abstract]
2019	$ 1,615,679
2020	1,534,204
2021	639,829
2022	40,080
Total	$ 3,829,792

License Agreements, Research Collaborations and Development Agreements - Additional Information (Details)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2019 USD ($) Agreement	Jun. 30, 2018 USD ($)	Jun. 30, 2019 USD ($) Agreement	Jun. 30, 2018 USD ($)	Dec. 31, 2018 USD ($) Agreement	Dec. 31, 2017 USD ($)
License Agreements Research Collaborations And Development Agreements [Line Items]
Revenue from contract	$ 1,009,543	$ 788,901	$ 2,029,720	$ 1,635,127	$ 2,946,307	$ 3,211,007
Royalty expense	62,500	62,500	125,000	125,000	250,000	257,186
Annual future minimum royalty payments due	250,000		250,000		250,000
Collaborations Revenue [Member]
License Agreements Research Collaborations And Development Agreements [Line Items]
Revenue from contract	500,000	155,276	1,000,000	359,316	516,016	397,178
Product [Member]
License Agreements Research Collaborations And Development Agreements [Line Items]
Revenue from contract	504,293	632,525	1,024,470	1,266,021	2,395,626	2,771,869
Laboratory Service Revenue [Member]
License Agreements Research Collaborations And Development Agreements [Line Items]
Revenue from contract	$ 5,250	$ 1,100	$ 5,250	$ 9,790	$ 34,665	$ 41,960
F I S H Product Line [Member]
License Agreements Research Collaborations And Development Agreements [Line Items]
Number of license agreements \| Agreement	1		1		1
New York State Department Of Health And I L U M Health Solutions L L C [Member]
License Agreements Research Collaborations And Development Agreements [Line Items]
Collaboration revenue receivable over 12 months of the project	$ 1,600,000		$ 1,600,000
Contractual agreement period			12 months
New York State Department Of Health And I L U M Health Solutions L L C [Member] \| Collaborations Revenue [Member]
License Agreements Research Collaborations And Development Agreements [Line Items]
Revenue from contract	$ 500,000		$ 1,000,000

License Agreements, Research Collaborations and Development Agreements - Additional Information (Details 1)	1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	Sep. 30, 2017 USD ($)	Jun. 30, 2019 USD ($) Agreement	Jun. 30, 2018 USD ($)	Jun. 30, 2019 USD ($) Agreement	Jun. 30, 2018 USD ($)	Dec. 31, 2018 USD ($) Agreement	Dec. 31, 2017 USD ($)
License Agreements Research Collaborations And Development Agreements [Line Items]
Royalty expense		$ 62,500	$ 62,500	$ 125,000	$ 125,000	$ 250,000	$ 257,186
Annual future minimum royalty payments due		250,000		250,000		250,000
Revenue		1,009,543	788,901	2,029,720	1,635,127	2,946,307	3,211,007
Collaborations Revenue [Member]
License Agreements Research Collaborations And Development Agreements [Line Items]
Revenue		500,000	155,276	1,000,000	359,316	516,016	397,178
Collaborations Revenue [Member] \| Collaborative Arrangement License Agreement [Member]
License Agreements Research Collaborations And Development Agreements [Line Items]
Revenue						12,397	25,000
Product [Member]
License Agreements Research Collaborations And Development Agreements [Line Items]
Revenue		504,293	632,525	1,024,470	1,266,021	2,395,626	2,771,869
Laboratory Service Revenue [Member]
License Agreements Research Collaborations And Development Agreements [Line Items]
Revenue		$ 5,250	$ 1,100	$ 5,250	$ 9,790	$ 34,665	41,960
F I S H Product Line [Member]
License Agreements Research Collaborations And Development Agreements [Line Items]
Number of license agreements \| Agreement		1		1		1
Centers For Disease Control And Prevention [Member]
License Agreements Research Collaborations And Development Agreements [Line Items]
Number of contract awarded year	1 year
Revenue						$ 503,881	$ 357,178
Centers For Disease Control And Prevention [Member] \| Cloud Based Mobile Software [Member]
License Agreements Research Collaborations And Development Agreements [Line Items]
Contract awarded value for funds development and evaluation of software	$ 860,000

Related Party Transactions - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended		26 Months Ended	32 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Jun. 30, 2019	Oct. 31, 2016
Merck Sharp And Dohme Corp [Member]
Related Party Transaction [Line Items]
Research and development agreement description			Under the agreement, MSD provided access to its archive of over 200,000 bacterial pathogens. The Company is initially performing molecular analyses on up to 10,000 pathogens to identify markers of resistance to support rapid decision making using the Acuitas Lighthouse, and to speed development of its rapid diagnostic products. MSD gains access to the high-resolution genotype data for the isolates as well as access to the Acuitas Lighthouse informatics to support internal research and development programs.		Under the agreement, Merck provided access to its archive of over 200,000 bacterial pathogens. The Company is initially performing molecular analyses on up to 10,000 pathogens to identify markers of resistance to support rapid decision making using the Acuitas Lighthouse, and to speed development of its rapid diagnostic products. Merck gains access to the high-resolution genotype data for the isolates as well as access to the Acuitas Lighthouse informatics to support internal research and development programs.
Maximum required amount to expend for procurement of materials									$ 175,000
Research And Development Expense [Member] \| Merck Sharp And Dohme Corp [Member]
Related Party Transaction [Line Items]
Procurement costs recognized	$ 0	$ 22,604	$ 0	$ 22,604	$ 22,603	$ 146,177	$ 171,646	$ 171,646
Service [Member]
Related Party Transaction [Line Items]
Cost of services	251,981	179,402	396,463	347,955	625,516	520,338
Service [Member] \| I L U M Health Solutions Limited Liability Company [Member] \| Subcontractor Agreement [Member]
Related Party Transaction [Line Items]
Cost of services	0	84,853	0	198,665	329,162	210,180
Product [Member]
Related Party Transaction [Line Items]
Cost of services	$ 198,493	$ 303,663	$ 419,195	$ 646,495	$ 1,222,919	$ 1,612,838

Related Party Transactions - Additional Information (Details 1) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended		26 Months Ended	32 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Jun. 30, 2019	Oct. 31, 2016
Merck Sharp And Dohme Corp [Member]
Related Party Transaction [Line Items]
Research and development agreement description			Under the agreement, MSD provided access to its archive of over 200,000 bacterial pathogens. The Company is initially performing molecular analyses on up to 10,000 pathogens to identify markers of resistance to support rapid decision making using the Acuitas Lighthouse, and to speed development of its rapid diagnostic products. MSD gains access to the high-resolution genotype data for the isolates as well as access to the Acuitas Lighthouse informatics to support internal research and development programs.		Under the agreement, Merck provided access to its archive of over 200,000 bacterial pathogens. The Company is initially performing molecular analyses on up to 10,000 pathogens to identify markers of resistance to support rapid decision making using the Acuitas Lighthouse, and to speed development of its rapid diagnostic products. Merck gains access to the high-resolution genotype data for the isolates as well as access to the Acuitas Lighthouse informatics to support internal research and development programs.
Maximum required amount to expend for procurement of materials									$ 175,000
Research And Development Expense [Member] \| Merck Sharp And Dohme Corp [Member]
Related Party Transaction [Line Items]
Procurement costs recognized	$ 0	$ 22,604	$ 0	$ 22,604	$ 22,603	$ 146,177	$ 171,646	$ 171,646
Service [Member]
Related Party Transaction [Line Items]
Cost of services	251,981	179,402	396,463	347,955	625,516	520,338
Service [Member] \| I L U M Health Solutions Limited Liability Company [Member] \| Subcontractor Agreement [Member]
Related Party Transaction [Line Items]
Cost of services	0	84,853	0	198,665	329,162	210,180
Product [Member]
Related Party Transaction [Line Items]
Cost of services	$ 198,493	$ 303,663	$ 419,195	$ 646,495	$ 1,222,919	$ 1,612,838